

SEMMELWEIS EGYETEM  
DOKTORI ISKOLA

**Ph.D. értekezések**

**2965.**

**MEZNERICS FANNI ADÉL**

**Bőrgyógyászat és venerológia**  
című program

Programvezető: Dr. Sárdy Miklós, egyetemi tanár

Témavezető: Dr. Bánvölgyi András, egyetemi adjunktus

# NEW FRONTIERS IN DISEASE ACTIVITY MONITORING AND THERAPY IN THE FIELD OF DERMATOLOGY AND RHEUMATOLOGY

Ph.D. Thesis

**Fanni Adél Meznerics M.D.**

Translational Medicine Program

Károly Rácz Conservative Medicine Doctoral School

SEMMELWEIS UNIVERSITY



Supervisor:

András Bánvölgyi, M.D., Ph.D.

Official reviewers:

Zsolt Molnár, M.D., Ph.D.

Bogdan Ionel Tamba, M.D., Ph.D.

Head of the Complex

Examination Committee:

Romána Zelkó, M.D., D.Sc.

Members of the Complex

Examination Committee:

István Zupkó, M.D., Ph.D.

László Köles, M.D., Ph.D.

Dániel Veres, M.D., Ph.D.

Előd Nagy, M.D., D.Sc.

Budapest

2023

***"There is no greater misfortune in the world than the loss of reason."***

*Mikhail Bulgakov, The Master and Margarita*

## TABLE OF CONTENTS

1. LIST OF ABBREVIATIONS .....	6
2. STUDENT PROFILE.....	9
2.1. Vision and mission statement, specific goals .....	9
2.2. Scientometrics .....	9
2.3. Future plans .....	9
3. SUMMARY OF THE PH.D.....	10
4. GRAPHICAL ABSTRACT .....	11
5. INTRODUCTION.....	12
5.1. Overview of the topic .....	12
5.1.1. What is the topic? .....	12
5.1.2. What is the problem to solve? .....	12
5.1.3. What is the importance of the topic? .....	12
5.1.4. What would be the impact of our research results?.....	12
5.2. Inflammation – a key player in dermatology and rheumatology.....	13
5.3. The implementation of innovative disease-monitoring and modifying methods in dermatology and rheumatology .....	14
5.3.1. Multi-biomarker disease activity score, a novel disease monitoring system	14
5.3.2. Platelet-rich plasma, a novel disease-modifying treatment modality.....	16
6. OBJECTIVES.....	18
6.1. Study I. – Investigating the utility of MBDA score for the monitoring of rheumatoid arthritis .....	18
6.2. Study II. – Investigating the efficacy of PRP in chronic wound management....	18
6.3. Study III. – Investigating the efficacy of PRP in the treatment of alopecia areata .....	18

7. METHODS.....	19
7.1. Literature search and eligibility criteria.....	19
7.2. Study selection and data collection .....	19
7.3. Quality assessment .....	20
7.4. Data synthesis and analysis .....	20
8. RESULTS.....	22
8.1. Search and selection, characteristics of the included studies .....	22
8.1.1. Study I. – Investigating the utility of MBDA score for the monitoring of rheumatoid arthritis .....	22
8.1.2. Study II. – Investigating the efficacy of PRP in chronic wound management .....	29
8.1.3. Study III. – Investigating the efficacy of PRP in the treatment of alopecia areata.....	37
8.2. Results of the quantitative analysis .....	39
8.2.1. Study I. – Investigating the utility of MBDA score for the monitoring of rheumatoid arthritis .....	39
8.2.1.1. MBDA score for the assessment of disease activity.....	39
8.2.1.2. MBDA score for the assessment of radiographic progression .....	42
8.2.2. Study II. – Investigating the efficacy of PRP in chronic wound management .....	45
8.2.2.1. Complete closure .....	45
8.2.2.2. Reduction of wound area.....	46
8.2.3. Study III. – Investigating the efficacy of PRP in the treatment of alopecia areata.....	48
8.2.3.1. Reduction of SALT score .....	48
8.3. Qualitative analysis .....	48

8.4. Quality assessment .....	48
8.4.1. Study I. – Investigating the utility of MBDA score for the monitoring of rheumatoid arthritis .....	48
8.4.2. Study II. – Investigating the efficacy of PRP in chronic wound management .....	49
8.4.3. Study III. – Investigating the efficacy of PRP in the treatment of alopecia areata.....	49
9. DISCUSSION.....	50
9.1. Summary of findings, international comparisons.....	50
9.2. Strengths .....	52
9.3. Limitations.....	53
10. CONCLUSION .....	54
11. IMPLEMENTATION FOR PRACTICE .....	55
12. IMPLEMENTATION FOR RESEARCH.....	56
13. IMPLEMENTATION FOR POLICYMAKERS.....	58
14. FUTURE PERSPECTIVES .....	59
15. REFERENCES .....	60
16. BIBLIOGRAPHY .....	75
16.1. Publications related to the thesis .....	75
16.2. Publications not related to the thesis .....	75
17. ACKNOWLEDGEMENTS .....	78

**1. LIST OF ABBREVIATIONS**

AA	alopecia areata
ACPA	anti-citrullinated peptide antibody
ADA	adalimumab
APG	autologous platelet gel
bDMARD	biological disease-modifying antirheumatic drug
c.c.	correlation coefficient
CDAI	Clinical Disease Activity Index
CI	confidence interval
COR	correlation
CRP	C-reactive protein
CsA	cyclosporin A
csDMARD	conventional synthetic disease-modifying antirheumatic drug
DAM	disease activity measure
DAS28	Disease Activity Score with 28-joint count
DMARD	Disease-Modifying Anti-Rheumatic Drug
DP	dermal papilla
EGF	epidermal growth factor
ESR	erythrocyte sedimentation rate
ETN	etanercept
EULAR	European Union League Against Rheumatism
FA	folic acid
GC	glucocorticoid
GRADE	Grades of Recommendation, Assessment, Development, and Evaluation
HAQ	Health Assessment Questionnaire
HCQ	hydroxychloroquine
HF	hair follicle
IFX	infliximab

IGF-1	insulin-like growth factor
IL-6	interleukin-6
ILC	innate lymphoid cell
IMID	immune-mediated inflammatory disease
IP	immune privilege
MBDA	multi-biomarker disease activity
MD	mean difference
MMP	matrix metalloproteinase
MTX	methotrexate
N/A	no data available
NSAID	Non-Steroidal Anti-Inflammatory Drug
OR	odds ratio
PBO	placebo
PC	platelet concentrate
PDGF	platelet-derived growth factor
PDUS	synovial power dopplers score based on ultrasonography
PICO	population-intervention-control-outcome
POS	prospective observational study
PPP	platelet-poor plasma
PRF	platelet-rich fibrin
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PRP	platelet-rich plasma
PtGA	Patient Global Assessment of Disease Activity
QUIPS	Quality In Prognosis Studies
RA	rheumatoid arthritis
RCT	randomized clinical trial
ReOS	retrospective observational study
RF	rheumatoid factor
RoB 2	Revised tool for assessing the risk of bias



ROS	reactive oxygen species
RP	radiographic progression
RTX	rituximab
SAA	serum amyloid A
SALT	Severity of Alopecia Tool
SDAI	Simplified Disease Activity Index
SJC28	Swollen Joint Count of 28 joints
SMD	standardized mean difference
SSZ	sulfasalazine
SvdH	Sharp/van der Heijde
TCZ	tocilizumab
TGF- $\beta$	transforming growth factor $\beta$
TJC28	Tender Joint Count of 28 joints
TNFi	TNF-alpha-inhibitor
TNFR1	tumor necrosis factor receptor type I
TrA	triamcinolone acetonide
VCAM-1	vascular cell adhesion molecule-1
VEGF	vascular endothelial growth factor

## 2. STUDENT PROFILE

### 2.1. Vision and mission statement, specific goals

My vision is to improve patient care, thus enhance the quality of life for patients with chronic dermatological and rheumatological conditions.



My mission is to urge the implementation of novel disease modifying and monitoring methods in clinical practice.

My specific goals include the investigation of the utility of MBDA score for the monitoring of rheumatoid arthritis, as well as the assessment of the efficacy of PRP in chronic wound management and in the treatment of alopecia areata.

### 2.2. Scientometrics

<b>Number of all publications:</b>	13
Cumulative IF:	26.20
Av IF/publication:	2.01
Ranking (Sci Mago):	D1: 2, Q1: 3, Q2: 5
<b>Number of publications related to the subject of the thesis:</b>	3
Cumulative IF:	14.10
Av IF/publication:	4.70
Ranking (Sci Mago):	D1: 1, Q1: 2, Q2: -
<b>Number of citations on Google Scholar:</b>	39
<b>Number of citations on MTMT (independent):</b>	11
<b>H-index:</b>	3

The detailed bibliography of the student can be found on page 75.

### 2.3. Future plans

My future plans revolve around the dual goals of continuing my research and gaining valuable experience in patient care as well.

I firmly believe that a comprehensive understanding of healthcare requires more than theoretical expertise alone. To enhance my skill set and broaden my perspective, I am keen on actively participating in patient care. By engaging directly with patients, I aspire to gain firsthand experience in addressing their unique needs, challenges, and concerns.

By integrating research and patient care, I aim to forge a career that not only advances scientific knowledge but also directly contributes to the well-being and improved healthcare outcomes of patients.

### **3. SUMMARY OF THE PH.D.**


The advancements achieved in dermatology and rheumatology call for an assessment of the efficacy of novel treatments, while also highlight the importance of monitoring disease activity to facilitate personalized treatment.

To advance clinical practice by promoting innovative disease-modifying and monitoring methods we conducted three meta-analyses. These analyses evaluated the effectiveness of the multi-biomarker disease activity (MBDA) score as a monitoring tool for rheumatoid arthritis (RA), as well as the efficacy of platelet-rich plasma (PRP) in treating two dermatological conditions, chronic wounds and alopecia areata (AA).

Our results showed moderate correlations between the MBDA score and conventional disease activity measures both at baseline and at follow-up. Regarding the efficacy of PRP, our findings demonstrated that the odds for complete wound closure were significantly higher in the PRP group compared to the control group when treating chronic wounds. When comparing the PRP and triamcinolone acetonide groups for the treatment of AA, the pooled MDs from the four studies of the quantitative analysis did not demonstrate a significant difference in the mean change of the SALT score.

In conclusion, our findings demonstrated the utility of MBDA score for the monitoring of RA and highlighted the potentials of PRP in the treatment of chronic wounds and alopecia areata. By implementing the use of MBDA score in clinical practice, the personalized treatment of RA patients could be further improved, while PRP could providing a potential treatment option for a wide range of patients.

4. GRAPHICAL ABSTRACT



## **5. INTRODUCTION**

### **5.1. Overview of the topic**

#### **5.1.1. What is the topic?**

Our main focus is the assessment of the utility of novel disease monitoring and modifying methods in the field of dermatology and rheumatology.

#### **5.1.2. What is the problem to solve?**

The progress made in the fields of dermatology and rheumatology necessitates the evaluation of the effectiveness of innovative therapies, while also emphasizing the significance of monitoring disease activity to enable tailored treatment approaches.

#### **5.1.3. What is the importance of the topic?**

Dermatological and rheumatological conditions can have a profound impact on patients' quality of life as well as on society as a whole. These conditions often bring about physical discomfort, pain, and visible symptoms, which can lead to significant psychological distress and emotional challenges for patients. Moreover, these conditions impose a financial burden on the healthcare system and society as the long-term management of these conditions often requires ongoing medical care, specialized treatments, and medications.

#### **5.1.4. What would be the impact of our research results?**

Through the assessment of the effectiveness of new therapies and the facilitation of widespread adoption of objective disease monitoring systems, the quality of life for patients can be significantly improved. The evaluation of the efficacy of emerging treatments allows healthcare professionals to determine the most suitable interventions for patients, leading to enhanced outcomes and better overall well-being. Additionally, the implementation of objective disease monitoring systems provides clinicians with valuable data on the progression and response to treatment, enabling personalized and timely adjustments to patient care plans.

## **5.2. Inflammation – a key player in dermatology and rheumatology**

Understanding the role of inflammation is critical in the diagnosis and management of dermatologic and rheumatologic conditions: serum markers of inflammation can help diagnosis, while anti-inflammatory agents can be valuable tools in disease management.

Inflammation can be both the trigger and the maintainer of a disease, often without the clear separation of the two phenomena. In case of autoimmune and immune-mediated inflammatory diseases (IMIDs), two common and well-known disease groups in the field of dermatology and rheumatology, it is usually both.

Alopecia areata (AA) is a non-scarring alopecia, mainly described as an autoimmune disease in the field of dermatology, characterized by inflammation-induced hair loss, which can affect the scalp, the beard, or even the whole body, leading to a serious deterioration in patients' quality of life (1). The loss of the immune privilege (IP) of the hair follicles (HF) plays a key role in the pathomechanism of AA, resulting in the influx of pro-inflammatory cells responding to the exposed HF autoantigens that induce HF damage (2-5). The reason behind the loss of IP is heavily investigated: the role of an autoimmune component with the ectopic expression of HF antigens, promoting the activation of autoreactive CD8<sup>+</sup> T cells, resulting IP collapse is widely accepted (2, 3, 6, 7). However, the theory of the non-autoimmune form of AA, where an environmental stress-induced reactive oxygen species (ROS) buildup in HF keratinocytes promotes pro-inflammatory activity from the innate immune system, resulting IP collapse, is also described in the literature (2, 3, 8, 9).

Inflammation is also a hallmark of several rheumatological autoimmune and immune mediated inflammatory diseases, such as rheumatoid arthritis (RA), a chronic disease that primarily affects the joints, causing inflammation, pain, and damage. The pathogenesis of RA is complex and multifactorial. Although the initial triggers for the breakdown of immune tolerance are yet to be identified, several genetic factors, such as epigenetic modifications and genetic polymorphisms affecting the immune function and environmental factors, including cigarette smoke, have been described in the literature (10, 11). In response to the initial trigger, the activation of the immune system leads to the production of autoantibodies and the release of pro-inflammatory cytokines that lead

to a systemic inflammation and also target the synovial tissue, causing the destruction of the joint cartilage and bone (10, 12).

As the maintainer of the condition, inflammation also plays a significant role in chronic wounds. Chronic wounds are common conditions that greatly impact patients' quality of life (13). They place a heavy burden on the healthcare system as the cost of wound management is estimated to account for 5.5% of all healthcare expenditures (14). Although a wide range of causes, including arterial and venous insufficiency, neuropathy, microangiopathy, and several additional factors underlie ulceration, the healing process consists of the same phases (15, 16). After the hemostasis, the phase of inflammation ensures the breakdown of the tissue and the clean-up of cellular, extra-cellular and pathogen debris (16, 17). The healing continues with the proliferative phase and ends with tissue remodeling (16, 17). The inflammation is an essential step of wound healing, however, in case of chronic wounds, the healing cascade is not as well defined as in case of acute trauma (16). Due to tissue hypoxia combined with the host response to repetitive stress, a chronic inflammation is sustained and the progression to the proliferative phase is consequently delayed, preventing the healing (16, 18).

### **5.3. The implementation of innovative disease-monitoring and modifying methods in dermatology and rheumatology**

The therapeutic landscape is expanding both in the field of dermatology and rheumatology, mainly driven by the emergence and widespread adoption of biological therapies. While the availability of multiple treatment options is noteworthy, the paramount objective is to optimize patient care by selecting the most effective therapy. Consequently, there is an escalating emphasis on monitoring disease activity to guide the selection of the optimal treatment based on individual disease status. Furthermore, the evaluation of novel therapies' efficacy, even besides biologics, remains imperative.

#### **5.3.1. Multi-biomarker disease activity score, a novel disease monitoring system**

The Multi-biomarker Disease Activity (MBDA) score is an objective tool using only serum biomarker levels for the assessment of disease activity in RA. The validated test that calculates MBDA score with an algorithm is commercially available as the Vectra® DA test, resulting a score from 0 to 100. It was created through the testing of 130 potential

biomarkers in feasibility studies. From these, 25 biomarkers were chosen to train the algorithm and 12 (interleukin-6 [IL-6], tumor necrosis factor receptor type I [TNFRI], vascular cell adhesion molecule 1 [VCAM-1], epidermal growth factor [EGF], vascular endothelial growth factor A [VEGF-A], YKL-40, matrix metalloproteinase 1 [MMP-1], MMP-3, C-reactive protein [CRP], serum amyloid A [SAA], leptin, and resistin) were selected as final biomarkers (19).

As per the recommendations of the European Union League Against Rheumatism (EULAR), the objective of therapy for rheumatoid arthritis (RA) is to attain either remission or, at least, minimize disease activity. (20). Current guidelines recommend early initiation of Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and employing a treat-to-target therapeutic approach to prevent long-term functional decline by minimizing damage to cartilage and bone (21-23).

Currently, the available options for monitoring disease activity and progression are predominantly subjective or lack specificity. The Disease Activity Score with 28-joint count (DAS28), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) are widely used but incorporate subjective evaluations of disease activity reported by either the patient or the healthcare provider (24-26). While non-specific inflammatory markers like CRP or erythrocyte sedimentation rate (ESR) are utilized in the calculation of DAS28 and SDAI, the inclusion of a scoring system that combines inflammatory markers with additional biomarkers could enhance the objectivity of disease activity measurement.

Assessing structural damage, a significant determinant of disease progression, can be achieved through radiography and quantified using the Sharp/van der Heijde (SvdH) score system (27). Several established risk factors for radiographic progression have been identified, including elevated disease activity monitored through non-specific inflammatory markers like CRP, seropositivity for rheumatoid factor (RF), and anti-citrullinated peptide antibody (ACPA) (28). Nevertheless, nor RF or ACPA are suitable for monitoring disease activity (29).

The utilization of the MBDA score as an objective disease monitoring system can play a significant role in tailoring personalized therapeutic plans and modifications aligned with



contemporary medical perspectives. Apart from its ability to monitor disease activity, the MBDA score also holds potential in predicting radiographic progression (30-33).

### **5.3.2. Platelet-rich plasma, a novel disease-modifying treatment modality**

Platelet-rich plasma (PRP) is a relatively new, presently evolving treatment modality. The term PRP was first described as a treatment alternative of thrombocytopenia and was used as a synonym of the category “platelet concentrate” (PC) (34). Since the appearance of the denser, second-generation PCs, such as platelet-rich fibrin (PRF) or autologous platelet gel (APG), PRP is also used as a subcategory of PCs to describe formulations with lower density (35, 36). PRP is prepared from whole blood by a centrifugation process to achieve a product that is rich in platelets, growth factors, and cytokines. PRP was shown to stimulate stem cell regeneration and tissue remodeling, promote cell proliferation in the dermal papilla (DP), increase DP cell survival through antiapoptotic effects, and stimulate hair regrowth by prolonging the anagen phase of the hair cycle (37-39).

Due to its beneficial effects on tissue regeneration, PRP is widely used in several fields of medicine, such as ortopedics, sports medicine, ophthalmology, oral surgery, gynecology, and urology (40-46). It has also been utilized in plastic surgery and dermatology for facial rejuvenation and for therapeutic purposes such as the treatment of androgenic alopecia, acne scars, or chronic wounds (47-50).

Depending on the format of the PC, it can be either injected, applied topically after a pre-treatment such as microneedling or CO<sub>2</sub> laser treatment, or applied in a gel format.

Both the management of chronic wounds and the treatment of AA are challenging. The key element of chronic wound management is the treatment of the underlying cause, however, promoting the wound healing through professional wound care is also essential; the gold standard methods are smart dressings and compression therapy (51). In the management of AA, a diverse range of topical and systemic treatments are employed. However, due to the variable response of the disease to therapy, there is a lack of consensus on a standardized treatment approach (52). According to guidelines, the first line of treatment in limited patchy AA is triamcinolone acetonide (TrA) administered intralesionally (53, 54). In addition to the often-debated effectiveness of TrA treatment,

common side effects like skin atrophy, telangiectasiae, and hypopigmentation are frequently observed. Moreover, the use of steroids can evoke concern in many, leading to a phenomenon known as steroid phobia (55). These factors further emphasize the need to explore alternative topical steroid-free treatment options.

## **6. OBJECTIVES**

### **6.1. Study I. – Investigating the utility of MBDA score for the monitoring of rheumatoid arthritis**

Although several studies have evaluated the utility of the MBDA score, and a meta-analysis has been conducted on the correlation of the MBDA score with conventional DAMs; the predictive and discriminative value of the MBDA score was yet to be analyzed in a comprehensive manner (56). Therefore, our aim was to conduct a systematic review and meta-analysis assessing the predictive and discriminate value of MBDA score besides its correlation with conventional DAMs.

### **6.2. Study II. – Investigating the efficacy of PRP in chronic wound management**

The effects of PRP on wound healing are heavily investigated, however, the current evidence is inconclusive (49). Therefore, we aimed to evaluate the efficacy of PRP in chronic wound management.

### **6.3. Study III. – Investigating the efficacy of PRP in the treatment of alopecia areata**

PRP showed promising results in the treatment of AA(57-62), but as there was no systematic evaluation of randomized trials reporting on the therapeutic effect of PRP on AA, we aimed to summarize the latest data on the efficacy of PRP in AA comprehensively.

## 7. METHODS

Our systematic reviews and meta-analyses are reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 Statement (63). The Cochrane Handbook's recommendations for Systematic Reviews of Interventions Version 6.1.0 (64) and Cochrane Prognosis Methods Group (65) were followed and the review protocols were registered on PROSPERO (Study I.: *CRD42021279474*; Study II.: *CRD42021287881*; Study III.: *CRD42021282807*).

### 7.1. Literature search and eligibility criteria

We performed a systematic literature search in five databases, MEDLINE (via PubMed), Cochrane Library (CENTRAL), Embase, Web of Science and Scopus for Study I, and four medical databases, MEDLINE (via PubMed), Cochrane Library (CENTRAL), Embase, and Web of Science for Study II. and Study III. The dates of the searches and the queries used are detailed in the original publications (66-68).

Original articles reporting on the performance of the MBDA score's correlation with conventional DAMs, or the predictive and the discriminative value of the MBDA score for radiographic progression, therapy response, remission, and relapse were included for Study I. Randomized clinical trials (RCTs) reporting on patients with chronic wounds treated with PRP, comparing additional PRP treatment with conventional ulcer therapy alone were included for Study II., while RCTs reporting on patients with AA treated with PRP, comparing PRP with TrA or placebo for Study III.

### 7.2. Study selection and data collection

We used EndNote X9 (Clarivate Analytics, Philadelphia, PA, USA) for the articles' selection. Two independent authors screened the publications separately for the title, abstract, and full text, and disagreements were resolved by a third author.

Two authors independently extracted data into a predefined Excel spreadsheet (Office 365, Microsoft, Redmond, WA, USA), and a third reviewer resolved the discrepancies.

The following data were collected from each eligible article: data regarding the article (first author, year of publication, DOI, language, study design, study duration, original study/data source), data regarding participants (demographics and subject characteristics:

age, sex, treatment applied, subgroups examined), data regarding outcomes (all possible data of the investigated outcomes were collected). Multiple reports of the same population were linked together.

### **7.3. Quality assessment**

The risk of bias assessment was carried out separately by two reviewers by using the Quality In Prognosis Studies (QUIPS) tool for Study I. (69) and the revised tool for assessing the risk of bias (RoB 2) (70) for Study II. and III. Disagreements were resolved by a third reviewer. To assess the quality of the evidence for Study II. and Study II., we followed the recommendation of the “Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)” workgroup and used GRADEPro Guideline Development Tool for visualization (71, 72).

### **7.4. Data synthesis and analysis**

The statistical analyses were performed with R (R Core Team 2022, v4.2.1) (73). Forest plots were used to graphically summarize the results. For calculations and plots we used the meta (Schwarzer 2022, v5.5.0) (74) and dmetar (Cuijpers, Furukawa, and Ebert 2022, v0.0.9000) (75) packages.

Random-effects meta-analyses were performed on the different datasets as we anticipated considerable between-study heterogeneity.

For dichotomous outcomes the odds ratio (OR) with 95% confidence interval (CI) was used for the effect measure; to calculate the OR, the total number of patients in each group and those with the event of interest were extracted from each study. Raw data from the selected studies were pooled using a random effect model with the Mantel-Haenszel method (76-78). For the pooled results exact Mantel-Haenszel method (no continuity correction) was used to handle zero cell counts (79). At individual studies zero cell count problem was adjusted by treatment arm continuity correction (80). In case of continuous outcomes, mean difference (MD) and standardized mean difference (SMD) with 95% CI were calculated as effect size. In case of correlations, the correlations retrieved from the studies belonged to three categories: Pearson's correlation coefficient (c.c.), Spearman's c.c. and those that the type of c.c. was not mentioned in the article. These three were analyzed separately as Pearson's c.c. and Spearman's c.c. are calculated differently, thus

analyzing them together or trying to transform them into each other might introduce some distortion to our results, undermining the reliability of the conclusions. For the meta-analyses, Fisher's z-transformation was carried out on the collected c.c.-s, which were then retransformed for the reporting of the results.

Between-study heterogeneity was described by the Higgins & Thompson's  $I^2$  statistics (81).


## 8. RESULTS

### 8.1. Search and selection, characteristics of the included studies

#### 8.1.1. Study I. – Investigating the utility of MBDA score for the monitoring of rheumatoid arthritis

Our systematic search provided 1190 records; after duplicate removal we screened 708 duplicate-free publications. Thirty eligible studies (30-33, 82-107) were identified after title, abstract and full-text selection, and two additional studies (108, 109) during citation search. Of these studies, we included 24 in the quantitative (30-32, 82-84, 86-88, 90, 91, 93-97, 99, 100, 102, 103, 105, 106, 108, 109) and eight only in the qualitative (33, 85, 89, 92, 98, 101, 104, 107) analysis. The summary of the selection process is shown in **Figure 1**.

**Figure 1.**



**Figure 1.** PRISMA Flow Diagram of the screening and selection process for Study I. (66)

Characteristics of the identified studies for the systematic review and meta-analysis are detailed in **Table 1**.

**Table 1.** Main characteristics of the included studies for Study I. (66)

<b>First author, year of publication</b>	<b>Country</b>	<b>Type of publication</b>	<b>Original study type</b>	<b>Treatment</b>	<b>Outcome</b>	<b>Timepoints of study</b>
<b>Studies included in the meta-analysis</b>						
<b>Baker, 2021 (82)</b>	US (Pennsylvania)	journal article	POS	MTX, bDMARD, GC	Spearman's correlation with conventional DAMs	baseline*
<b>Bakker, 2012 (30)</b>	Netherlands	journal article	RCT	MTX, CsA, intraarticular GC, NSAID	Pearson's correlation with conventional DAMs <sup>++</sup> , predicting radiographic progression, remission <sup>++</sup>	baseline*, month 1,3,6*, year 2 <sup>+</sup>
<b>Bechman, 2018 (83)</b>	UK	journal article	POS	csDMARD, bDMARD, GC	Spearman's correlation with conventional DAMs, relapse <sup>++</sup>	month 3, 6, 9, 12*
<b>Bijlsma, 2013 (84)</b>	Netherlands	conference abstract	RCT	group A: MTX+PBO group B: MTX+GC	Spearman's correlation with conventional DAMs	baseline*, month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12*



<b>First author, year of publication</b>	<b>Country</b>	<b>Type of publication</b>	<b>Original study type</b>	<b>Treatment</b>	<b>Outcome</b>	<b>Timepoints of study</b>
<b>Bouman, 2017 (86)</b>	Netherlands	journal article	RCT	MTX, csDMARD, ADA, ETN, NSAID, GC	Spearman's correlation with conventional DAMs, predicting radiographic progression <sup>++</sup> , relapse <sup>++</sup>	baseline*, month 3, 6, 9, 12, 15, 18
<b>Brahe, 2016 (87)</b>	Denmark	conference abstract	RCT	group A: MTX+PBO group B: MTX+ADA	Spearman's correlation with conventional DAMs	baseline*, month 3*, 6, 12*
<b>Brahe, 2019 (31)</b>	Denmark	journal article	RCT	group A: MTX+PBO group B: MTX+ADA	Spearman's correlation with conventional DAMs, predicting radiographic progression, remission <sup>++</sup>	baseline*, month 1, 2, 3*, 6*, 9, 12
<b>Genovese, 2017 (88)</b>	US	conference abstract	RCT	group A: MTX+PBO group B: MTX+100 mg filogitinib group C: MTX+200 mg filogitinib	Spearman's correlation with conventional DAMs	baseline*, week 12*

<b>First author, year of publication</b>	<b>Country</b>	<b>Type of publication</b>	<b>Original study type</b>	<b>Treatment</b>	<b>Outcome</b>	<b>Timepoints of study</b>
<b>Hambardzumyan, 2013 (90)</b>	Sweden	conference abstract	RCT	MTX, other DMARD, IFX	Spearman's correlation with conventional DAMs	baseline*, year 1*
<b>Hambardzumyan, 2015 (32)</b>	Sweden	conference abstract	RCT	MTX, HCQ, SSZ, IFX	predicting radiographic progression	month 3, year 1 <sup>+</sup>
<b>Hirata, 2013 (108)</b>	Netherlands, Japan	journal article	RCT	DMARD, IFX	Spearman's correlation with conventional DAMs, remission <sup>++</sup>	baseline*, year 1*
<b>Hirata, 2015 (109)</b>	Japan	journal article	REOS	ADA, ETN, IFX, MTX	Spearman's correlation with conventional DAMs, therapy response <sup>++</sup>	baseline*, week 24, 52*
<b>Hirata, 2016 (93)</b>	Japan	journal article	REOS	MTX, ADA, ETN, IFX	Spearman's correlation with conventional DAMs, predicting radiographic progression <sup>++</sup>	baseline*, week 52*
<b>Jurgens, 2020 (94)</b>	Netherlands	journal article	RCT	MTX, GC, CsA, ADA, PBO	Spearman's correlation with conventional DAMs	baseline*, month 1, 2, 3*, 4, 5, 6, 7, 8, 9, 10, 11, 12

<b>First author, year of publication</b>	<b>Country</b>	<b>Type of publication</b>	<b>Original study type</b>	<b>Treatment</b>	<b>Outcome</b>	<b>Timepoints of study</b>
<b>Krabbe, 2017 (95)</b>	Denmark	journal article	POS	MTX, ADA	Spearman's correlation with conventional DAMs, predicting radiographic progression <sup>++</sup>	baseline*, week 26, 52*
<b>Lee, 2016 (96)</b>	USA (Massachusetts)	journal article	POS	csDMARD, bDMARD	Spearman's correlation with conventional DAMs	baseline*
<b>Li, 2013 (97)</b>	Sweden	conference abstract	POS	MTX	Spearman's correlation with conventional DAMs, therapy response <sup>++</sup>	baseline*, month 3*
<b>Ma, 2014 (100)</b>	UK	conference abstract	POS	N/A	Spearman's correlation with conventional DAMs	baseline*, year 1*
<b>Maijer, 2013 (102)</b>	Netherlands	conference abstract	POS	N/A	Spearman's correlation with conventional DAMs	baseline*

<b>First author, year of publication</b>	<b>Country</b>	<b>Type of publication</b>	<b>Original study type</b>	<b>Treatment</b>	<b>Outcome</b>	<b>Timepoints of study</b>
<b>Reiss, 2016 (105)</b>	USA (California)	journal article	RCT	TCZ, MTX, GC	Spearman's correlation with conventional DAMs	baseline*, week 4, 12, 24*
<b>Roodenrijs, 2018 (106)</b>	Netherlands, UK	journal article	POS	RTX, GC	Spearman's correlation with conventional DAMs, therapy response <sup>++</sup>	baseline*, month 6*
<b>Studies included in the systematic review</b>						
<b>Boeters, 2019 (85)</b>	Netherlands	journal article	POS	csDMARDS, bDMARDS	relapse	annually
<b>Hambardzumyan, 2019 (89)</b>	Sweden	journal article	RCT	MTX, HCQ, SSZ, IFX	therapy response	month 0, 3
<b>He, 2020 (91)</b>	US	conference abstract	database analysis	DMARD	Pearson's correlation with conventional DAMs	baseline*
<b>Hirata, 2012 (92)</b>	Netherlands	conference abstract	RCT	N/A	remission	baseline, year 1
<b>Li, 2016 (98)</b>	Netherlands	journal article	POS	csDMARD, TNFi	predicting radiographic progression	annually

<b>First author, year of publication</b>	<b>Country</b>	<b>Type of publication</b>	<b>Original study type</b>	<b>Treatment</b>	<b>Outcome</b>	<b>Timepoints of study</b>
<b>Luedders, 2020 (99)</b>	USA (Nebraska)	journal article	POS	MTX, FA, GC, NSAID	Pearson's correlation with conventional DAMs, remission	baseline*, week 8, 16*
<b>Ma, 2020 (101)</b>	UK, Singapore	journal article	POS	csDMARDs, TNFi, GC	remission	baseline, month 3,6
<b>Markusse, 2014 (33)</b>	Netherlands	journal article	RCT	csDMARD, IFX, GC	predicting and discriminating radiographic progression	baseline, year 1
<b>Moghadam, 2018 (107)</b>	Netherlands	journal article	RCT	csDMARD	relapse	baseline, month 3, 6, 9, 12
<b>Razmjou, 2020 (103)</b>	USA (California)	journal article	POS	csDMARD, To facitinib	Pearson's correlation with conventional DAMs	baseline*, week 2, 6, 12*
<b>Rech, 2016 (104)</b>	Germany	journal article	RCT	csDMARDs, bDMARDs	relapse	baseline, month 3, 6, 9, 12

ADA-adalimumab; CsA-cyclosporin A; bDMARD-biological disease-modifying antirheumatic drug; csDMARD- conventional synthetic disease-modifying antirheumatic drug; ETN-etanercept; FA-folic acid; GC-glucocorticoid; HCQ-hydroxychloroquine; IFX-infliximab; MTX-methotrexate; N/A-no data available; NSAID- NonSteroidal Anti-Inflammatory Drug; PBO-placebo; POS-prospective observational study; RCT-randomized clinical trial; ReOS-retrospective observational study; RTX-rituximab; SSZ-sulfasalazine; TCZ-tocilizumab;TNFi-TNF-alpha-inhibitor


\* timepoint used for calculating correlation

+ timepoint used for calculating radiological progression

++ not included in the meta-analysis

### 8.1.2. Study II. – Investigating the efficacy of PRP in chronic wound management

Our systematic search provided a total of 2,688 articles; after duplicate removal, we screened 1,910 duplicate-free publications. Following the title, abstract and full-text selection, we identified 46 RCTs matching our population-intervention-control-outcome (PICO) framework (68-113) and two additional articles (114, 115) after citation search. The full text of 10 articles could not be retrieved even after contacting the authors (116-125). The summary of the selection process is shown in **Figure 2**.



**Figure 2.** PRISMA Flow Diagram of the screening and selection process for Study II. (67)

The characteristics of the identified RCTs for the systematic review and meta-analysis are detailed in **Table 2**.

**Table 2.** Main characteristics of the included studies for Study II. (67)

<b>First author, year of publication</b>	<b>Country</b>	<b>Ulcer etiology</b>	<b>Intervention</b>	<b>Control</b>	<b>Outcome</b>
<b>Studies included in the meta-analysis</b>					
<b>Abd El-Mabood, 2018 (110)</b>	Egypt	diabetic	topical PRP + conventional therapy	conventional therapy	complete closure, healing rate, infection, and pain
<b>Ahmed, 2017 (111)</b>	Egypt	diabetic	topical PRP + conventional therapy	conventional therapy	complete closure, healing rate, and infection
<b>Amato, 2020 (112)</b>	Italy	mixed	topical PRP + conventional therapy	conventional therapy	reduction of wound area, complete closure, infection, and pain
<b>Burgos-Alonso, 2018 (113)</b>	Spain	venous	topical PRP + conventional therapy	conventional therapy	reduction of wound area, complete closure, infection, pain, adverse events, and quality of life
<b>Driver, 2006 (114)</b>	US	diabetic	topical PRP + conventional therapy	conventional therapy	reduction of wound area, healing rate, complete closure, healing time, and adverse events
<b>Elbarbary, 2020 (115)</b>	India	venous	topical/injected PRP + conventional therapy	conventional therapy	reduction of wound area, complete closure, healing time, and recurrence
<b>Elgarhy, 2020 (116)</b>	India	venous	topical/injected PRP + conventional therapy	conventional therapy	reduction of wound area, complete closure, and healing time

<b>First author, year of publication</b>	<b>Country</b>	<b>Ulcer etiology</b>	<b>Intervention</b>	<b>Control</b>	<b>Outcome</b>
<b>Elsaid, 2020 (117)</b>	Egypt	diabetic	topical PRP + conventional therapy	conventional therapy	reduction of wound area, complete closure, and healing time
<b>Game, 2018 (118)</b>	UK	diabetic	topical PRP + conventional therapy	conventional therapy	reduction of wound area, complete closure, healing time, infection, pain, amputation, and adverse events
<b>Glukhov, 2017 (119)</b>	Russia	venous	topical PRP + conventional therapy	conventional therapy	complete closure, and pain
<b>Goda, 2018 1 (120)</b>	Egypt	diabetic	topical PRP + conventional therapy	topical PPP + conventional therapy	healing rate, and complete closure
<b>Goda, 2018 2 (121)</b>	Egypt	venous	topical PRP + conventional therapy	conventional therapy	reduction of wound area, and complete closure
<b>Gude, 2019 (122)</b>	US	diabetic	topical PRP + conventional therapy	conventional therapy	complete closure, and amputation
<b>Helmy, 2021 (123)</b>	Egypt	venous	PRP injection + conventional therapy	conventional therapy	reduction of wound area, complete closure, healing time, pain, adverse events, and recurrence
<b>Hongying, 2020 (124)</b>	China	pressure	PRP injection + conventional therapy	conventional therapy	reduction of wound area, and complete closure



<b>First author, year of publication</b>	<b>Country</b>	<b>Ulcer etiology</b>	<b>Intervention</b>	<b>Control</b>	<b>Outcome</b>
<b>Kakagia, 2007 (125)</b>	Greece	diabetic	topical PRP + conventional therapy	conventional therapy	reduction of wound area, and complete closure
<b>Karimi, 2016 (126)</b>	Iran	diabetic	topical PRP + conventional therapy	conventional therapy	reduction of wound area, complete closure, and amputation
<b>Li, 2015 (127)</b>	China	diabetic	topical PRP + conventional therapy	conventional therapy	reduction of wound area, complete closure, healing time, infection, amputation, and adverse events
<b>Moneib, 2018 (128)</b>	Egypt	venous	topical PRP + conventional therapy	conventional therapy	reduction of wound area, complete closure, pain, and adverse events
<b>Obolenskiy, 2014 (129)</b>	Russia	mixed	topical PRP + conventional therapy	conventional therapy	complete closure, and healing time
<b>Obolenskiy, 2017 (130)</b>	Russia	mixed	topical PRP + conventional therapy	conventional therapy	healing rate, complete closure, and healing time
<b>Rainys, 2019 (131)</b>	Lithuania	N/A	topical PRP + conventional therapy	conventional therapy	reduction of wound area, complete closure, infection, and adverse events
<b>Ramos-Torrecilla, 2015 (132)</b>	Spain	pressure	topical PRP + conventional therapy	conventional therapy	reduction of wound area, complete closure, and infection

<b>First author, year of publication</b>	<b>Country</b>	<b>Ulcer etiology</b>	<b>Intervention</b>	<b>Control</b>	<b>Outcome</b>
<b>Saad Setta, 2011 (133)</b>	Egypt	diabetic	topical PRP + conventional therapy	topical PPP + conventional therapy	complete closure, and healing time
<b>Saha, 2020 (134)</b>	India	leprosy	PRP injection + conventional therapy	conventional therapy	reduction of wound area, complete closure, and pain
<b>Senet, 2003 (135)</b>	France	venous	topical PRP + conventional therapy	conventional therapy	reduction of wound area, healing rate, complete closure, infection, and adverse events
<b>Singh, 2018 (136)</b>	India	diabetic	PRP injection + conventional therapy	conventional therapy	complete closure, healing time, amputation, and adverse events
<b>Singh, 2021 (137)</b>	India	pressure	PRP injection + conventional therapy	conventional therapy	reduction of wound area
<b>Sokolov, 2017 (138)</b>	Bulgaria	not defined	topical PRP + conventional therapy	conventional therapy	complete closure
<b>Somani, 2017 (139)</b>	India	venous	topical PRP + conventional therapy	conventional therapy	reduction of wound area, and complete closure
<b>Tsachiridi, 2019 (140)</b>	Greece	pressure	topical PRP + conventional therapy	conventional therapy	reduction of wound area, and healing rate

<b>First author, year of publication</b>	<b>Country</b>	<b>Ulcer etiology</b>	<b>Intervention</b>	<b>Control</b>	<b>Outcome</b>
<b>Yang, 2017 (141)</b>	China	diabetic	topical PRP + conventional therapy	conventional therapy	healing rate, healing time, infection, pain, and adverse events
<b>Yuvasri, 2020 (142)</b>	India	venous	topical PRP + conventional therapy	conventional therapy	reduction of wound area, and complete closure
<b>Studies included in the systematic review</b>					
<b>Alamdari, 2021 (143)</b>	Iran	diabetic	topical PRP + conventional therapy	conventional therapy	healing time, and amputation
<b>Anitua, 2008 (144)</b>	Spain	mixed	topical PRP + conventional therapy	conventional therapy	reduction of wound area, and infection
<b>Cardenosa, 2017 (145)</b>	Spain	venous	topical PRP + conventional therapy	conventional therapy	reduction of wound area, pain, and adverse events
<b>Chandanwale, 2020 (146)</b>	India	arterial	PRP injection + conventional therapy	conventional therapy	reduction of wound area
<b>de Oliveira, 2017 (147)</b>	Brazil	venous	topical PRP + conventional therapy	conventional therapy	reduction of wound area, and infection

<b>First author, year of publication</b>	<b>Country</b>	<b>Ulcer etiology</b>	<b>Intervention</b>	<b>Control</b>	<b>Outcome</b>
<b>Khorvash, 2017 (148)</b>	Iran	diabetic	topical PRP + conventional therapy	conventional therapy	reduction of wound area, infection, pain, and quality of life
<b>Kulkarni, 2019 (149)</b>	India	N/A	topical PRP + conventional therapy	conventional therapy	reduction of wound area, healing time, and adverse events
<b>Milek, 2019 (150)</b>	Poland	venous	topical PRP + conventional therapy	conventional therapy	reduction of wound area, and complete closure
<b>Mohammad, 2017 (151)</b>	Iran	diabetic	topical PRP + conventional therapy	conventional therapy	reduction of wound area
<b>Pires, 2021 (152)</b>	Brazil	venous	topical PRP + conventional therapy	conventional therapy	infection
<b>Pu, 2019 (153)</b>	China	arterial	topical PRP + conventional therapy	conventional therapy	reduction of wound area, healing rate, and amputation
<b>Qin, 2019 (154)</b>	China	diabetic	topical/injected PRP + conventional therapy	conventional therapy	reduction of wound area
<b>Semenic, 2018 (155)</b>	Slovenia	mixed	topical PRP + conventional therapy	conventional therapy	reduction of wound area, and adverse events
<b>Tsai, 2019 (156)</b>	US	mixed	topical/injected PRP	conventional therapy	reduction of wound area

---


<b>First author, year of publication</b>	<b>Country</b>	<b>Ulcer etiology</b>	<b>Intervention</b>	<b>Control</b>	<b>Outcome</b>
<b>Ucar, 2020 (157)</b>	Turkey	pressure	topical PRP + conventional therapy	conventional therapy	reduction of wound area

---

PRP-platelet-rich plasma, PPP-platelet-poor plasm

### 8.1.3. Study III. – Investigating the efficacy of PRP in the treatment of alopecia areata

Our systematic search provided a total of 2747 articles; after duplicate removal, we screened 2002 duplicate-free records. After the title, abstract and full-text selection, we identified 6 RCTs matching our PICO framework (57-62); of these articles, we could use 4 RCTs for our quantitative synthesis (57, 59-61). The summary of the selection process is shown in **Figure 3**.



**Figure 3.** PRISMA Flow Diagram of the screening and selection process for Study III. (68)

Characteristics of the identified RCTs for the systematic review and meta-analysis are detailed in **Table 3**.

**Table 3.** Main characteristics of the included studies for Study III. (68)

<b>First Author, Year of Publication</b>	<b>Country</b>	<b>Intervention</b>	<b>Control</b>	<b>Administration</b>	<b>Timepoints of evaluation (weeks)*</b>
<b>Studies included in the meta-analysis</b>					
<b>Albalat, 2019 (57)</b>	Egypt	PRP injection (double-spin method)	TrA injection (5 mg/ml)	3-5 sessions, 2-week intervals	12
<b>Fawzy, 2020 (59)</b>	Egypt	PRP injection (single-spin method)	TrA injection (5 mg/ml)	3 sessions, 4-week intervals	12
<b>Hegde, 2020 (60)</b>	India	PRP injection (double-spin method)	TrA injection (10 mg/ml), placebo	3 sessions, 4-week intervals	16
<b>Kapoor, 2020 (61)</b>	India	PRP injection (single-spin method)	TrA injection (10 mg/ml)	4 sessions, 3-week intervals	3, 6, 9, 12 <sup>+</sup> , 24
<b>Studies included in the systematic review</b>					
<b>Balakrishnan, 2020 (58)</b>	India	PRP injection (double-spin method)	TrA injection (10 mg/ml)	3 sessions, 4-week intervals	0, 4, 8, 12
<b>Trink, 2013 (62)</b>	Italy	PRP injection (single-spin method)	TrA injection (2,5 mg/ml), placebo	3 sessions, 4-week intervals	8, 24, 48

\* weeks after the first treatment session, <sup>+</sup>timepoint used in our calculations  
 PRP-platelet-rich plasma, TrA-triamcinolone acetone

## 8.2. Results of the quantitative analysis

### 8.2.1. Study I. – Investigating the utility of MBDA score for the monitoring of rheumatoid arthritis

#### 8.2.1.1. MBDA score for the assessment of disease activity

The studies that evaluated the utility of the MBDA score for monitoring disease activity examined the correlation between MBDA scores and conventional disease activity measures. Studies using Pearson's correlations could not be included in the meta-analysis due to a lack of statistical power, but are displayed in forest plots for visualization (see the Supplementary Material of the original publication) (66). The results of studies using Spearman's correlation are detailed below.

Six study groups of five publications (86, 88, 95, 105, 106) with a total of 667 subjects showed a moderate correlation between baseline MBDA score and baseline DAS28-CRP (COR = 0.45, CI: 0.28-0.59;  $I^2 = 71.0\%$ ) (see **Figure 4A**). Excluding conference abstracts from the analysis, similar results were observed; four publications (86, 95, 105, 106) with a total of 324 subjects demonstrated a moderate correlation between baseline MBDA score and baseline DAS28-CRP (COR = 0.46, CI: 0.10-0.72;  $I^2 = 81.0\%$ ) (66).

Assessing the correlations of baseline MBDA scores with baseline DAS28-ESR, a moderate correlation was found based on the results of two publications with a total of 127 subjects (COR = 0.55, CI: 0.19-0.78;  $I^2 = 0.0\%$ ) (see **Figure 4A**) (66).

Further metrics associated with disease activity (CRP, ESR, SJC28, TJC28, PtGA, CDAI, PDUS) showed low and moderate correlations, and are detailed in the Supplementary Material of the original publication (66).

Six study groups of four publications (88, 95, 105, 106) with a total of 287 subjects revealed a moderate correlation between follow-up MBDA score and follow-up DAS28-CRP (COR = 0.44, CI: 0.28-0.57;  $I^2 = 70.0\%$ ) (see **Figure 4B**). After the exclusion of conference abstracts from the analysis, three articles (95, 105, 106) with a total of 137 subjects showed a moderate correlation between baseline MBDA score and baseline DAS28-CRP (COR = 0.38, CI: -0.02-0.68;  $I^2 = 18.0\%$ ) (66).




The only study investigating the correlations of follow-up MBDA scores with follow-up DAS28-ESR found a moderate correlation (COR=0.49, CI: 0.22-0.69) between MBDA score and DAS28-ESR (**Figure 4B**) (66, 106).

Other parameters associated with disease activity (ESR, SJC28, TJC28, PtGA, PDUS) showed low-to-moderate correlations and are detailed in the Supplementary Material of the original publication (66).

Ten study groups of six articles (31, 87, 88, 95, 106, 109) with a total of 698 subjects demonstrated a moderate correlation between the change in MBDA score and the change of DAS28-CRP (COR = 0.40, CI: 0.32-0.48;  $I^2 = 19.0\%$ ). Seven study groups of six articles (84, 94, 97, 106, 108, 109) with a total of 543 subjects exhibited a moderate correlation between the change of MBDA score and the change of DAS28-ESR (COR = 0.56, CI: 0.51-0.60;  $I^2 = 71.0\%$ ) (see **Figure 4C**). Excluding conference abstracts from the analysis, similar results were recorded. The change of MBDA moderately correlates with the change of DAS28-CRP (COR = 0.43, CI: 0.25-0.59;  $I^2 = 47.0\%$ ) based on the results of six study groups of four publications (31, 95, 106, 109) with a total of 418 subjects, and with DAS28-ESR (COR = 0.52 CI: 0.43-0.60;  $I^2 = 0.0\%$ ) based on the results of four publications (94, 106, 108, 109) with a total of 298 subjects (66).


Further parameters linked to disease activity (CRP, CDAI, SDAI, HAQ) showed low-to-moderate correlations and are detailed in the Supplementary Material of the original publication (66).



**Figure 4.** Forest plot for the correlation of MBDA score with DAS28-CRP/ESR (A) Forest plot for the correlation of baseline MBDA score with baseline DAS28-CRP/ESR (B) Forest plot for the correlation of follow-up MBDA score with follow-up DAS28-CRP/ESR (C) Forest plot for the change of baseline MBDA score with the change of DAS28-CRP/ESR (66)


### 8.2.1.2. MBDA score for the assessment of radiographic progression

Three study groups of three articles with a total of 22 subjects showed a low correlation between baseline MBDA score and baseline SvdH score (COR = 0.13, CI: -0.25-0.47;  $I^2 = 79.0\%$ ), and five study groups of four articles with a total of 307 subjects demonstrated a low correlation between the change of MBDA score and the change of SvdH score (COR = 0.08, CI: -0.06-0.21;  $I^2 = 79.0\%$ ) as well (see **Figure 5**) (66).



**Figure 5.** Forest plots for the correlations of MBDA score with SvdH score (**A**) Forest plot for the correlation of baseline MBDA score with baseline SvdH score (**B**) Forest plot for the correlation of the change of MBDA score with the change of SvdH score (66)

When evaluating the predictive value of MBDA score for radiographic progression, three studies (30-32) with a total of 481 subjects showed that the odds of radiographic progression are significantly higher for patients with a high baseline MBDA score (>44) than for patients with a low baseline MBDA score (<30) (OR = 1.03, CI: 1.02-1.05;  $I^2 = 10.0\%$ ) (see **Figure 6A**). In contrast, the odds of progression for patients with a high baseline DAS28-CRP were not significantly higher than for patients with a low baseline DAS28-CRP (OR = 1.12, CI: 0.91-1.37;  $I^2 = 0.0\%$ ) (see **Figure 6B**) (66).



**Figure 6.** Forest plots for the predictive value of MBDA score and DAS28-CRP. for radiographic progression (A) Forest plot for the predictive value of MBDA score (B) Forest plot for the predictive value of DAS28-CRP (66)

The characteristics of the studies evaluating the predictive value of the MBDA score and DAS28-CRP for radiographic progression are detailed in **Table 4**.

**Table 4.** Characteristics of studies evaluating the predictive value of MBDA score and DAS28-CRP for radiographic progression (66)


<b>First author, year of publication</b>	<b>Time of evaluating RP</b>	<b>Definition of RP</b>	<b>Low MBDA score</b>	<b>High MBDA score</b>	<b>Low DAS28-CRP</b>	<b>High DAS28-CRP</b>
<i>Studies included in the meta-analysis</i>						
<b>Bakker, 2012 (30)</b>	2 years	>0 units increase of SvdH score	<30	>44	≤2.7	>2.7
<b>Brahe, 2019 (31)</b>	1 year	>2 units increase of SvdH score	<30	>44	≤5.1	>5.1
<b>Hambardzumyan, 2015 (32)</b>	1 year	>5 units increase of SvdH score	<30	>44	≤2.7	>4.1
<i>Studies included in the systematic review</i>						
<b>Bouman, 2017 (86)</b>	1.5 years	>0.5 units increase of SvdH score	<30	>44	<2.7	>4.1
<b>Hirata, 2016 (93)</b>	1 year	>3 units increase of SvdH score	<30	>44	≤3.2	>5.1
<b>Krabbe, 2017 (95)</b>	0.5, 1 year	N/A	<30	>44	≤3.2	>5.1
<b>Li, 2016 (98)</b>	1 year	>3 units increase of SvdH score	<30	>44	≤2.67	>4.09
<b>Markuse, 2014 (33)</b>	1 year	>0.5 units increase of SvdH score	<30	>44	≤2.4	>3.7

N/A-no data available; RP-radiographic progression; SvdH score- Sharp/van der Heijde score; MBDA score- Multi-biomarker Disease Activity score; CRP-C-reactive protein; : DAS28-CRP-Disease Activity Score with 28-joint count

## 8.2.2. Study II. – Investigating the efficacy of PRP in chronic wound management

### 8.2.2.1. Complete closure

Thirty-three study groups of 29 RCTs with a total of 2,198 wounds showed that the odds for complete closure were significantly higher in the PRP group than in the control group (OR=5.32; CI: 3.37; 8.40;  $I^2=58%$ ) (see **Figure 6**) (67).



**Figure 6.** Forest plot for complete closure, platelet-rich plasma compared to conventional ulcer therapy (67)

The visualized results of the subgroup analysis are detailed in the Supplementary Material of the original publication (67).

When subgrouping was based on ulcer etiologies, the odds for complete closure were significantly higher in the PRP group than in the control group, both in diabetic foot ulcers


(OR=2.26; CI: 1.50; 3.41;  $I^2=12.0\%$ ) as well as venous leg ulcers (OR=8.02; CI: 3.63; 17.71;  $I^2=10.0\%$ ). The test for subgroup difference showed a significant difference between the two groups ( $\chi^2=9.88$ ; df=1; p=0.002), the odds for complete closure were significantly higher in venous ulcers than in the diabetic foot ulcers treated with PRP (67).

Subgrouping based on the way of the application of PRP showed similar results. The odds for complete closure were significantly higher both in the topically applied (OR=4.74; CI: 2.87; 7.83;  $I^2=60\%$ ) and injected (OR=9.42; CI: 3.32; 26.76;  $I^2=0\%$ ) PRP groups than in the control group, with no significant subgroup difference ( $\chi^2=2.34$ ; df=1; p=0.126) (67).

The odds for complete closure were significantly higher in the PRP group than in the control group in the short (OR=6.03; CI: 3.21; 11.33;  $I^2=47\%$ ), medium (OR=3.38; CI: 1.15; 9.89;  $I^2=73\%$ ), and long (OR=8.24; CI: 1.66; 40.87;  $I^2=0\%$ ) follow-up categories as well with no significant subgroup differences ( $\chi^2=2.50$ ; df=3; p=0.476) (67).

#### 8.2.2.2. *Reduction of wound area*

Pooled SMDs from 18 study groups of 16 RCTs with a total of 1,062 wounds showed a significant difference between the post-treatment wound size of the PRP and the control groups (SMD = -1.21, CI: -1.74; -0.68;  $I^2 = 92.5\%$ ), the PRP group showing greater improvement (see **Figure 7**) (67).



**Figure 7.** Forest plot for the reduction of wound area, platelet-rich plasma compared to conventional ulcer therapy (67)

The visualized results of the subgroup analysis are detailed in the Supplementary Material of the original publication (67).


Subgrouping based on ulcer etiology, application method, and follow-up length showed similar results (67). The post-treatment wound size was significantly smaller in the PRP group than in the control group in diabetic (SMD = -0.68, CI: -1.31; -0.06;  $I^2 = 93.64\%$ ), venous (SMD = -1.26, CI: -2.28; -0.24;  $I^2 = 90.76\%$ ), topically applied (SMD = -0.94, CI: -1.43; -0.46;  $I^2 = 91.26\%$ ), and injected (SMD = -1.03, CI: -1.79; -0.26;  $I^2 = 86.63\%$ ) subgroups, as well as in the short follow-up subgroup (SMD = -1.00, CI: -1.64; -0.35;  $I^2 = 89.41\%$ ). However, the difference between the PRP and the control groups was not significant in the medium (SMD = -1.38, CI: -2.96; 0.19;  $I^2 = 54.51\%$ ), and long (SMD = -0.63, CI: -1.64; 0.37;  $I^2 = 93.88\%$ ) follow-up groups. No significant subgroup differences were recorded (67).



### 8.2.3. Study III. – Investigating the efficacy of PRP in the treatment of alopecia areata

#### 8.2.3.1. Reduction of SALT score

Two studies evaluated the post-treatment SALT score 12 weeks after the first treatment session (57, 59), one study 16 weeks after the first treatment session (60), and one at multiple timepoints: weeks 3, 6, 9, 12, and 24 (61) (see Table 1). We used the SALT score of the 12<sup>th</sup> week evaluation of this study for our meta-analytical calculations. Pooled MDs from four RCTs with a total of 201 subjects did not show a significant difference in mean change in SALT scores between the PRP and TrA groups (MD = - 2.04, CI: -4.72-0.65;  $I^2 = 80.4%$ ,  $p = 0.14$ ) (see **Figure 8**) (68).



**Figure 8.** Forest plot for mean decrease of SALT score, platelet-rich plasma (PRP) compared to triamcinolone acetonide (TrA) (68)

### 8.3. Qualitative analysis

The results of the studies that could not be included in the quantitative analyses are detailed in the discussion and in the systematic review sections of the original publications (66-68).

### 8.4. Quality assessment

#### 8.4.1. Study I. – Investigating the utility of MBDA score for the monitoring of rheumatoid arthritis

The majority of the outcomes of the studies included in the meta-analysis ( $n=79$ ) and the systematic review ( $n=37$ ) were rated as having a low or moderate risk of bias. The risk of bias was low in 35 outcomes of the studies included in the meta-analysis and 29 outcomes

of studies included in the systematic review; moderate in 32 outcomes of the studies included in the meta-analysis and five outcomes of studies included in the systematic review; and a high risk of bias was determined in 12 outcomes of studies included in the meta-analysis and three outcomes of studies included in the systematic review. Common methodological limitations across studies were attrition rates, study confounding, and statistical analysis and reporting.

The quality assessment scores for all outcomes are shown in the supplementary material of the original publications (66).

#### **8.4.2. Study II. – Investigating the efficacy of PRP in chronic wound management**

None of the studies included in the meta-analysis was at high risk of bias. In 30 studies (111-114, 119, 122, 123, 125, 127-130, 132, 133, 135, 137-142, 144, 146, 149-151, 154-157) the 'randomization process' domain, in 12 studies (112, 122, 124, 125, 127, 129, 133, 136, 139, 151, 154, 157) the 'deviations from intended interventions' domain, in one study (144) the 'missing outcome data' domain, in five studies (124, 125, 133, 151, 154) the 'measurement of the outcome' domain, and in eight studies (111, 122, 131, 132, 136, 139, 142, 147) the 'selection of the reported result' domain were rated as 'some concerns' for our primary outcome.

The results of the risk of bias assessment and the Summary of Findings table can be found in the supplementary material of the original publication (67).

#### **8.4.3. Study III. – Investigating the efficacy of PRP in the treatment of alopecia areata**

None of the studies included in the meta-analysis were at high risk of bias. In 3 articles the randomization process (57, 59, 61) and in two articles the measurement of the outcome (60, 61) were ranked as "some concerns". Deviation from the intended intervention, missing outcome data, and selection of the reported results domains were at low risk of bias. The quality of evidence was low for the primary outcome.

The results of the risk of bias assessment are detailed in the supplementary material of the original publication (68).

## 9. DISCUSSION

### 9.1. Summary of findings, international comparisons

Given the growing therapeutic advancements in dermatology and rheumatology, there is an increasing focus on not only assessing the effectiveness of novel treatments but also on monitoring disease activity to determine the most suitable treatment for each individual based on their specific disease status.

As that the treat-to-target therapeutic approach is essential for the treatment of RA and necessitates close monitoring of disease activity, the importance of objective score systems is indisputable. Our objective in conducting a systematic review and meta-analysis was to evaluate the effectiveness of the MBDA score in assessing disease activity, radiographic progression, remission, and relapse. Through this analysis, we aimed to provide valuable insights to support clinical decision-making and determine the suitability of the MBDA score in practical clinical settings.

We observed moderate correlations when analyzing the correlations between the MBDA score and conventional disease activity measures using a random-effects model, consistent with the findings of the meta-analysis of Johnson *et al.* (56). Both DAS28-CRP and DAS28-ESR, the gold standard DAMs in RA, showed moderate correlations with MBDA at baseline and follow-up, as well as in the change of DAS28-CRP and DAS28-ESR with the change of MBDA. Other DAMs detailed in the supplement of the original publication showed weaker correlations with MBDA score, except for CRP, as the correlation between the MBDA score and CRP alone was found to be stronger than with DAS28-CRP. (66). It is not surprising that the MBDA score deviates from conventional disease activity measures, as it does not incorporate clinical assessment results. However, since the purpose of the MBDA score is to complement rather than replace conventional disease activity measures, its deviation from such measures can even offer advantages (158).

Considering that the MBDA score, in addition to the inflammatory markers found in currently-used disease activity measures like CRP, includes markers indicating cartilage and bone damage such as MMP-3, there is a realistic possibility that the MBDA score may surpass conventional measures in accurately predicting radiological progression

(159). Based on the findings of our meta-analysis, it appears that the MBDA score can serve as an independent predictor of radiological progression. Our results indicate a significant increase in the odds of radiographic progression for patients with a high baseline MBDA score compared to those with a low baseline MBDA score. In contrast, there was no significant difference in radiographic progression between low- and high-baseline DAS28-CRP groups. It should be noted, however, that the included studies utilized consistent cutoff values for defining high and low MBDA scores, while different cutoff values were employed for defining DAS28-CRP subgroups. This discrepancy in cutoff values may have an impact on the results, underscoring the need for further investigation in this area. Moreover, our analysis revealed a weak correlation between the SvdH score and the MBDA score at both baseline and follow-up, suggesting that caution should be exercised when interpreting these data. These findings align with the results of the studies included in our systematic review and are consistent with the previous meta-analysis by Curtis *et al.* and the systematic review by Abdelhafiz *et al.* (160, 161).

While the efficacy of the newly emerging biologics is indisputable, the significance of alternative treatments that are cost-effective, repeatable, and more widely available should not be overlooked. PRP therapy offers ease of application and demonstrates versatility in addressing various dermatological conditions, thereby providing a potential treatment option for a wide range of patients.

The management of chronic ulcers is a serious problem worldwide and places a heavy burden on the health care system. On the basis of our systematic review and meta-analysis, PRP is an effective add-on treatment modality to enhance wound healing. The PRP group demonstrated significantly higher odds of achieving complete wound closure compared to the control group. Additionally, PRP treatment led to a significantly greater reduction in wound area when compared to conventional therapy.

Subgroup analyses were conducted in order to reduce heterogeneity, and these analyses yielded similar results while also highlighting differences based on ulcer etiologies and PRP application methods. Injected PRP appeared to have a greater impact on improvement compared to topically applied PRP. However, it is important to exercise caution when drawing conclusions from this subgroup analysis due to the relatively small sample size. Regarding ulcer etiologies, PRP demonstrated superiority over conventional

therapy in terms of complete closure and reduction of wound area for both diabetic and venous ulcers, however, better outcomes were observed in the venous ulcer group. This phenomenon could be attributed to the fact that diabetic ulcers tend to be more challenging to heal. Additionally, the higher frequency of injected PRP administration in the venous ulcer group may have contributed to the better results observed in this subgroup. Furthermore, the effectiveness of PRP was demonstrated across various follow-up times, including short, medium, and long durations, in achieving complete closure of the ulcers.

PRP also showed promising results in the treatment of AA. The studies included in our systematic review and meta-analysis all showed a significant decrease in SALT score in the PRP and TrA groups as well (57-62). Pooled MDs from the four RCTs did not show a significant difference in mean change in SALT score between the PRP and TrA groups. Although we could not conduct a meta-analysis comparing PRP to placebo, the included studies all concluded the superiority of PRP treatment (60, 62). The obtained results provide evidence of the effectiveness of PRP as an alternative steroid-free treatment approach, however, it is essential to consider various factors that might have influenced these outcomes, including variations in TrA dosages and differences in the duration of follow-up periods. The strength of the effect of TrA can be dose-dependent: RCTs investigating the optimal dilution of TrA have revealed that the 10 mg/ml dose elicits the most favorable therapeutic response. Nonetheless, considering the escalating risk of adverse effects associated with increasing doses, it is recommended to commence treatment with lower doses. (162, 163). Two of the four studies included in our meta-analysis used 5 mg/ml TrA, and two studies used 10 mg/ml TrA as a comparator (61). The decrease in SALT score was higher in the studies using a higher dose of TrA, however, one of the latter studies registered atrophy in five cases, assumably due to the higher doses of TrA. In contrast, PRP can be utilized for an unlimited number of treatment sessions without heightening the risk of adverse effects (57, 58, 60-62).

## **9.2. Strengths**

There are several strengths of our studies. We implemented a rigorous methodology to achieve the highest quality of evidence and provide a structured analysis of the outcomes discussed in the literature. We provide a comprehensive summary on the utility of MBDA

score for the monitoring of RA disease activity and also the predictive and discriminative value of MBDA score for radiographic progression, therapy response, remission and relapse. We summarized the latest evidence including only RCTs on the wound healing properties of PRP for the management of chronic wounds assessing the most objective outcome measure, the change of the wound area; and also on the efficacy of PRP in the treatment of AA.

### **9.3. Limitations**

Our main limitation is the heterogeneity of the populations. In our first study, a wide range of anti-rheumatic drugs was used in the included publications, with potentially varying effects on the MBDA score: by inhibiting receptor binding, the IL-6 receptor-blocker tocilizumab may increase the serum level of IL-6, thus affecting the change in MBDA score via one of the 12 included biomarkers (105). TNF inhibitors can potentially have an indirect impact on the MBDA score as well, by reducing the serum level of TNF-alpha. Hirata *et al.* compared anti-TNF-alpha and anti-TNF-alpha-receptor drugs, revealing no significant difference between the two groups, however, additional research is required to evaluate the influence of targeted therapies on the serum levels of the biomarkers incorporated in the MBDA score, and consequently, their impact on the alteration of the MBDA score (93). Moreover, the utilization of varying follow-up times to evaluate disease activity can contribute to increased heterogeneity. In our second study, the principal factor for the substantial heterogeneity is likely the divergence in control groups, encompassing a wide array of dressings utilized as part of conventional therapy. In our third study, apart from the limited sample size, the heterogeneity could be attributed to the different PRP preparation methods employed across the included studies. Previous research has demonstrated the superiority of the double-spin preparation method over the single-spin method, which could potentially contribute to the observed heterogeneity (164, 165).

## **10. CONCLUSION**

The utilization of the MBDA score in the management of RA patients holds significant value, serving as a valuable tool for monitoring disease activity and predicting radiological progression. However, to further enhance our understanding of the utility of the MBDA score and the specific contributions of individual biomarkers in disease activity monitoring, additional studies are warranted. These future investigations will provide valuable insights and contribute to the ongoing advancement of RA patient care

PRP has demonstrated both safety and efficacy as a modality for promoting wound healing. Its integration into clinical practice has the potential to transform it into a widely utilized and valuable tool. By leveraging the benefits of PRP, patients' quality of life can be enhanced while simultaneously reducing the healthcare burden associated with wound management.

PRP offers a promising alternative as a topical steroid-free treatment option for AA. While no significant difference was observed between PRP and conventional treatment (TrA), it is imperative to conduct further high-quality RCTs to better evaluate the efficacy of PRP and enhance the strength of the existing evidence.

## **11. IMPLEMENTATION FOR PRACTICE**

The early application of research results in clinical practice has an unequivocal importance (166, 167).

By implementing the use of MBDA score in clinical practice, the personalized treatment of RA patients could be further improved. Applied together with the currently used DAMs, MBDA score would be an objective addition that could help clinicians' decision-making regarding therapy modifications. As a promising predictor of radiographic progression, MBDA score could also influence initial therapeutic choices following the establishment of the diagnosis, urging the earlier use of highly potent therapies in case of a potentially higher chance for radiographic progression.

Due to its wound healing properties, platelet-rich plasma could become a widely used, valuable tool in chronic wound management. PRP can be administered topically or intralesionally, and it can also be used in conjunction with a diverse range of smart dressings. This versatility allows for personalized treatment approaches, offering physicians a multitude of options to tailor the therapy according to individual patient needs. As a steroid free therapeutic modality for treatment of AA, PRP can be used in a virtually unlimited number of treatment sessions without increasing the risk of steroid-specific adverse effects (57, 58, 60-62). The adverse effects associated with TrA treatment, such as atrophy, teleangiectasiae, and hypopigmentation, can pose particular challenges when treating the facial region. Given that PRP is safely employed in facial rejuvenation procedures, it may present an optimal therapeutic option for localized AA affecting the face (55, 168, 169). In the context of the facial region and extensive cases of AA, employing PRP in conjunction with microneedling or fractional carbon dioxide laser treatment may offer a more tolerable way of administration (170).



## 12. IMPLEMENTATION FOR RESEARCH

To facilitate a more comprehensive analysis and promote the adoption of the MBDA score in daily clinical practice, future studies should consider including a larger patient cohort, standardizing the follow-up duration for evaluation, and establishing consistent cut-off values of DAS28-CRP for defining remission. These measures would enhance the assessment of the MBDA score's utility and provide a more robust foundation for its implementation in clinical settings.

To enable further comprehensive analysis on the efficacy of PRP in chronic wound management, it is important for future studies to report their outcomes in a standardized manner. Specifically, the change in wound size should be consistently recorded as the most objective measure of PRP efficacy, with baseline and post-treatment wound area always reported. However, there is a need for better reporting guidelines that include detailed descriptive statistics such as median and interquartile range in addition to mean and standard deviation. Moreover, the methods used to measure wound size can introduce bias. Chronic wounds commonly affect the leg, and simple photographic measurements may not account for the overall leg circumference affected by the wound. Additionally, assessing wound size solely based on width and length can yield inaccurate results due to the asymmetrical nature of ulcer areas. We suggest that a precise measurement approach involves tracing the wound outline on carbon paper, which can be digitalized for further calculations. In addition to baseline and post-treatment wound area, the number of completely closed wounds is a critical outcome measure that demonstrates treatment efficacy and should always be reported.

Regarding the use of PRP in AA, the limited evidence warrants further high-quality RCTs to accurately assess its efficacy. The implementation of objective and comparable outcome measurements beyond the SALT score could help evaluate complete remission, recurrence rates, and adverse effects more effectively. This would contribute to a better understanding of the benefits and drawbacks of each treatment modality and enable future systematic analyses using these parameters to enhance the quality of the existing evidence. Furthermore, future RCTs should focus on comparing PRP with different doses of TrA. While higher doses of TrA may lead to greater improvement, they can also increase the risk of adverse effects (162, 163). Opting for a steroid-free treatment such as

PRP as the primary choice can offer potential benefits, even if the rate of improvement is relatively slower. Implementing longer follow-up protocols extending beyond 4 months would allow for the observation of additional differences between the two treatment modalities. This extended duration would enable a more comprehensive assessment of complete remission and recurrence rates, providing a clearer understanding of the relative effectiveness of each approach.

### **13. IMPLEMENTATION FOR POLICYMAKERS**

It is imperative for policymakers to emphasize the importance of disease monitoring and the integration of new therapies into healthcare systems. By recognizing the value of disease monitoring, policymakers can support its implementation and encourage healthcare facilities to adopt effective monitoring systems. This entails allocating resources to ensure the availability and accessibility of novel therapies in various healthcare settings, enabling patients to benefit from the latest advancements. Policymakers can also play a crucial role in revising and updating guidelines to reflect emerging evidence and best practices. By actively engaging in policy decisions, policymakers can facilitate the necessary changes to enhance disease monitoring and promote the integration of new therapies into clinical practice.

#### **14. FUTURE PERSPECTIVES**

Looking ahead, the future holds promising opportunities for the utilization of MBDA score and PRP. The adoption of objective disease monitoring systems, such as the MBDA score or similar methodologies, presents compelling possibilities within the realm of rheumatology. Furthermore, with its regenerative properties, PRP shows potential for delivering therapeutic benefits in a wide range of diseases.

**15. REFERENCES**

1. Rencz F, Gulácsi L, Péntek M, Wikonkál N, Baji P, Brodszky V. (2016) Alopecia areata and health-related quality of life: a systematic review and meta-analysis. *Br J Dermatol*, 175: 561-571.
2. Rajabi F, Drake LA, Senna MM, Rezaei N. (2018) Alopecia areata: a review of disease pathogenesis. *Br J Dermatol*, 179: 1033-1048.
3. Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R. (2020) Hair follicle immune privilege and its collapse in alopecia areata. *Exp Dermatol*, 29: 703-725.
4. Paus R, Slominski A, Czarnetzki BM. (1993) Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? *Yale J Biol Med*, 66: 541-554.
5. Todes-Taylor N, Turner R, Wood GS, Stratte PT, Morhenn VB. (1984) T cell subpopulations in alopecia areata. *J Am Acad Dermatol*, 11: 216-223.
6. Sundberg JP, Cordy WR, King LE, Jr. (1994) Alopecia areata in aging C3H/HeJ mice. *J Invest Dermatol*, 102: 847-856.
7. McElwee KJ, Hoffmann R. (2002) Alopecia areata - animal models. *Clin Exp Dermatol*, 27: 410-417.
8. Prie BE, Voiculescu VM, Ionescu-Bozdog OB, Petrutescu B, Iosif L, Gaman LE, Clatici VG, Stoian I, Giurcaneanu C. (2015) Oxidative stress and alopecia areata. *J Med Life*, 8 Spec Issue: 43-46.
9. Bakry OA, Elshazly RM, Shoeib MA, Gooda A. (2014) Oxidative stress in alopecia areata: a case-control study. *Am J Clin Dermatol*, 15: 57-64.
10. Smolen JS, Aletaha D, McInnes IB. (2016) Rheumatoid arthritis. *Lancet*, 388: 2023-2038.
11. Scherer HU, Häupl T, Burmester GR. (2020) The etiology of rheumatoid arthritis. *Journal of Autoimmunity*, 110: 102400.
12. McInnes IB, Schett G. (2011) The pathogenesis of rheumatoid arthritis. *N Engl J Med*, 365: 2205-2219.
13. Kapp S, Miller C, Santamaria N. (2018) The quality of life of people who have chronic wounds and who self-treat. *J Clin Nurs*, 27: 182-192.
14. Phillips CJ, Humphreys I, Fletcher J, Harding K, Chamberlain G, Macey S. (2016) Estimating the costs associated with the management of patients with chronic wounds using linked routine data. *Int Wound J*, 13: 1193-1197.
15. Morton LM, Phillips TJ. (2016) Wound healing and treating wounds: Differential diagnosis and evaluation of chronic wounds. *J Am Acad Dermatol*, 74: 589-605; quiz 605-586.
16. Zhao R, Liang H, Clarke E, Jackson C, Xue M. (2016) Inflammation in Chronic Wounds. *Int J Mol Sci*, 17.
17. Velnar T, Bailey T, Smrkolj V. (2009) The wound healing process: an overview of the cellular and molecular mechanisms. *J Int Med Res*, 37: 1528-1542.

18. Eming SA, Krieg T, Davidson JM. (2007) Inflammation in wound repair: molecular and cellular mechanisms. *J Invest Dermatol*, 127: 514-525.
19. Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, Turner M, Sutton C, Smith DR, Haney DJ, Chernoff D, Hesterberg LK, Carulli JP, Taylor PC, Shadick NA, Weinblatt ME, Curtis JR. (2013) Development of a multi-biomarker disease activity test for rheumatoid arthritis. *PLoS One*, 8: e60635.
20. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgerit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruysen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D. (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 79: 685-699.
21. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*, 68: 1-25.
22. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis*, 75: 3-15.
23. Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Pchelnikova P, Blaas E, Senolt L, Szekanecz Z, Choy EH, Dougados M, Jacobs JW, Geenen R, Bijlsma JW, Zink A, Aletaha D, Schoneveld L, van Riel P, Dumas S, Prior Y, Nikiphorou E, Ferraccioli G, Schett G, Hyrich KL, Mueller-Ladner U, Buch MH, McInnes IB, van der Heijde D, van Laar JM. (2022) EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. *Ann Rheum Dis*, 81: 20-33.
24. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum*, 39: 34-40.

25. Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS. (2012) Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. *Ann Rheum Dis*, 71: 1190-1196.
26. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS. (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. *Arthritis Res Ther*, 7: R796-806.
27. van der Heijde D. (2000) How to read radiographs according to the Sharp/van der Heijde method. *J Rheumatol*, 27: 261-263.
28. Scott DL. (2004) Radiological progression in established rheumatoid arthritis. *J Rheumatol Suppl*, 69: 55-65.
29. Barra L, Bykerk V, Pope JE, Haraoui BP, Hitchon CA, Thorne JC, Keystone EC, Boire G. (2013) Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. *J Rheumatol*, 40: 1259-1267.
30. Bakker MF, Cavet G, Jacobs JW, Bijlsma JW, Haney DJ, Shen Y, Hesterberg LK, Smith DR, Centola M, van Roon JA, et al. (2012) Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. *Annals of the rheumatic diseases*, 71: 1692-1697.
31. Brahe CH, Østergaard M, Johansen JS, Defranoux N, Wang X, Bolce R, Sasso EH, Ørnberg LM, Hørslev-Petersen K, Stengaard-Pedersen K, et al. (2019) Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. *Scandinavian journal of rheumatology*, 48: 9-16.
32. Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, Forslind K, Petersson IF, Geborek P, van Vollenhoven RF. (2015) Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. *Annals of the rheumatic diseases*, 74: 1102-1109.
33. Markusse IM, Dirven L, van den Broek M, Bijkerk C, Han KH, Roday HK, Bolce R, Sasso EH, Kerstens PJ, Lems WF, et al. (2014) A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study. *Journal of rheumatology*, 41: 2114-2119.
34. Kingsley CS. (1954) Blood coagulation; evidence of an antagonist to factor VI in platelet-rich human plasma. *Nature*, 173: 723-724.
35. Mariani E, Pulsatelli L. (2020) Platelet Concentrates in Musculoskeletal Medicine. *Int J Mol Sci*, 21.
36. Everts PA, Knape JT, Weibrich G, Schönberger JP, Hoffmann J, Overdevest EP, Box HA, van Zundert A. (2006) Platelet-rich plasma and platelet gel: a review. *J Extra Corpor Technol*, 38: 174-187.

37. Li ZJ, Choi HI, Choi DK, Sohn KC, Im M, Seo YJ, Lee YH, Lee JH, Lee Y. (2012) Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. *Dermatol Surg*, 38: 1040-1046.
38. Hesseler MJ, Shyam N. (2019) Platelet-rich plasma and its utility in medical dermatology: A systematic review. *J Am Acad Dermatol*, 81: 834-846.
39. Eppley BL, Woodell JE, Higgins J. (2004) Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. *Plast Reconstr Surg*, 114: 1502-1508.
40. Mlynarek RA, Kuhn AW, Bedi A. (2016) Platelet-Rich Plasma (PRP) in Orthopedic Sports Medicine. *Am J Orthop (Belle Mead NJ)*, 45: 290-326.
41. Alio JL, Arnalich-Montiel F, Rodriguez AE. (2012) The role of "eye platelet rich plasma" (E-PRP) for wound healing in ophthalmology. *Curr Pharm Biotechnol*, 13: 1257-1265.
42. Simonpieri A, Del Corso M, Vervelle A, Jimbo R, Inchingolo F, Sammartino G, Dohan Ehrenfest DM. (2012) Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 2: Bone graft, implant and reconstructive surgery. *Curr Pharm Biotechnol*, 13: 1231-1256.
43. Del Corso M, Vervelle A, Simonpieri A, Jimbo R, Inchingolo F, Sammartino G, Dohan Ehrenfest DM. (2012) Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 1: Periodontal and dentoalveolar surgery. *Curr Pharm Biotechnol*, 13: 1207-1230.
44. Streit-Ciećkiewicz D, Kołodyńska A, Futyma-Gąbka K, Grzybowska ME, Gołacki J, Futyma K. (2022) Platelet Rich Plasma in Gynecology-Discovering Undiscovered-Review. *Int J Environ Res Public Health*, 19.
45. Alkandari MH, Touma N, Carrier S. (2022) Platelet-Rich Plasma Injections for Erectile Dysfunction and Peyronie's Disease: A Systematic Review of Evidence. *Sex Med Rev*, 10: 341-352.
46. Israeli JM, Lokeshwar SD, Efimenko IV, Masterson TA, Ramasamy R. (2022) The potential of platelet-rich plasma injections and stem cell therapy for penile rejuvenation. *Int J Impot Res*, 34: 375-382.
47. Xiao H, Xu D, Mao R, Xiao M, Fang Y, Liu Y. (2021) Platelet-Rich Plasma in Facial Rejuvenation: A Systematic Appraisal of the Available Clinical Evidence. *Clin Cosmet Investig Dermatol*, 14: 1697-1724.
48. Hesseler MJ, Shyam N. (2019) Platelet-rich plasma and its utility in the treatment of acne scars: A systematic review. *J Am Acad Dermatol*, 80: 1730-1745.
49. Qu W, Wang Z, Hunt C, Morrow AS, Urtecho M, Amin M, Shah S, Hasan B, Abd-Rabu R, Ashmore Z, Kubrova E, Prokop LJ, Murad MH. (2021) The Effectiveness and Safety of Platelet-Rich Plasma for Chronic Wounds: A Systematic Review and Meta-analysis. *Mayo Clin Proc*, 96: 2407-2417.



50. Gupta AK, Cole J, Deutsch DP, Everts PA, Niedbalski RP, Panchaprateep R, Rinaldi F, Rose PT, Sinclair R, Vogel JE, Welter RJ, Zufelt MD, Puig CJ. (2019) Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia. *Dermatol Surg*, 45: 1262-1273.
51. Powers JG, Higham C, Broussard K, Phillips TJ. (2016) Wound healing and treating wounds: Chronic wound care and management. *J Am Acad Dermatol*, 74: 607-625; quiz 625-606.
52. Fukumoto T, Fukumoto R, Magno E, Oka M, Nishigori C, Horita N. (2021) Treatments for alopecia areata: A systematic review and network meta-analysis. *Dermatol Ther*, 34: e14916.
53. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. (2012) British Association of Dermatologists' guidelines for the management of alopecia areata 2012. *Br J Dermatol*, 166: 916-926.
54. Meah N, Wall D, York K, Bhojrul B, Bokhari L, Sigall DA, Bergfeld WF, Betz RC, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Donovan J, Eisman S, Farrant P, Green J, Grimalt R, Harries M, Hordinsky M, Irvine AD, Itami S, Jolliffe V, King B, Lee WS, McMichael A, Messenger A, Mirmirani P, Olsen E, Orlow SJ, Piraccini BM, Rakowska A, Reygagne P, Roberts JL, Rudnicka L, Shapiro J, Sharma P, Tosti A, Vogt A, Wade M, Yip L, Zlotogorski A, Sinclair R. (2020) The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. *J Am Acad Dermatol*, 83: 123-130.
55. Contento M, Cline A, Russo M. (2021) Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions. *Am J Clin Dermatol*, 22: 837-851.
56. Johnson TM, Register KA, Schmidt CM, O'Dell JR, Mikuls TR, Michaud K, England BR. (2019) Correlation of the Multi-Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis. *Arthritis Care Res (Hoboken)*, 71: 1459-1472.
57. Albalat W, Ebrahim HM. (2019) Evaluation of platelet-rich plasma vs intralesional steroid in treatment of alopecia areata. *Journal of cosmetic dermatology*, 18: 1456-1462.
58. Balakrishnan A, Joy B, Thyvalappil A, Mathew P, Sreenivasan A, Sridharan R. (2020) A comparative study of therapeutic response to intralesional injections of platelet-rich plasma versus triamcinolone acetonide in alopecia areata. *INDIAN DERMATOLOGY ONLINE JOURNAL*, 11: 920-924.
59. Fawzy MM, Abdel Hay R, Mohammed FN, Sayed KS, Ghanem MED, Ezzat M. (2021) Trichoscopy as an evaluation method for alopecia areata treatment: A comparative study. *Journal of Cosmetic Dermatology*, 20: 1827-1836.
60. Hegde P, Relhan V, Sahoo B, Garg VK. (2020) A randomized, placebo and active controlled, split scalp study to evaluate the efficacy of platelet-rich plasma in patchy alopecia areata of the scalp. *Dermatologic therapy*, 33: e14388.
61. Kapoor P, Kumar S, Brar BK, Kukar N, Arora H, Brar SK. (2020) Comparative Evaluation of Therapeutic Efficacy of Intralesional Injection of Triamcinolone

- Acetonide versus Intralesional Autologous Platelet-rich Plasma Injection in Alopecia Areata. *J Cutan Aesthet Surg*, 13: 103-111.
62. Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, Rinaldi F. (2013) A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. *British journal of dermatology*, 169: 690-694.
  63. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*, 372: n71.
  64. Chandler J, Hopewell S. (2013) Cochrane methods - twenty years experience in developing systematic review methods. *Systematic Reviews*, 2: 76.
  65. Debray TP, Damen JA, Snell KI, Ensor J, Hooft L, Reitsma JB, Riley RD, Moons KG. (2017) A guide to systematic review and meta-analysis of prediction model performance. *Bmj*, 356: i6460.
  66. Meznerics FA, Kemény LV, Gunther E, Bakó E, Dembrovszky F, Szabó B, Ascsillán A, Lutz E, Csupor D, Hegyi P, Bánvölgyi A, Nagy G. (2023) Multi-biomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis. *Rheumatology (Oxford)*, 62: 2048-2059.
  67. Meznerics FA, Fehérvári P, Dembrovszky F, Kovács KD, Kemény LV, Csupor D, Hegyi P, Bánvölgyi A. (2022) Platelet-Rich Plasma in Chronic Wound Management: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *J Clin Med*, 11.
  68. Meznerics FA, Illés K, Dembrovszky F, Fehérvári P, Kemény LV, Kovács KD, Wikonkál NM, Csupor D, Hegyi P, Bánvölgyi A. (2022) Platelet-Rich Plasma in Alopecia Areata-A Steroid-Free Treatment Modality: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *Biomedicines*, 10.
  69. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. (2013) Assessing bias in studies of prognostic factors. *Ann Intern Med*, 158: 280-286.
  70. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernan MA, Hopewell S, Hrobjartsson A, Junqueira DR, Juni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*, 366: l4898.
  71. Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, McGinn T, Hayden J, Williams K, Shea B, Wolff R, Kujpers T, Perel P, Vandvik PO, Glasziou P, Schunemann H, Guyatt G. (2015) Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. *BMJ*, 350: h870.

72. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2022. Available from [gradepro.org](http://gradepro.org)
73. Team RC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2022.
74. Schwarzer G. meta: General Package for Meta-Analysis, 2022.
75. Cuijpers P, Furukawa T, Ebert DD. dmetar: Companion R Package for the Guide Doing Meta-Analysis in R, 2022.
76. Mantel N, Haenszel W. (1959) Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease. *JNCI: Journal of the National Cancer Institute*, 22: 719-748.
77. Robins J, Greenland S, Breslow NE. (1986) A general estimator for the variance of the Mantel-Haenszel odds ratio. *Am J Epidemiol*, 124: 719-723.
78. Thompson SG, Turner RM, Warn DE. (2001) Multilevel models for meta-analysis, and their application to absolute risk differences. *Statistical Methods in Medical Research*, 10: 375-392.
79. *The handbook of research synthesis and meta-analysis*. Russell Sage Foundation, New York, 2009.
80. J. Sweeting M, J. Sutton A, C. Lambert P. (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Statistics in Medicine*, 23: 1351-1375.
81. Higgins JPT, Thompson SG. (2002) Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine*, 21: 1539-1558.
82. Baker JF, Curtis JR, Chernoff D, Flake DD, 2nd, Sasso E, Long J, Taratuta E, George MD. (2021) Evaluation of the impact of age and adiposity on a multi-biomarker disease activity score before and after adjustment. *Clin Rheumatol*, 40: 2419-2426.
83. Bechman K, Tweehuysen L, Garrood T, Scott DL, Cope AP, Galloway JB, Ma MHY. (2018) Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes. *J Rheumatol*, 45: 1515-1521.
84. Bijlsma JWJ, Jurgens MS, Jacobs JWJ, Bakker M, Lafeber FPJ, Welsing PMJ, Cavet G, Chernoff D, Sasso EH, Li W, Haney DJ. (2013) Response to MTX plus prednisone in camera II using A multi-biomarker disease activity (Vectratm Da ) test and DA S28-ESR. *Annals of the Rheumatic Diseases*, 72: A80.
85. Boeters DM, Burgers LE, Sasso EH, Huizinga TWJ, van der Helm-van Mil AHM. (2019) ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. *Arthritis Res Ther*, 21: 121.
86. Bouman CAM, van der Maas A, van Herwaarden N, Sasso EH, van den Hoogen FHJ, den Broeder AA. (2017) A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive

- value for clinical and radiographic outcomes. *Rheumatology (Oxford, England)*, 56: 973-980.
87. Brahe CH, Ostergaard M, Johansen J, Defranoux N, Hwang CC, Bolce R, Sasso E, Horslev-Petersen K, Steengaard-Pedersen K, Junker P, et al. (2016) Changes in multi-biomarker disease activity (MBDA) score correlate with changes in established disease activity measurements in patients with early RA from the opera study. *Annals of the rheumatic diseases*, 75: 450-.
  88. Genovese MC, Galien R, Pan Y, Van Der Aa A, Jamoul C, Harrison P, Tasset C, Goyal L, Li W, Tarrant J. (2017) Correlation of multi-biomarker disease activity score with clinical disease activity measures for the jak1-selective inhibitor filgotinib as monotherapy and in combination with methotrexate in rheumatoid arthritis patients. *Arthritis and Rheumatology*, 69.
  89. Hambardzumyan K, Bolce RJ, Wallman JK, van Vollenhoven RF, Saevarsdottir S. (2019) Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: results from the SWEFOT Trial. *Journal of rheumatology*, 46: 555-563.
  90. Hambardzumyan K, Saevarsdottir S, Bolce R, Forslind K, Ernestam S, Petersson I, Geborek P, Chernoff D, Haney D, Sasso EH, et al. (2013) Multi-biomarker disease activity (MBDA) score and the 12 individual biomarkers in early rheumatoid arthritis patients relate differentially to clinical response and radiographic progression: results from the swefot trial. *Annals of the rheumatic diseases*, 72.
  91. He E, Yalamanchi P, Arnold W, Arnold E. (2020) Assessment of the Components of RAPID3 Patient Reported Outcomes in an Community Rheumatology Practice. *Arthritis and Rheumatology*, 72: 3484-3485.
  92. Hirata S, Dirven L, Cavet G, Centola M, Lems WF, Tanaka Y, Huizinga TW, Allaart CF. (2012) A multi-biomarker disease activity score (the vectra DA algorithm score) reflects clinical remission for rheumatoid arthritis (RA) in the best study. *Annals of the Rheumatic Disease*, 71.
  93. Hirata S, Li W, Kubo S, Fukuyo S, Mizuno Y, Hanami K, Sawamukai N, Yamaoka K, Saito K, Defranoux NA, Tanaka Y. (2016) Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. *Mod Rheumatol*, 26: 850-856.
  94. Jurgens MS, Safy-Khan M, de Hair MJH, Bijlsma JWJ, Welsing PMJ, Tekstra J, Lafeber F, Sasso EH, Jacobs JWG. (2020) The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial. *Arthritis research & therapy*, 22: 205.
  95. Krabbe S, Bolce R, Brahe CH, Døhn UM, Ejbjerg BJ, Hetland ML, Sasso EH, Chernoff D, Hansen MS, Knudsen LS, Hansen A, Madsen OR, Hasselquist M, Møller J, Østergaard M. (2017) Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging,

- computed tomography, ultrasonography, and radiography parameters of inflammation and damage. *Scand J Rheumatol*, 46: 353-358.
96. Lee YC, Hackett J, Frits M, Iannaccone CK, Shadick NA, Weinblatt ME, Segurado OG, Sasso EH. (2016) Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. *Rheumatology (Oxford)*, 55: 640-648.
  97. Li W, Hensvold AH, Saevarsdottir S, Defranoux NA, Klareskog L, Catrina AI. (2013) Characterization of the multi-biomarker disease activity (vectra da™ algorithm) score in a subgroup of patients from the epidemiological investigation of rheumatoid arthritis (EIRA) cohort receiving methotrexate. *Annals of the Rheumatic Diseases*, 72.
  98. Li W, Sasso EH, van der Helm-van Mil AH, Huizinga TW. (2016) Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. *Rheumatology (Oxford)*, 55: 357-366.
  99. Luedders BA, Johnson TM, Sayles H, Thiele GM, Mikuls TR, O'Dell JR, England BR. (2020) Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate. *Semin Arthritis Rheum*, 50: 1058-1063.
  100. Ma MH, Garrood T, Li W, Defranoux N, Kingsley GH, Scott DL, Cope AP. (2014) Multi-biomarker disease activity (vectra® da algorithm) score is associated with power doppler ultrasound in patients with rheumatoid arthritis in low disease activity state: The remira cohort. *Annals of the Rheumatic Diseases*, 73.
  101. Ma MHY, Defranoux N, Li W, Sasso EH, Ibrahim F, Scott DL, Cope AP. (2020) A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. *Arthritis Res Ther*, 22: 158.
  102. Maijer KI, De Hair MJH, Li W, Defranoux NA, Sasso EH, Gerlag DM, Tak PP. (2013) Evaluation of a multi-biomarker disease activity (vectra™ da algorithm) in early rheumatoid arthritis and unclassified arthritis patients. *Annals of the Rheumatic Diseases*, 72.
  103. Razmjou AA, Brook J, Elashoff D, Kaeley G, Choi S, Kermani T, Ranganath VK. (2020) Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis. *BMC Rheumatology*, 4.
  104. Rech J, Hueber AJ, Finzel S, Englbrecht M, Haschka J, Manger B, Kleyer A, Reiser M, Cobra JF, Figueiredo C, et al. (2016) Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. *Annals of the rheumatic diseases*, 75: 1637-1644.

105. Reiss WG, Devenport JN, Low JM, Wu G, Sasso EH. (2016) Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis. *Rheumatology international*, 36: 295-300.
106. Roodenrijs NMT, De Hair MJH, Wheeler G, Elshahaly M, Tekstra J, Teng YKO, Lafeber FPJG, Hwang CC, Liu X, Sasso EH, Van Laar JM. (2018) The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: A post hoc analysis of three cohort studies 11 Medical and Health Sciences 1103 Clinical Sciences. *Arthritis Research and Therapy*, 20.
107. Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, Schilder AM, Visser H, Sasso EH, Chernoff D, Lems WF, van Schaardenburg DJ, Landewe R, Bernelot Moens HJ, Radstake T, van Riel P, van de Laar M, Jansen TL. (2018) Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. *PLoS One*, 13: e0192425.
108. Hirata S, Dirven L, Shen Y, Centola M, Cavet G, Lems WF, Tanaka Y, Huizinga TW, Allaart CF. (2013) A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. *Rheumatology (Oxford)*, 52: 1202-1207.
109. Hirata S, Li W, Defranoux N, Cavet G, Bolce R, Yamaoka K, Saito K, Tanaka Y. (2015) A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. *Modern Rheumatology*, 25: 344-349.
110. Abd El-Mabood EA, Ali HE. (2018) Platelet-rich plasma versus conventional dressing: does this really affect diabetic foot wound-healing outcomes? *Egyptian Journal of Surgery*, 37: 16-26.
111. Ahmed M, Reffat SA, Hassan A, Eskander F. (2017) Platelet-Rich Plasma for the Treatment of Clean Diabetic Foot Ulcers. *Annals of Vascular Surgery*, 38: 206-211.
112. Amato B, Farina MA, Campisi S, Ciliberti M, Di Donna V, Florio A, Grasso A, Miranda R, Pompeo F, Farina E, et al. (2020) CGF treatment of leg ulcers: a randomized controlled trial. *Open medicine (poland)*, 14: 959-967.
113. Burgos-Alonso N, Lobato I, Hernandez I, San Sebastian K, Rodriguez B, March AG, Perez-Salvador A, Arce V, Garcia-Alvarez A, Gomez-Fernandez MC, Grandes G, Andia I. (2018) Autologous platelet-rich plasma in the treatment of venous leg ulcers in primary care: a randomised controlled, pilot study. *Journal of Wound Care*, 27: S20-S24.
114. Driver VR, Hanft J, Fylling CP, Beriou JM. (2006) A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. *Ostomy/wound management*, 52: 68-70, 72, 74 passim.
115. Elbarbary AH, Hassan HA, Elbendak EA. (2020) Autologous platelet-rich plasma injection enhances healing of chronic venous leg ulcer: A prospective randomised study. *International Wound Journal*, 17: 992-1001.

116. Elgarhy LH, El-Ashmawy AA, Bedeer AE, Al-bahnasy AM. (2020) Evaluation of safety and efficacy of autologous topical platelet gel vs platelet rich plasma injection in the treatment of venous leg ulcers: A randomized case control study. *Dermatologic Therapy*, 33.
117. Elsaid A, El-Said M, Emile S, Youssef M, Khafagy W, Elshobaky A. (2020) Randomized Controlled Trial on Autologous Platelet-Rich Plasma Versus Saline Dressing in Treatment of Non-healing Diabetic Foot Ulcers. *World journal of surgery*, 44: 1294-1301.
118. Game F, Jeffcoate W, Tarnow L, Jacobsen JL, Whitham D, Harrison EF, Ellender SJ, Fitzsimmons D, Londahl M, LeucoPatch IITT. (2018) LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. *Lancet Diabetes & Endocrinology*, 6: 870-878.
119. Glukhov AA, Aralova MV. (2017) The study of the effectiveness of the drug combination of collagen and platelet-rich plasma for the regional treatment of venous ulcers. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 8: 2258-2263.
120. Goda AA, Metwally M, Ewada A, Ewees H. (2018) Platelet-rich plasma for the treatment of diabetic foot ulcer: a randomized, double-blind study. *Egyptian Journal of Surgery*, 37: 178-184.
121. Goda AA. (2018) Autogenous leucocyte-rich and platelet-rich fibrin for the treatment of leg venous ulcer: a randomized control study. *Egyptian Journal of Surgery*, 37: 316-321.
122. Gude W, Hagan D, Abood F, Clausen P. (2019) Aurix Gel Is an Effective Intervention for Chronic Diabetic Foot Ulcers: A Pragmatic Randomized Controlled Trial. *Advances in skin & wound care*, 32: 416-426.
123. Helmy Y, Farouk N, Ali Dahy A, Abu-Elsoud A, Fouad khattab R, Elshahat Mohammed S, Abdullbary Gad L, Altramsy A, Hussein E, Farahat A. (2021) Objective assessment of Platelet-Rich Plasma (PRP) potentiality in the treatment of Chronic leg Ulcer: RCT on 80 patients with Venous ulcer. *Journal of Cosmetic Dermatology*, 20: 3257-3263.
124. Hongying J, Liang Z, Xi Y, Jing H, Xiaona X, Zhengyan L, Hongchen H. (2020) Effect of platelet-rich plasma on pressure ulcers after spinal cord injury. *Chinese Journal of Tissue Engineering Research*, 25: 1149-1153.
125. Kakagia DD, Kazakos KJ, Xarchas KC, Karanikas M, Georgiadis GS, Tripsiannis G, Manolas C. (2007) Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. *Journal of Diabetes and its Complications*, 21: 387-391.
126. Karimi R, Afshar M, Salimian M, Sharif A, Hidariyan M. (2016) The Effect of Platelet Rich Plasma Dressing on Healing Diabetic Foot Ulcers. *Nursing and Midwifery Studies*, 5.
127. Li L, Chen D, Wang C, Yuan N, Wang Y, He L, Yang Y, Chen L, Liu G, Li X, et al. (2015) Autologous platelet-rich gel for treatment of diabetic chronic refractory

- cutaneous ulcers: a prospective, randomized clinical trial. *Wound repair and regeneration*, 23: 495-505.
128. Moneib HA, Youssef SS, Aly DG, Rizk MA, Abdelhakeem YI. (2018) Autologous platelet-rich plasma versus conventional therapy for the treatment of chronic venous leg ulcers: A comparative study. *Journal of Cosmetic Dermatology*, 17: 495-501.
  129. Obolenskiy VN, Ermolova DA, Laberko LA, Semenova TV. (2014) Efficacy of platelet-rich plasma for the treatment of chronic wounds. *EWMA journal*, 14: 37-41.
  130. Obolenskiy VN, Ermolova DA, Laberko LA. (2017) Clinical and economic effectiveness of the use of platelet-rich plasma in the treatment of chronic wounds. *Wound Medicine*, 19: 27-32.
  131. Rainys D, Cepas A, Dambrauskaite K, Nedzelskiene I, Rimdeika R. (2019) Effectiveness of autologous platelet-rich plasma gel in the treatment of hard-to-heal leg ulcers: a randomised control trial. *Journal of wound care*, 28: 658-667.
  132. Ramos-Torrecillas J, García-Martínez O, De Luna-Bertos E, Ocaña-Peinado FM, Ruiz C. (2015) Effectiveness of platelet-rich plasma and hyaluronic acid for the treatment and care of pressure ulcers. *Biological research for nursing*, 17: 152-158.
  133. Saad Setta H, Elshahat A, Elsherbiny K, Massoud K, Safe I. (2011) Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: A comparative study. *International Wound Journal*, 8: 307-312.
  134. Saha S, Patra AC, Gowda SP, Mondal N, Rahaman S, Ahmed SKS, Debbarma S, Vitthal KPK, Sarkar S, Sil A, Das NK. (2020) Effectiveness and safety of autologous platelet-rich plasma therapy with total contact casting versus total contact casting alone in treatment of trophic ulcer in leprosy: An observer-blind, randomized controlled trial. *Indian J Dermatol Venereol Leprol*, 86: 262-271.
  135. Senet P, Bon F-X, Benbunan M, Bussel A, Traineau R, Calvo F, Dubertret L, Dosquet C. (2003) Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers. *Journal of Vascular Surgery*, 38: 1342-1348.
  136. Singh SP, Kumar V, Pandey A, Pandey P, Gupta V, Verma R. (2018) Role of platelet-rich plasma in healing diabetic foot ulcers: a prospective study. *Journal of wound care*, 27: 550-556.
  137. Singh G, Borah D, Khanna G, Jain S. (2021) Efficacy of Local Autologous Platelet-Rich Plasma in the Treatment of Pressure Ulcer in Spinal Cord Injury Patients. *Cureus*, 13.
  138. Sokolov T, Manukova A, Karakoleva S, Valentinov B, Petrova N. (2017) ANALYSIS OF THE RESULTS OF APPLYING THE METHOD PLATELET-RICH PLASMA (PRP) FOR THE TREATMENT OF PROBLEMATIC SKIN WOUNDS. *Journal of Imab*, 23: 1460-1465.



139. Somani A, Rai R. (2017) Comparison of efficacy of autologous platelet-rich fibrin versus saline dressing in chronic venous leg ulcers: a randomised controlled trial. *Journal of cutaneous and aesthetic surgery*, 10: 8-12.
140. Tsachiridi M, Galyfos G, Andreou A, Sianou A, Sigala F, Zografos G, Filis K. (2019) Autologous platelet-rich plasma for nonhealing ulcers: A comparative study. *Vascular Specialist International*, 35: 22-27.
141. Yang L, Gao L, Lv Y, Wang J. (2017) Autologous platelet-rich gel for lower-extremity ischemic ulcers in patients with type 2 diabetes. *International Journal of Clinical and Experimental Medicine*, 10: 13796-13801.
142. Yuvasri G, Rai R. (2020) Comparison of efficacy of autologous platelet-rich fibrin versus Unna's paste dressing in chronic venous leg ulcers: A comparative study. *Indian Dermatology Online Journal*, 11: 58-61.
143. Alamdari NM, Sha A, Mirmohseni A, Besharat S. (2021) Evaluation of the efficacy of platelet-rich plasma on healing of clean diabetic foot ulcers: A randomized clinical trial in Tehran, Iran. *Diabetes & Metabolic Syndrome-Clinical Research & Reviews*, 15: 621-626.
144. Anitua E, Aguirre JJ, Algorta J, Ayerdi E, Cabezas AI, Orive G, Andia I. (2008) Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. *Journal of Biomedical Materials Research - Part B Applied Biomaterials*, 84: 415-421.
145. Cardenosa ME, Dominguez-Maldonado G, Cordoba-Fernandez A. (2017) Efficacy and safety of the use of platelet-rich plasma to manage venous ulcers. *Journal of Tissue Viability*, 26: 138-143.
146. Chandanwale KA, Mahakalkar CC, Kothule AK, Khithani DV. (2020) Management of Wounds of Peripheral Arterial Disease Using Platelet Rich Plasma. *Journal of Evolution of Medical and Dental Sciences-Jemds*, 9: 2239-2245.
147. de Oliveira MG, Abbade LPF, Miot HA, Ferreira RR, Deffune E. (2017) Pilot study of homologous platelet gel in venous ulcers. *Anais Brasileiros de Dermatologia*, 92: 499-504.
148. Khorvash F, Pourahmad M, Khoshchingol N, Avijgan M, Mohammadi M, Saheb nazari K. (2017) Comparing the effects of the platelet-rich plasma gel with wound therapeutic methods on the treatment of diabetic foot. *Journal of Isfahan Medical School*, 35: 1389-1395.
149. Kulkarni SR, Chawla A. (2019) STUDY OF EFFICACY OF PLATELET RICH PLASMA DRESSING IN MANAGEMENT OF CHRONIC NON-HEALING LEG ULCERS. *Journal of Evolution of Medical and Dental Sciences-Jemds*, 8: 1307-1310.
150. Milek T, Nagraba L, Mitek T, Wozniak W, Mlosek K, Olszewski W, Ciostek P, Deszczynski J, Kuchar E, Stolarczyk A. Autologous Platelet-Rich Plasma Reduces Healing Time of Chronic Venous Leg Ulcers: A Prospective Observational Study. In: Pokorski M (szerk.), *Advances in Biomedicine Vol. 1176*, 2019: 109-117.

151. Mohammad A, Rohangiz K, Morteza S, Alireza S, Abolfazl A. (2017) Comparison of Platelet Rich Plasma and Normal Saline Dressing Effectiveness in the Improvement of Diabetic Foot Ulcers. *Journal of diabetic nursing*, 5: 246-255.
152. Pires B, Baptista de Oliveira BGR, Bokehi LC, Luiz RR, Carvalho BTF, Santana RF, Alfradique de Souza P, Renato de Paula G, Teixeira LA. (2021) Clinical and Microbiological Outcomes Associated With Use of Platelet-Rich Plasma in Chronic Venous Leg Uclers: a Randomized Controlled Trial. *Journal of wound, ostomy, and continence nursing : official publication of the wound, ostomy and continence nurses society*, 48: 292-299.
153. Pu D, Lei X, Leng W, Zheng Y, Chen L, Liang Z, Chen B, Wu Q. (2019) Lower limb arterial intervention or autologous platelet-rich gel treatment of diabetic lower extremity arterial disease patients with foot ulcers. *Annals of Translational Medicine*, 7.
154. Qin X, Wang J. (2019) Clinical study of local injection of autologous platelet-rich plasma in treatment of diabetic foot ulcer. *Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery*, 33: 1547-1551.
155. Semenič D, Cirman T, Rožman P, Smrke DM. (2018) Regeneration of chronic wounds with allogeneic platelet gel versus hydrogel treatment: A prospective study. *Acta Clinica Croatica*, 57: 434-442.
156. Tsai HC, Lehman CW, Chen CM. (2019) Use of platelet-rich plasma and platelet-derived patches to treat chronic wounds. *Journal of wound care*, 28: 15-21.
157. Ucar O, Celik S. (2020) Comparison of platelet-rich plasma gel in the care of the pressure ulcers with the dressing with serum physiology in terms of healing process and dressing costs. *International Wound Journal*, 17: 831-841.
158. Curtis JR, Wright GC, Strand V, Davis CS, Hitraya E, Sasso EH. (2017) Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al. *Arthritis Rheumatol*, 69: 863-865.
159. Lerner A, Neidhöfer S, Reuter S, Matthias T. (2018) MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis. *Best Pract Res Clin Rheumatol*, 32: 550-562.
160. Curtis JR, Brahe CH, Østergaard M, Lund Hetland M, Hambardzumyan K, Saevarsdottir S, Wang X, Flake Ii DD, Sasso EH, Huizinga TW. (2019) Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. *Curr Med Res Opin*, 35: 1483-1493.
161. Abdelhafiz D, Baker T, Glasgow DA, Abdelhafiz A. (2022) Biomarkers for the diagnosis and treatment of rheumatoid arthritis - a systematic review. *Postgrad Med*, doi:10.1080/00325481.2022.2052626: 1-10.

162. Chu TW, AlJasser M, Alharbi A, Abahussein O, McElwee K, Shapiro J. (2015) Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: An intrasubject pilot study. *J Am Acad Dermatol*, 73: 338-340.
163. Rajan MB, Bhardwaj A, Singh S, Budania A, Bains A, Thirunavukkarasu P, Kumar MP. (2021) Identification of novel step-up regimen of intralesional triamcinolone acetonide in scalp alopecia areata based on a double-blind randomized controlled trial. *Dermatol Ther*, 34: e14555.
164. El-Husseiny R, Saleh H, Moustafa A, Salem S. (2021) Comparison between single- versus double-spin prepared platelet-rich plasma injection in treatment of female pattern hair loss: clinical effect and relation to vascular endothelial growth factor. *Archives of Dermatological Research*, 313: 1-10.
165. Salem SA, Elhusseiny RM, Saleh HM. (2021) A Split Scalp Study of Single versus Double Spin Platelet-rich plasma Injections in Treatment of Female Pattern Hair Loss: Clinical Effect and Relation to Vascular Endothelial Growth Factor in PRP. *QJM: An International Journal of Medicine*, 114.
166. Hegyi P, Eröss B, Izbéki F, Párniczky A, Szentesi A. (2021) Accelerating the translational medicine cycle: the Academia Europaea pilot. *Nat Med*, 27: 1317-1319.
167. Hegyi P, Petersen OH, Holgate S, Eröss B, Garami A, Szakács Z, Dobszai D, Balaskó M, Kemény L, Peng S, Monteiro J, Varró A, Lamont T, Laurence J, Gray Z, Pickles A, FitzGerald GA, Griffiths CEM, Jassem J, Rusakov DA, Verkhatsky A, Szentesi A. (2020) Academia Europaea Position Paper on Translational Medicine: The Cycle Model for Translating Scientific Results into Community Benefits. *Journal of Clinical Medicine*, 9: 1532.
168. Maisel-Campbell AL, Ismail A, Reynolds KA, Poon E, Serrano L, Grushchak S, Farid C, West DP, Alam M. (2020) A systematic review of the safety and effectiveness of platelet-rich plasma (PRP) for skin aging. *Arch Dermatol Res*, 312: 301-315.
169. Pototschnig H, Madl MT. (2020) Successful Treatment of Alopecia Areata Barbae with Platelet-rich Plasma. *Cureus*, 12: e7495.
170. Ragab SEM, Nassar SO, Morad HA, Hegab DS. (2020) Platelet-rich plasma in alopecia areata: intradermal injection versus topical application with transepidermal delivery via either fractional carbon dioxide laser or microneedling. *ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA*, 29: 169-173.

## 16. BIBLIOGRAPHY

### 16.1. Publications related to the thesis

**Meznerics FA**, Kemény LV, Gunther E, Bakó E, Dembrovszky F, Szabó B, Ascsillán A, Lutz E, Csupor D, Hegyi P, Bánvölgyi A, Nagy G. (2023) Multi-biomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis. **Rheumatology (Oxford)**, 62: 2048-2059.

**D1, IF: 5.50**

**Meznerics FA**, Fehérvári P, Dembrovszky F, Kovács KD, Kemény LV, Csupor D, Hegyi P, Bánvölgyi A. (2022) Platelet-Rich Plasma in Chronic Wound Management: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. **J Clin Med**, 11.

**Q1, IF: 3.90**

**Meznerics FA**, Illés K, Dembrovszky F, Fehérvári P, Kemény LV, Kovács KD, Wikonkál NM, Csupor D, Hegyi P, Bánvölgyi A. (2022) Platelet-Rich Plasma in Alopecia Areata-A Steroid-Free Treatment Modality: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. **Biomedicines**, 10.

**Q1, IF: 4.70**

### 16.2. Publications not related to the thesis

Illés K, **Meznerics FA**, Dembrovszky F, Fehérvári P, Bánvölgyi A, Csupor D, Hegyi P, Horváth T. (2023) Mastoid Obliteration Decreases the Recurrent and Residual Disease: Systematic Review and Meta-analysis. **Laryngoscope**, 133: 1297-1305.

**D1, IF: 2.60**

Cantisani C, Ambrosio L, Cucchi C, **Meznerics FA**, Kiss N, Bánvölgyi A, Rega F, Grignaffini F, Barbuto F, Frezza F, Pellacani G. (2022) Melanoma Detection by Non-Specialists: An Untapped Potential for Triage? **Diagnostics (Basel)**, 12.

**Q2, IF: 3.60**

Bánvölgyi A, Avci P, Kiss N, **Meznerics FA**, Jobbágy A, Fésűs L, Hársing J, Kuroli E, Szepesi Á, Marschalkó M. (2023) Scrofuloderma and granuloma annulare-like lesions:

Challenges of diagnosing cutaneous tuberculosis in developed countries. **J Clin Tuberc Other Mycobact Dis**, 31: 100370.

**Q2, IF: 2.00**

Bozsányi S, Czurkó N, Becske M, Kasek R, Lázár BK, Boostani M, **Meznerics FA**, Farkas K, Varga NN, Gulyás L, Bánvölgyi A, Fehér BÁ, Fejes E, Lőrincz K, Kovács A, Gergely H, Takács S, Holló P, Kiss N, Wikonkál N, Lázár I. (2023) Assessment of Frontal Hemispherical Lateralization in Plaque Psoriasis and Atopic Dermatitis. **J Clin Med**, 12.

**Q1, IF: 3.90**

Lőrincz K, **Meznerics FA**, Jobbágy A, Kiss N, Madarász M, Belvon L, Tóth B, Tamási B, Wikonkál NM, Marschalkó M, Bánvölgyi A. (2022) STIs during the COVID-19 Pandemic in Hungary: Gonorrhoea as a Potential Indicator of Sexual Behavior. **Int J Environ Res Public Health**, 19.

**Q2**

Jobbágy A, Kiss N, **Meznerics FA**, Farkas K, Plázár D, Bozsányi S, Fésűs L, Bartha Á, Szabó E, Lőrincz K, Sárdy M, Wikonkál NM, Szoldán P, Bánvölgyi A. (2022) Emergency Use and Efficacy of an Asynchronous Teledermatology System as a Novel Tool for Early Diagnosis of Skin Cancer during the First Wave of COVID-19 Pandemic. **Int J Environ Res Public Health**, 19.

**Q2**

Cantisani C, Rega F, Ambrosio L, Grieco T, Kiss N, **Meznerics FA**, Bánvölgyi A, Vespasiani G, Arienzo F, Rossi G, Soda G, Pellacani G. (2023) Syphilis, the Great Imitator-Clinical and Dermoscopic Features of a Rare Presentation of Secondary Syphilis. **Int J Environ Res Public Health**, 20.

**Q2**

Fésűs L, Kiss N, Jobbágy A, Farkas K, **Meznerics FA**, Bozsányi S, Bánvölgyi A, Wikonkál NM, Lőrincz K. (2022) Innovative in vivo imaging techniques in dermatology. **Bőrgyógyászati és Venerológiai Szemle**, 98: 133-141.

Jobbágy A, **Meznerics FA**, Farkas K, Plázár D, Bozsányi S, Fésűs L, Róbert L, Schveibert Á, Kuzmanovszki D, Szoldán P, Lőrincz K, Kiss N, Wikonkál NM, Sárdy M, Bánvölgyi A. (2022) Teledermatology: the new era of digitalization in dermatology care. **Bőrgyógyászati és Venerológiai Szemle**, 98: 100-107.

Jobbágy A, Varga NN, Hamilton-Meikle PK, Lőrincz K, **Meznerics FA**, Blága K, Poór A, Medvecz M, Sárdy M, Holló P, Wikonkál NM, Kiss N, Bánvölgyi A. (2023) Digitalisation and modern imaging technologies in dermatology. **Bőrgyógyászati és Venerológiai Szemle**, 99: 25-30.

## 17. ACKNOWLEDGEMENTS

I must pay tribute to those without whom my scientific work would not have been possible.

Firstly, I would like to express my gratitude to my supervisor, András Bánvölgyi M.D. Ph.D. Without his help, my research and the writing of this thesis would not have been possible. His professional and personal support from the very beginning encouraged me during my work as an undergraduate researcher, and later as a Ph.D. student. I was motivated and inspired by his commitment to both research and high-quality patient care.

I would like to thank Norbert Wikonkál M.D., Ph.D., D.Sc, who gave me the opportunity to join the Photobiology and Photocarcinogenesis Laboratory and become a part of a vibrant and motivating research team.

I would like to express my appreciation to Péter Hegyi M.D., Ph.D. D.Sc., MAE, the director of the Centre for Translational Medicine Ph.D. Program, who gave me the opportunity to join a continuously evolving and cohesive research community and showed me the importance of the ‘learning by doing’ approach.

I would also like to thank Péter Holló M.D., Ph.D., the head of the Department of Dermatology, Venereology and Dermatocology, Semmelweis University, and Miklós Sárdy M.D., Ph.D., the head of the doctoral program for supporting my scientific work.

I am grateful to György Nagy M.D., Ph.D. D.Sc, who gave me the opportunity to join his project and helped me through every step of the workflow.

I owe a special thanks to my co-investigators, Fanni Dembrovszky M.D., Péter Fehérvári Ph.D., Rita Nagy M.D., Bence Szabó, Lajos Kemény M.D. Ph.D., Emese Gunther M.D., Kata Illés M.D., and Kata Dorottya Kovács M.D., without whom my research would not have been possible.

I would like to thank Norbert Kiss M.D. Ph.D. for his continuous support, valuable insights, and constructive criticism, which contributed to the current direction of the research and raised the quality of my work, as well as Kende Lőrincz M.D. Ph.D. for his help and advice during my studies.

I would like to express my gratitude to the members of our research laboratory, Antal Jobbágy M.D., Szabolcs Bozsányi M.D. Ph.D., Luca Fésűs M.D. Ph.D., Klára Farkas M.D., Pálma Anker M.D., and Dóra Plázár M.D., to whom I could turn for help and advice at any time. Their work ethic, attitude to scientific work and enthusiasm served as an example for me.


I would like to highlight that our research was supported by the Semmelweis 250+ Excellence Scholarship, and grants from the National Scientific Research Programs OTKA K-131479 Rheuma Tolerance for Cure H2020 777357, and Competitive Central Hungary Operational Programme VEKOP-2.3.2-16-2016-00002. Project no. TKP-76-8/PALY-2021 has been implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development, and Innovation Fund, financed under the TKP2021-EGA/TKP2021-NVA/TKP2021-NKTA funding scheme. Project no. TKP2021-EGA-23 has been implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA funding scheme.

Finally, I would like to thank my family and friends who have supported me throughout my Ph.D. studies.



## Clinical science

# Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis

Fanni A. Meznerics<sup>1,2,†</sup>, Lajos V. Kemény<sup>1,3,†</sup>, Emese Gunther<sup>2,4</sup>, Eszter Bakó<sup>2,5</sup>,  
Fanni Dembrowszky<sup>2,6</sup>, Bence Szabó<sup>2</sup>, Anna Ascsillán<sup>1</sup>, Elmar Lutz<sup>1</sup>, Dezső Csupor<sup>2,6,7</sup>,  
Péter Hegyi<sup>2,6,8</sup>, András Bánvölgyi<sup>1,‡</sup>, György Nagy <sup>9,10,11,\*</sup>

<sup>1</sup>Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary

<sup>2</sup>Centre for Translational Medicine, Semmelweis University, Budapest, Hungary

<sup>3</sup>HCEMM-SU Translational Dermatology Research Group, Department of Physiology, Semmelweis University, Budapest, Hungary

<sup>4</sup>Department of Rheumatology, Petz Aladár County Teaching Hospital, Győr, Hungary

<sup>5</sup>Department of Pharmacognosy, Faculty of Pharmacy, Semmelweis University, Budapest, Hungary

<sup>6</sup>Institute for Translational Medicine, Medical School, Szentágotthai Research Centre, University of Pécs, Pécs, Hungary

<sup>7</sup>Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary

<sup>8</sup>Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary

<sup>9</sup>Department of Rheumatology and Clinical Immunology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary

<sup>10</sup>Heart and Vascular Centre, Semmelweis University, Budapest, Hungary

<sup>11</sup>Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary

\*Correspondence to: György Nagy, Department of Rheumatology and Clinical Immunology, Department of Internal Medicine and Oncology, Semmelweis University, 7 Árpád fejedelem útja, Budapest H-1023, Hungary. E-mail: nagy.gyorgy2@med.semmelweis-univ.hu

<sup>†</sup>Fanni A. Meznerics and Lajos V. Kemény are both the first authors.

<sup>‡</sup>András Bánvölgyi and György Nagy shares the last authorship.

## Abstract

**Objectives:** The multibiomarker disease activity (MBDA) score is an objective tool for monitoring disease activity in RA. Here we report a systematic review and meta-analysis of the clinical value of the MBDA score in RA.

**Methods:** We performed a systematic literature search in five medical databases—MEDLINE (via PubMed), Cochrane Library (CENTRAL), Embase, Scopus and Web of Science—from inception to 13 October 2021. Original articles reporting on the performance of the MBDA score's correlation with conventional disease activity measures or the predictive and discriminative values of the MBDA score for radiographic progression, therapy response, remission and relapse were included.

**Results:** Our systematic search provided a total of 1190 records. After selection and citation searches, we identified 32 eligible studies. We recorded moderate correlations between MBDA score and conventional disease activity measures at baseline [correlation (COR) 0.45 (CI 0.28, 0.59),  $r^2 = 71.0\%$  for the 28-joint DAS with CRP (DAS28-CRP) and COR 0.55 (CI 0.19, 0.78),  $r^2 = 0.0\%$  for DAS28 with ESR] and at follow-up [COR 0.44 (CI 0.28, 0.57),  $r^2 = 70.0\%$  for DAS28-CRP] and found that the odds of radiographic progression were significantly higher for patients with a high baseline MBDA score (>44) than for patients with a low baseline MBDA score (<30) [OR 1.03 (CI 1.02–1.05),  $I^2 = 10.0\%$ ].

**Conclusion:** The MBDA score might be used as an objective disease activity marker. In addition, it is also a reliable prognostic marker of radiographic progression.

**Keywords:** RA, MBDA score, disease activity monitoring, radiographic progression

### Rheumatology key messages

- The multibiomarker disease activity (MBDA) score is an objective tool for the monitoring of rheumatoid arthritis.
- The MBDA score showed moderate correlations with conventional disease activity measures.
- The MBDA score may be an independent predictor of radiological progression.

Received: 14 July 2022. Accepted: 20 December 2022

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

## Introduction

RA is a systemic autoimmune disease affecting  $\approx 0.5\text{--}1\%$  of the population [1]. According to the EULAR recommendations, the aim of the therapy in RA is to achieve remission, or at least low disease activity [2]. Early treatment with DMARDs and a treat-to-target treatment strategy are recommended by current guidelines and are considered to be the optimal way to prevent long-term functional decline by minimizing cartilage and bone damage [3–5].

Given that the treat-to-target therapeutic approach requires close monitoring of disease activity, the need for reliable, objective disease activity measures (DAMs) is undeniable. The currently available, widely used options for monitoring disease activity and progression are either subjective or non-specific: the 28-joint DAS (DAS28), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) all include subjective assessments of disease activity by the patient and/or the provider [6–8]. Although non-specific inflammatory markers such as CRP and ESR are used to calculate the DAS28 and SDAI, the incorporation of a scoring system based on the combination of inflammatory markers and additional biomarkers could further objectify the measurement of disease activity. Structural damage, a major factor defining the course of the disease, can be assessed by radiography and quantified with the Sharp–van der Heijde (SvdH) scoring system [9]. There are several known risk factors for radiographic progression, including high disease activity monitored by non-specific inflammatory markers such as CRP, RF and ACPA seropositivity [10]. However, RF and ACPA are not suitable for monitoring disease activity [11].

The multibiomarker disease activity (MBDA) score system is an algorithm based on the serum level of 12 biomarkers [IL-6, TNF receptor type 1 (TNFR1), vascular cell adhesion molecule 1 (VCAM-1), epidermal growth factor (EGF), vascular EGF A (VEGF-A), YKL-40, matrix metalloproteinase-1 (MMP-1), MMP-3, CRP, serum amyloid A (SAA), leptin and resistin], resulting in a scale from 0 to 100 [12]. The MBDA score presents an objective disease monitoring system and thus may contribute to personalized therapeutic plans conforming to modern medical views. In addition to monitoring disease activity, the MBDA score may also predict radiographic progression [13–16].

Several studies have evaluated the utility of the MBDA score and a meta-analysis has been conducted on the correlation of the MBDA score with conventional DAMs; however, the predictive and discriminative values of the MBDA score has yet to be analysed in a comprehensive manner [17]. Here we report a systematic review and meta-analysis of the clinical value and utility of the MBDA score for monitoring RA by determining the correlation of the MBDA score with conventional DAMs and the predictive and the discriminative values of the MBDA score for radiographic progression, therapy response, remission and relapse.

## Materials and methods

Our systematic review and meta-analysis are reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Statement [18]. The recommendations of the Cochrane Prognosis Methods Group [19] were followed and the review protocol was registered on PROSPERO.

We performed a systematic literature search of five medical databases—MEDLINE (via PubMed), Cochrane Library (CENTRAL), Embase, Scopus and Web of Science—from inception to 13 October 2021. Original articles reporting on the performance of the unadjusted MBDA score's correlation with conventional DAMs or the predictive and discriminative values of the MBDA score for radiographic progression, therapy response, remission and relapse were included in the systematic review and meta-analysis. Single case reports were excluded.

RA was defined by the ACR 1987 [20] and ACR/EULAR 2010 [21] classification criteria. Radiographic progression was measured by the change in the SvdH score per time unit, therapy response was defined by the EULAR criteria for therapy response and remission and relapse were defined by the different cut-off values of conventional DAMs.

Study selection and data extraction were carried out by two independent reviewers and disagreements were resolved by a third reviewer. The quality assessment of the outcomes was carried out separately by two reviewers using the Quality In Prognosis Studies (QUIPS) tool for assessing the risk of bias [22].

Further details regarding the search and selection strategy, data extraction, data synthesis and analysis are detailed in the [supplementary methods](#) available at *Rheumatology* online.

## Results

### Search and selection and characteristics of the included studies


Our systematic search provided 1190 records; after duplicate removal we screened 708 duplicate-free records. Thirty eligible studies [13–16, 23–48] were identified after title, abstract and full-text selection and two additional studies [49, 50] during citation search. Of these studies, we included 24 in the quantitative analysis [13–15, 23–25, 27–29, 31, 32, 34–38, 40, 41, 43, 44, 46, 47, 49, 50] and 8 in the qualitative analysis [16, 26, 30, 33, 39, 42, 45, 48]. The summary of the selection process is shown in [Fig. 1](#). We conducted a meta-analysis assessing the correlation of MBDA scores with conventional DAMs and the predictive value of the MBDA score for radiographic progression. Studies that could not be included in the meta-analysis and reports of other outcomes are detailed in the systematic review.

The characteristics of the identified studies for the systematic review and meta-analysis and the patient characteristics of included studies are detailed in [Table 1](#) and [Supplementary Table S1](#), available at *Rheumatology* online.

### MBDA score for the assessment of disease activity

Studies assessing the utility of the MBDA score for disease activity monitoring calculated the correlation of MBDA scores with conventional DAMs. Studies using Pearson's correlations could not be included in the meta-analysis due to a lack of statistical power, but are displayed in forest plots for visualization (see [Supplementary Figs S1–S3](#), available at *Rheumatology* online). The results of studies using Spearman's correlation are detailed below.

Six study groups in five publications [27, 29, 36, 46, 47] with a total of 667 subjects showed a moderate correlation between baseline MBDA score and baseline DAS28-CRP [correlation (COR) 0.45 (CI 0.28, 0.59),  $I^2 = 71.0\%$ ] (see



**Figure 1.** PRISMA flow diagram of the screening and selection process according to PRISMA 2020 guidelines [18]

Fig. 2A). Excluding conference abstracts from the analysis, similar results were observed; four publications [27, 36, 46, 47] with a total of 324 subjects demonstrated a moderate correlation between baseline MBDA score and baseline DAS28-CRP [COR 0.46 (CI 0.10, 0.72),  $I^2 = 81.0\%$ ].

Assessing the correlations of baseline MBDA scores with baseline DAS28-ESR, a moderate correlation was found based on the results of two publications with a total of 127 subjects [COR 0.55 (CI 0.19, 0.78),  $I^2 = 0.0\%$ ] (see Fig. 2A).

Further metrics associated with disease activity [CRP, ESR, 28-joint swollen joint count, 28-joint tender joint count, patient global assessment (PtGA), CDAI, power Doppler ultrasound (PDUS)] showed low and moderate correlations and are detailed in Supplementary Fig. S4, available at *Rheumatology* online.

Six study groups from four publications [29, 36, 46, 47] with a total of 287 subjects revealed a moderate correlation between follow-up MBDA score and follow-up DAS28-CRP [COR 0.44 (CI 0.28, 0.57),  $I^2 = 70.0\%$ ] (see Fig. 2B). After the exclusion of conference abstracts from the analysis, three articles [36, 46, 47] with a total of 137 subjects showed a moderate correlation between baseline MBDA score and baseline DAS28-CRP [COR 0.38 (CI -0.02, 0.68),  $I^2 = 18.0\%$ ].

The only study investigating the correlations of follow-up MBDA scores with follow-up DAS28-ESR found a moderate correlation [COR 0.49 (CI 0.22, 0.69)] between MBDA score and DAS28-ESR (Fig. 2B) [47].

Other parameters associated with disease activity (ESR, SJC28, TJC28, PtGA, PDUS) showed low-moderate correlations and are detailed in Supplementary Fig. S5, available at *Rheumatology* online.

Ten study groups from six articles [14, 28, 29, 36, 47, 50] with a total of 698 subjects demonstrated a moderate correlation between the change in MBDA score and the change in DAS28-CRP [COR 0.40 (CI 0.32, 0.48),  $I^2 = 19.0\%$ ]. Seven study groups from six articles [25, 35, 38, 47, 49, 50] with a

total of 543 subjects exhibited a moderate correlation between the change in MBDA score and the change in DAS28-ESR [COR 0.56 (CI 0.51, 0.60),  $I^2 = 71.0\%$ ] (see Fig. 2C). Excluding conference abstracts from the analysis, similar results were recorded. The change in MBDA score moderately correlates with the change in DAS28-CRP [COR 0.43 (CI 0.25, 0.59),  $I^2 = 47.0\%$ ] based on the results of six study groups of four publications [14, 36, 47, 50] with a total of 418 subjects, and with DAS28-ESR [COR 0.52 (CI 0.43, 0.60),  $I^2 = 0.0\%$ ] based on the results of four publications [35, 47, 49, 50] with a total of 298 subjects.

Further parameters linked to disease activity (CRP, CDAI, SDAI, HAQ) showed low-moderate correlations and are shown in Supplementary Fig. S6, available at *Rheumatology* online.

The results of the subgroup analysis based on the length of the follow-up showed similar results and are displayed in Supplementary Figs S7 and S8, available at *Rheumatology* online.

### MBDA score for the assessment of radiographic progression

Three study groups of three articles with a total of 22 subjects showed a low correlation between baseline MBDA score and baseline SvdH score [COR 0.13 (CI -0.25-0.47),  $I^2 = 79.0\%$ ] and five study groups of four articles with a total of 307 subjects demonstrated a low correlation between the change in MBDA score and the change in SvdH score [COR 0.08 (CI -0.06-0.21),  $I^2 = 79.0\%$ ] as well (see Fig. 3).

When evaluating the predictive value of the MBDA score for radiographic progression, three studies [13-15] with a total of 481 subjects showed that the odds of radiographic progression are significantly higher for patients with a high baseline MBDA score (>44) than for patients with a low baseline MBDA score (<30) [OR 1.03 (CI 1.02, 1.05),  $I^2 = 10.0\%$ ] (see Fig. 4). In contrast, the odds of progression

**Table 1.** Characteristics of included studies

First author, year of publication	Type of publication	Original study type	Original study name	Clinical trial registration number of RCT	Study duration	Time points of study	Country	Treatment	Outcome
Studies included in the meta-analysis									
Baker, 2021 [23]	Journal article	POS	Pennsylvania and Philadelphia VA Medical Centre	–	N/A	Baseline <sup>a</sup>	USA (Pennsylvania)	MTX, bDMARD, GC	Spearman's correlation with conventional DAMs
Bakker, 2012 [13]	Journal article	RCT	CAMERA	N/A	2 years	Baseline <sup>a</sup> , month 1, 3, 6 <sup>a</sup> , year 2 <sup>b</sup>	Netherlands	MTX, CsA, intra-articular GC, NSAID	Pearson's correlation with conventional DAMs <sup>c</sup> predicting radiographic progression and remission <sup>c</sup>
Bechman, 2018 [24]	Journal article	POS	REMIRA	–	1 year	Months 3, 6, 9 and 12 <sup>a</sup>	UK	csDMARD, bDMARD, GC	Spearman's correlation with conventional DAMs, relapse <sup>c</sup>
Bijlsma, 2013 [25]	Conference abstract	RCT	CAMERA-II	<a href="https://isrctn.com">https://isrctn.com</a> (ISRCTN 70365169)	1 year	Baseline <sup>a</sup> , months 1–12 <sup>a</sup>	Netherlands	Group A: MTX + PBO; group B: MTX + GC	Spearman's correlation with conventional DAMs
Bouman, 2017 [27]	Journal article	RCT	DRESS	<a href="https://trialregister.nl">https://trialregister.nl</a> (NTR3216)	18 months	Baseline <sup>a</sup> , months 3, 6, 9, 12, 15 and 18	Netherlands	MTX, csDMARD, ADA, ETN, NSAID, GC	Spearman's correlation with conventional DAMs, predicting radiographic progression <sup>c</sup> and relapse <sup>c</sup>
Brahe, 2016 [28]	Conference abstract	RCT	OPERA	<a href="https://clinicaltrials.gov">https://clinicaltrials.gov</a> (NCT00660647)	1 year	Baseline <sup>a</sup> , months 3 <sup>a</sup> , 6 and 12 <sup>a</sup>	Denmark	Group A: MTX + PBO; group B: MTX + ADA	Spearman's correlation with conventional DAMs
Brahe, 2019 [14]	Journal article	RCT	OPERA	<a href="https://clinicaltrials.gov">https://clinicaltrials.gov</a> (NCT00660647)	1 year	Baseline <sup>a</sup> , months 1, 2, 3 <sup>a</sup> , 6 <sup>a</sup> , 9 and 12	Denmark	Group A: MTX + PBO; group B: MTX + ADA	Spearman's correlation with conventional DAMs, predicting radiographic progression and remission <sup>c</sup>
Genovese, 2017 [29]	Conference abstract	RCT	DARWIN 1, DARWIN 2	<a href="https://clinicaltrials.gov">https://clinicaltrials.gov</a> (NCT01888874; NCT01894516)	24 weeks	Baseline <sup>a</sup> , week 12 <sup>a</sup>	USA	Group A: MTX + PBO; group B: MTX + 100 mg filogitinib; group C: MTX + 200 mg filogitinib	Spearman's correlation with conventional DAMs
Hambardzumyan, 2013 [31]	Conference abstract	RCT	SWEFOT	<a href="https://clinicaltrials.gov">https://clinicaltrials.gov</a> (NCT00764725)	1 year	Baseline <sup>a</sup> , year 1 <sup>a</sup>	Sweden	MTX, other DMARD, IFX	Spearman's correlation with conventional DAMs
Hambardzumyan, 2015 [15]	Conference abstract	RCT	SWEFOT	<a href="https://clinicaltrials.gov">https://clinicaltrials.gov</a> (NCT00764725)	1 year	Month 3, year 1 <sup>b</sup>	Sweden	MTX, HCQ, SSZ, IFX	Predicting radiographic progression
Hirata, 2013 [49]	Journal article	RCT	BEST	N/A	1 year	Baseline <sup>a</sup> , year 1 <sup>a</sup>	Netherlands, Japan	DMARD, IFX	Spearman's correlation with conventional DAMs, remission <sup>c</sup>
Hirata, 2015 [50]	Journal article	ROS	UOEH	–	1 year	Baseline <sup>a</sup> , weeks 24 and 52 <sup>a</sup>	Japan	ADA, ETN, IFX, MTX	Spearman's correlation with conventional DAMs, therapy response <sup>c</sup>
Hirata, 2016 [34]	Journal article	ROS	UOEH	–	7 years	Baseline <sup>a</sup> , week 52 <sup>a</sup>	Japan	MTX, ADA, ETN, IFX	Spearman's correlation with conventional DAMs, predicting radiographic progression <sup>c</sup>

(continued)

Table 1. (continued)

First author, year of publication	Type of publication	Original study type	Original study name	Clinical trial registration number of RCT	Study duration	Time points of study	Country	Treatment	Outcome
Jurgens, 2020 [35]	Journal article	RCT	CAMERA-II	<a href="https://www.isrctn.com">https://www.isrctn.com</a> (ISRCTN 70365169)	1 year	Baseline <sup>a</sup> , months 1, 2, 3 <sup>a</sup> , 4–12	Netherlands	MTX, GC, CsA, ADA, PBO	Spearman's correlation with conventional DAMs
Krabbe, 2017 [36]	Journal article	POS	HURRAH	–	52 weeks	Baseline <sup>a</sup> , weeks 26 and 52 <sup>a</sup>	Denmark	MTX, ADA	Spearman's correlation with conventional DAMs, predicting radiographic progression <sup>c</sup>
Lee, 2016 [37]	Journal article	POS	BRASS	–	2 years	Baseline <sup>a</sup>	USA	(Massachusetts)	csDMARD, bDMARD
Spearman's correlation with conventional DAMs									
Li, 2013 [38]	Conference abstract	POS	EIRA	–	3 months	Baseline <sup>a</sup> , month 3 <sup>a</sup>	Sweden	MTX	Spearman's correlation with conventional DAMs, therapy response <sup>c</sup>
Ma, 2014 [41]	Conference abstract	POS	REMIRA	–	1 year	Baseline <sup>a</sup> , year 1 <sup>a</sup>	UK	N/A	Spearman's correlation with conventional DAMs
Maijer, 2013 [43]	Conference abstract	POS	Academic Medical Centre Amsterdam	–	2 years	Baseline <sup>a</sup>	Netherlands	N/A	Spearman's correlation with conventional DAMs
Reiss, 2016 [46]	Journal article	RCT	ACT-RAY	N/A	24 weeks	Baseline <sup>a</sup> , weeks 4, 12 and 24 <sup>a</sup>	USA (California)	TCZ, MTX, GC	Spearman's correlation with conventional DAMs
Roodenrijs, 2018 [47]	Journal article	POS	LUMC, UMC, HORUS	–	1 year	Baseline <sup>a</sup> , month 6 <sup>a</sup>	Netherlands, UK	RTX, GC	Spearman's correlation with conventional DAMs, therapy response <sup>c</sup>
Studies included only in the systematic review									
Boeters, 2019 [26]	Journal article	POS	LUMC	–	N/A	Annually	Netherlands	csDMARDS, bDMARDS	Relapse
Hambardzumyan, 2019 [30]	Journal article	RCT	SWEFOT	<a href="https://clinicaltrials.gov">https://clinicaltrials.gov</a> (NCT00764725)	3 months	months 0, 3	Sweden	MTX, HCQ, SSZ, IFX	Therapy response
He, 2020 [32]	Conference abstract	Database analysis	N/A	–	N/A	Baseline <sup>a</sup>	USA	DMARD	Pearson's correlation with conventional DAMs
Hirata, 2012 [33]	Conference abstract	RCT	BEST	N/A	1 year	Baseline, year 1	Netherlands	N/A	remission

(continued)



Table 1. (continued)


First author, year of publication	Type of publication	Original study type	Original study name	Clinical trial registration number of RCT	Study duration	Time points of study	Country	Treatment	Outcome
Li, 2016 [48]	Journal article	POS	LUMC	–	N/A	Annually	Netherlands	csDMARD, TNFi	predicting radiographic progression
Luedders, 2020 [40]	Journal article	POS	N/A	–	16 weeks	Baseline <sup>a</sup> , weeks 8 and 16 <sup>a</sup>	USA (Nebraska)	MTX, FA, GC, NSAID	Pearson's correlation with conventional DAMs, remission
Ma, 2020 [42]	Journal article	POS	REMIRA	–	1 year	Baseline, months 3 and 6	UK, Singapore	csDMARDs, TNFi, GC	Remission
Markusse, 2014 [16]	Journal article	RCT	BEST	N/A	1 year	Baseline, year 1	Netherlands	csDMARD, IFX, GC	predicting and discriminating radiographic progression
Ghiti Moghadam, 2018 [48]	Journal article	RCT	POET	<a href="https://trialregister.nl">https://trialregister.nl</a> (NTR3112)	1 year	Baseline, months 3, 6, 9 and 12	Netherlands	csDMARD	Relapse
Razmjou, 2020 [44]	Journal article	POS	N/A	–	12 weeks	Baseline <sup>a</sup> , weeks 2, 6 and 12 <sup>a</sup>	USA (California)	csDMARD, tofacitinib	Pearson's correlation with conventional DAMs
Rech, 2016 [45]	Journal article	RCT	RETRO	<a href="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</a> (2009-015740-42)	1 year	Baseline, months 3, 6, 9 and 12	Germany	csDMARDS, bDMARDS	Relapse

<sup>a</sup> Time point used for calculating correlation.


<sup>b</sup> Time point used for calculating radiological progression.

<sup>c</sup> Not included in the meta-analysis.


ADA: adalimumab; CsA: ciclosporin A; bDMARD: biological DMARD; csDMARD: conventional synthetic DMARD; ETN: etanercept; FA: folic acid; GC: glucocorticoid; IFX: infliximab; N/A: no data available; PBO: placebo; POS: prospective observational study; RCT: randomized clinical trial; ROS: retrospective observational study; RTX: rituximab; TCZ: tocilizumab; TNFi: TNF- $\alpha$  inhibitor.



**Figure 2.** Forest plot for the correlation of MBDA score with DAS28-CRP/ESR. (A) Forest plot for the correlation of baseline MBDA score with baseline DAS28-CRP/ESR. (B) Forest plot for the correlation of follow-up MBDA score with follow-up DAS28-CRP/ESR. (C) Forest plot for the change in baseline MBDA score with the change in DAS28-CRP/ESR



**Figure 3.** Forest plots for the correlations of MBDA score with SvdH score. (A) Forest plot for the correlation of baseline MBDA score with baseline SvdH score. (B) Forest plot for the correlation of the change in MBDA score with the change in SvdH score



**Figure 4.** Forest plot of the predictive value of MBDA score for radiographic progression

for patients with a high baseline DAS28-CRP were not significantly higher than for patients with a low baseline DAS28-CRP [OR 1.12 (CI 0.91–1.37),  $I^2 = 0.0\%$ ] (see [Supplementary Fig. S9](#), available at *Rheumatology* online). The characteristics of the studies evaluating the predictive value of the MBDA score and DAS28-CRP for radiographic progression are detailed in [Table 2](#).

Five additional studies evaluating the utility of the MBDA score for the assessment of radiographic progression could not be included in our quantitative synthesis [16, 27, 34, 36, 39]. Markusse *et al.* [16] found that higher MBDA scores at baseline were associated with an increased risk of radiographic progression in the subsequent year, therefore the

MBDA score can be considered an independent predictor for radiographic progression. The discriminative value of the MBDA score was also assessed and the results showed that the MBDA score discriminated more between radiographic progression and no radiographic progression than the DAS at baseline and 1 year. Hirata *et al.* [34] reported that patients with moderate or high MBDA scores had a greater risk of radiographic progression than patients with low or moderate MBDA scores. Li *et al.* [39] also found that radiographic progression was not frequent when MBDA scores were low; univariate and multivariate analyses showed that high MBDA scores were strongly associated with radiographic progression. In a study by Krabbe *et al.* [36], none of the patients



**Table 2.** Characteristics of studies evaluating the predictive value of MBDA score and DAS28-CRP for radiographic progression

First author, year of publication	Time of evaluating RP	Definition of RP	Low MBDA score	High MBDA score	Low DAS28-CRP	High DAS28-CRP
Studies included in the meta-analysis						
Bakker, 2012 [13]	2 years	>0 units increase of SvdH score	<30	>44	≤2.7	>2.7
Brahe, 2019 [14]	1 year	>2 units increase of SvdH score	<30	>44	≤5.1	>5.1
Hambardzumyan, 2015 [15]	1 year	>5 units increase of SvdH score	<30	>44	≤2.7	>4.1
Studies included in the systematic review						
Bouman, 2017 [27]	1.5 years	>0.5 unit increase in SvdH score	<30	>44	<2.7	>4.1
Hirata, 2016 [34]	1 year	>3 unit increase in SvdH score	<30	>44	≤3.2	>5.1
Krabbe, 2017 [36]	0.5, 1 year	N/A	<30	>44	≤3.2	>5.1
Li, 2016 [39]	1 year	>3 unit increase in SvdH score	<30	>44	≤2.67	>4.09
Markusse, 2014 [16]	1 year	>0.5 unit increase in SvdH score	<30	>44	≤2.4	>3.7

N/A: no data available; RP: radiographic progression.

with radiographic progression had low MBDA scores. In contrast, Bouman *et al.* [27] found no association between baseline MBDA score and radiographic progression.

### MBDA score for the assessment of therapy response, remission and relapse

We identified four studies [30, 34, 38, 47] investigating the utility of the MBDA score for the assessment of therapy response, six studies [13, 14, 33, 40, 42, 49] for remission and five studies [24, 26, 27, 45, 48] for relapse. However, these studies were not eligible for quantitative synthesis due to the widely varying outcome measures.

The change of MBDA score from baseline to 6 months was significantly associated with good or moderate EULAR response *vs* non-response at 6 months by Roodenrijs *et al.* [47]; however, the baseline MBDA score was not associated with EULAR response *vs* non-response. Similar results were recorded by Li *et al.* [38]. Although the baseline MBDA score was not associated with EULAR response at 3 months, changes in MBDA scores differentiated responders from non-responders. Hambardzumyan *et al.* [30] also reported that the MBDA score was significantly associated with treatment outcomes at 3 months. In the study of Hirata *et al.* [49], EULAR good responders were found to have significantly greater reductions in the MBDA score from baseline than EULAR moderate responders and EULAR moderate responders had significantly greater reductions than EULAR non-responders.

The MBDA score was found to be an appropriate discriminator of remission/low disease activity and moderate/high disease activity, according to two studies [13, 42]. Ma *et al.* [42] reported that the baseline MBDA score and the time-integrated MBDA score discriminated between remission and non-remission at 1 year as well. Two studies found no significant association between baseline MBDA score and remission, although, according to Brahe *et al.* [14, 40], the change in MBDA score was associated with clinical remission. Hirata *et al.* [33, 49] recorded the association of MBDA remission with clinical remission.

High baseline MBDA scores were associated with significantly greater proportions of patients experiencing relapse based on the results of Ghiti Moghadam *et al.* [48] and significantly higher MBDA scores were recorded in relapsed patients by Rech *et al.* [45]. Boeters *et al.* [26] found that high MBDA scores during DMARD treatment and before treatment reduction were associated with an increased risk of relapses in patients who reduced or stopped DMARD treatments. Bouman *et al.* [27] reported the borderline positive

predictive value of baseline MBDA score for flare of patients with low disease activity at baseline. According to Bechman *et al.* [24], baseline MBDA scores were not predictive of flare. However, a sensitivity analysis limited to flares with an increase in high disease activity determined by MBDA score (> 44) did show an association between baseline MBDA value and flare risk.

### Funnel plots and leave-one-out analysis

No evidence of publication bias was observed in the funnel plots for the correlations of MBDA scores with conventional DAMs (see [Supplementary Figs S10–S12](#), available at *Rheumatology* online). The results of the leave-one-out analysis are detailed in [Supplementary Tables S2–S4](#), available at *Rheumatology* online, showing no outlier article.

### Risk of bias assessment

The majority of the outcomes of the studies included in the meta-analysis ( $n=79$ ) and the systematic review ( $n=37$ ) were rated as having a low or moderate risk of bias. The risk of bias was low in 35 outcomes of the studies included in the meta-analysis and 29 outcomes of the studies included in the systematic review, moderate in 32 outcomes of the studies included in the meta-analysis and 5 outcomes of the studies included in the systematic review and high in 12 outcomes of the studies included in the meta-analysis and 3 outcomes of the studies included in the systematic review. Common methodological limitations across studies were attrition rates, study confounding and statistical analysis and reporting. The quality assessment scores for all outcomes are shown in [Supplementary Tables S5 and S6](#), available at *Rheumatology* online.

### Discussion

Since the recommendation for the treatment of RA—the treat-to-target therapeutic approach—requires close monitoring of disease activity, the importance of objective scoring systems is indisputable. By conducting a systematic review and meta-analysis on the utility of the MBDA score to assess disease activity, radiographic progression, remission and relapse, we aim to promote decision making on the applicability of the MBDA score in clinical practice.

When analysing the correlations of MBDA score with conventional DAMs by a random-effects model, moderate correlations were recorded, similar to the meta-analysis conducted by Johnson *et al.* [17]. DAS28-CRP and DAS28-ESR, which

are considered the gold standard DAMs in RA, both showed moderate correlations with MBDA at baseline and follow-up, as well as in the change in DAS28-CRP and DAS28-ESR with the change in MBDA. Other DAMs detailed in the supplement showed weaker correlations with MBDA score, except for CRP. The correlation of the MBDA score with CRP individually was stronger than with DAS28-CRP. As the MBDA score does not contain the results of clinical assessment, its deviation from the conventional DAMs is not surprising. However, the MBDA score was designed to complement, not replace conventional DAMs, therefore its deviation from conventional DAMs can even be advantageous [51].

Since the MBDA score contains markers of cartilage and bone damage, such as MMP-3, in addition to the inflammatory markers implemented in currently used DAMs, such as CRP, it is a realistic possibility that it can outperform conventional DAMs in predicting radiological progression [52]. The results of our meta-analysis suggest that the MBDA score can be an independent predictor of radiological progression, as the odds of radiographic progression were significantly higher for patients with a high baseline MBDA score than for patients with a low baseline MBDA score, while there was no significant difference between low- and high-baseline DAS28-CRP. However, while the cut-off values for high and low MBDA scores were the same in the included studies, different cut-off values were used to define DAS28-CRP subgroups, which may influence these results and highlight the need for further investigations (see Table 2). Furthermore, the SvdH score showed a low correlation with the MBDA score at baseline and at follow-up, which suggests that these data should be interpreted with caution. These results are in line with the results of the studies included in our systematic review and also with the results of the previous meta-analysis by Curtis *et al.* [53] and the systematic review by Abdelhafiz *et al.* [54]. The limitation of both our study and the study by Curtis *et al.* [53] is the lack of included studies investigating the efficacy of DAS28-CRP for predicting radiographic progression independent of the MBDA score, potentially leading to biased results.

Based on the studies included in the systematic review, the change in MBDA score is associated with therapeutic response and seems to discriminate between therapy responders and non-responders [30, 38, 47, 49]. However, baseline MBDA scores were not predictive of therapy response [38, 47]. Similarly, while the change in MBDA score was found to be associated with remission and MBDA score discriminated remission/low disease activity and moderate/high disease activity [13, 14, 33, 42, 49], no significant associations were found between baseline MBDA scores and remission [14, 40]. In contrast, in the case of relapse, the baseline MBDA score was reported to be a predictor, although no clear conclusions can be drawn due to the heterogeneity of study designs and the potential for false positivity due to multiple testing [24, 27, 48].

There are several strengths of our study. We implemented a rigorous methodology to achieve the highest quality of evidence and provide a structured analysis of the outcomes discussed in the literature. We provide a comprehensive summary on the utility of the MBDA score for monitoring RA disease activity and also the predictive and discriminative value of the MBDA score for radiographic progression, therapy response, remission and relapse, presenting the results of quantitative analysis for both the correlation of the MBDA

score with conventional DAMs and the predictive value of the MBDA score for radiographic progression.

Our main limitation is the heterogeneity of the populations. A wide range of anti-rheumatic drugs was used in the included studies, with potentially varying effects on the MBDA score: the IL-6 receptor-blocker tocilizumab may increase the serum level of IL-6 by preventing receptor binding, therefore influencing the change in MBDA score via one of the 12 included biomarkers [46]. TNF inhibitors may also influence MBDA score indirectly by decreasing the serum level of TNF- $\alpha$ . Hirata *et al.* [34] compared anti-TNF- $\alpha$  and anti-TNF- $\alpha$ -receptor drugs and found no significant difference between the two groups; however, further studies are needed to assess the effect of targeted therapies on the serum level of the biomarkers included in the MBDA score and therefore their effect on the change of MBDA score [34]. Furthermore, the different follow-up times used for the assessment of disease activity may also increase the heterogeneity.

By including a higher number of patients and uniformizing the follow-up time for evaluation and the cut-off values of DAS28-CRP for remission, future studies would enable further comprehensive analysis to urge implementation of the MBDA score in daily clinical practice.

## Conclusion

The MBDA score can be highly valuable in RA patient care, both for monitoring disease activity and for predicting radiological progression. However, further studies are needed to better assess the utility of the MBDA score and also the potential role of individual biomarkers in disease activity monitoring.

## Supplementary material

Supplementary material is available at *Rheumatology* online.

## Data availability

The datasets used in this study can be found in the full-text articles included in the systematic review and meta-analysis. The data underlying this article will be shared upon reasonable request to the corresponding author.

## Authors' contributions

L.V.K. and F.A.M. were responsible for conceptualization, project administration, data curation, visualization and writing the original draft. E.G. was responsible for conceptualization, project administration, data curation and visualization. E.B. was responsible for conceptualization and data curation. F.D. was responsible for conceptualization, data curation and methodology. B.S. was responsible for methodology, formal analysis, validation and visualization. A.A. and E.L. were responsible for data curation and visualization. D.C. and P.H. were responsible for conceptualization, methodology and supervision. A.B. and G.N. were responsible for conceptualization, methodology, supervision and writing the original draft. All authors provided critical conceptual input and approved the final version of the article.

## Funding

This work was supported by grants from National Scientific Research Programs (OTKA K-131479), Rheuma Tolerance for Cure (H2020 777357) and the Competitive Central Hungary Operational Programme (VEKOP-2.3.2-16-2016-00002). Project TKP-76-8/PALY-2021 has been implemented with support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development, and Innovation Fund financed under the TKP2021-EGA/TKP2021-NVA/TKP2021-NKTA funding scheme.

**Disclosure statement:** The authors have declared no conflicts of interest.

## Acknowledgments

No ethical approval was required for this review as all data were already published in peer-reviewed journals. No patients were involved in the design, conduct or interpretation of our study.

## References

- Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. *Semin Arthritis Rheum* 2006;36:182–8.
- Smolen JS, Landewé RBM, Bijlsma JWJ *et al.* EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis* 2020;79:685–99.
- Singh JA, Saag KG, Bridges SL Jr *et al.* 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2016;68:1–25.
- Smolen JS, Breedveld FC, Burmester GR *et al.* Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis* 2016;75:3–15.
- Nagy G, Roodenrys NMT, Welsing PMJ *et al.* EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. *Ann Rheum Dis* 2022;81:20–33.
- van Gestel AM, Prevoo ML, van 't Hof MA *et al.* Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum* 1996;39:34–40.
- Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. *Ann Rheum Dis* 2012;71:1190–6.
- Aletaha D, Nell VP, Stamm T *et al.* Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. *Arthritis Res Ther* 2005;7:R796–806.
- van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. *J Rheumatol* 2000;27:261–3.
- Scott DL. Radiological progression in established rheumatoid arthritis. *J Rheumatol Suppl* 2004;69:55–65.
- Barra L, Bykerk V, Pope JE *et al.* Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. *J Rheumatol* 2013;40:1259–67.
- Curtis JR, van der Helm-van Mil AH, Knevel R *et al.* Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. *Arthritis Care Res (Hoboken)* 2012;64:1794–803.
- Bakker MF, Cavet G, Jacobs JW *et al.* Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. *Ann Rheum Dis* 2012;71:1692–7.
- Brahe CH, Østergaard M, Johansen JS *et al.* Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. *Scand J Rheumatol* 2019;48:9–16.
- Hambardzumyan K, Bolce R, Saevarsdottir S *et al.* Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. *Ann Rheum Dis* 2015;74:1102–9.
- Markus IM, Dirven L, van den Broek M *et al.* A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study. *J Rheumatol* 2014;41:2114–9.
- Johnson TM, Register KA, Schmidt CM *et al.* Correlation of the multi-biomarker disease activity score with rheumatoid arthritis disease activity measures: a systematic review and meta-analysis. *Arthritis Care Res (Hoboken)* 2019;71:1459–72.
- Page MJ, McKenzie JE, Bossuyt PM *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71.
- Debray TP, Damen JA, Snell KI *et al.* A guide to systematic review and meta-analysis of prediction model performance. *BMJ* 2017;356:i6460.
- Arnett FC, Edworthy SM, Bloch DA *et al.* The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315–24.
- Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. *Rheumatology (Oxford)* 2012;51(Suppl 6):vi5–9.
- Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. *Ann Intern Med* 2013;158:280–6.
- Baker JF, Curtis JR, Chernoff D *et al.* Evaluation of the impact of age and adiposity on a multi-biomarker disease activity score before and after adjustment. *Clin Rheumatol* 2021;40:2419–26.
- Bechman K, Tweehuysen L, Garrood T *et al.* Flares in rheumatoid arthritis patients with low disease activity: predictability and association with worse clinical outcomes. *J Rheumatol* 2018;45:1515–21.
- Bijlsma JWJ, Jurgens MS, Jacobs JWG *et al.* Response to MTX plus prednisone in camera II using a multi-biomarker disease activity (Vectra™ DA) test and DAS28-ESR. *Ann Rheum Dis* 2013;72:A80.1–A80.
- Boeters DM, Burgers LE, Sasso EH, Huizinga TWJ, van der Helm-van Mil AHM. ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. *Arthritis Res Ther* 2019;21:121.
- Bouman CAM, van der Maas A, van Herwaarden N *et al.* A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. *Rheumatology (Oxford)* 2017;56:973–80.
- Brahe CH, Østergaard M, Johansen J *et al.* Changes in multi-biomarker disease activity (MBDA) score correlate with changes in established disease activity measurements in patients with early RA from the OPERA study. *Ann Rheum Dis* 2016;75:450.1.
- Genovese MC, Galien R, Pan Y *et al.* Correlation of multi-biomarker disease activity score with clinical disease activity measures for the JAK1-selective inhibitor filgotinib as monotherapy and in combination with methotrexate in rheumatoid arthritis patients. *Arthritis Rheumatol* 2017;69(Suppl 10):abstract 1458.
- Hambardzumyan K, Bolce RJ, Wallman JK, van Vollenhoven RF, Saevarsdottir S. Serum biomarkers for prediction of response to methotrexate monotherapy in early rheumatoid arthritis: results from the SWEFOT trial. *J Rheumatol* 2019;46:555–63.

31. Hambarzumyan K, Saevarsdottir S, Bolce R *et al*. Multi-biomarker disease activity (MBDA) score and the 12 individual biomarkers in early rheumatoid arthritis patients relate differentially to clinical response and radiographic progression: results from the SWEFOT trial. *Ann Rheum Dis* 2013;72(Suppl 3):A388–9.
32. He E, Yalamanchi P, Arnold W, Arnold E. Assessment of the components of RAPID3 patient reported outcomes in a community rheumatology practice. *Arthritis Rheumatol* 2020;72:3484–5.
33. Hirata S, Dirven L, Cavet G *et al*. A multi-biomarker disease activity score (the VECTRA™ DA algorithm score) reflects clinical remission for rheumatoid arthritis (RA) in the best study. *Ann Rheum Dis* 2012;71:355.
34. Hirata S, Li W, Kubo S *et al*. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. *Mod Rheumatol* 2016;26:850–6.
35. Jurgens MS, Safy-Khan M, de Hair MJH *et al*. The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial. *Arthritis Res Ther* 2020;22:205.
36. Krabbe S, Bolce R, Brahe CH *et al*. Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage. *Scand J Rheumatol* 2017;46:353–8.
37. Lee YC, Hackett J, Frits M *et al*. Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. *Rheumatology (Oxford)* 2016;55:640–8.
38. Li W, Hensvold AH, Saevarsdottir S *et al*. Characterization of the multi-biomarker disease activity (Vectra Da™ algorithm) score in a subgroup of patients from the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) cohort receiving methotrexate. *Ann Rheum Dis* 2013;72:A591.1.
39. Li W, Sasso EH, van der Helm-van Mil AH, Huizinga TW. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2016;55:357–66.
40. Luedders BA, Johnson TM, Sayles H *et al*. Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate. *Semin Arthritis Rheum* 2020;50:1058–63.
41. Ma MH, Garrood T, Li W *et al*. Multi-biomarker disease activity (Vectra® DA algorithm) score is associated with power Doppler ultrasound in patients with rheumatoid arthritis in low disease activity state: the Remira cohort. *Ann Rheum Dis* 2014;73:606.
42. Ma MHY, Defranoux N, Li W *et al*. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. *Arthritis Res Ther* 2020;22:158.
43. Maijer KI, De Hair MJH, Li W *et al*. Evaluation of a multi-biomarker disease activity (vectra™ da algorithm) in early rheumatoid arthritis and unclassified arthritis patients. *Ann Rheum Dis* 2013;72:A389.
44. Razmjou AA, Brook J, Elashoff D *et al*. Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis. *BMC Rheumatol* 2020;4:55.
45. Rech J, Hueber AJ, Finzel S *et al*. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. *Ann Rheum Dis* 2016;75:1637–44.
46. Reiss WG, Devenport JN, Low JM, Wu G, Sasso EH. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis. *Rheumatol Int* 2016;36:295–300.
47. Roodenrijs NMT, De Hair MJH, Wheeler G *et al*. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies. *Arthritis Res Ther* 2018;20:256.
48. Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE *et al*. Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. *PLoS One* 2018;13:e0192425.
49. Hirata S, Dirven L, Shen Y *et al*. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. *Rheumatology (Oxford)* 2013;52:1202–7.
50. Hirata S, Li W, Defranoux N *et al*. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: a retrospective observational study. *Mod Rheumatol* 2015;25:344–9.
51. Curtis JR, Wright GC, Strand V *et al*. Reanalysis of the multi-biomarker disease activity score for assessing disease activity in the abatacept versus adalimumab comparison in biologic-naive rheumatoid arthritis subjects with background methotrexate study: comment on the article by Fleischmann. *Arthritis Rheumatol* 2017; 69:863–65.
52. Lerner A, Neidhöfer S, Reuter S, Matthias T. MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2018;32:550–62.
53. Curtis JR, Brahe CH, Østergaard M *et al*. Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. *Curr Med Res Opin* 2019;35:1483–93.
54. Abdelhafiz D, Baker T, Glasgow DA, Abdelhafiz Ah. Biomarkers for the diagnosis and treatment of rheumatoid arthritis – a systematic review. *Postgrad Med* 2022;1–10.



## Systematic Review

# Platelet-Rich Plasma in Chronic Wound Management: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Fanni Adél Meznerics<sup>1,2</sup>, Péter Fehérvári<sup>2,3</sup>, Fanni Dembrovszky<sup>2,4</sup>, Kata Dorottya Kovács<sup>1</sup>, Lajos Vince Kemény<sup>1,5</sup>, Dezső Csupor<sup>2,4,6</sup>, Péter Hegyi<sup>2,4,7</sup> and András Bánvölgyi<sup>1,\*</sup>

- <sup>1</sup> Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, 1085 Budapest, Hungary  
<sup>2</sup> Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary  
<sup>3</sup> Department of Biostatistics, University of Veterinary Medicine, 1085 Budapest, Hungary  
<sup>4</sup> Institute for Translational Medicine, Medical School, Szentágotthai Research Centre, University of Pécs, 7624 Pécs, Hungary  
<sup>5</sup> HCEMM-SU Translational Dermatology Research Group, Department of Physiology, Semmelweis University, 1094 Budapest, Hungary  
<sup>6</sup> Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary  
<sup>7</sup> Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, 1085 Budapest, Hungary  
 \* Correspondence: banvolgyi.andras@med.semmelweis-univ.hu



**Citation:** Meznerics, F.A.; Fehérvári, P.; Dembrovszky, F.; Kovács, K.D.; Kemény, L.V.; Csupor, D.; Hegyi, P.; Bánvölgyi, A. Platelet-Rich Plasma in Chronic Wound Management: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *J. Clin. Med.* **2022**, *11*, 7532. <https://doi.org/10.3390/jcm11247532>

Academic Editor: Ingo Ludolph

Received: 14 November 2022

Accepted: 14 December 2022

Published: 19 December 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** Background: Chronic wounds place a heavy burden on the healthcare system due to the prolonged, continuous need for human resources for wound management. Our aim was to investigate the therapeutic effects of platelet-rich plasma on the treatment of chronic wounds. Methods: The systematic literature search was performed in four databases. Randomized clinical trials reporting on patients with chronic wounds treated with platelet-rich plasma (PRP) were included, comparing PRP with conventional ulcer therapy. We pooled the data using the random effects model. Our primary outcome was the change in wound size. Results: Our systematic search provided 2688 articles, and we identified 48 eligible studies after the selection and citation search. Thirty-three study groups of 29 RCTs with a total of 2198 wounds showed that the odds for complete closure were significantly higher in the PRP group than in the control group (OR = 5.32; CI: 3.37; 8.40;  $I^2 = 58\%$ ). Conclusions: PRP is a safe and effective modality to enhance wound healing. By implementing it in clinical practice, platelet-rich plasma could become a widely used, valuable tool as it could not only improve patients' quality of life but also decrease the healthcare burden of wound management.

**Keywords:** wound healing; dressing; platelet-rich plasma

## 1. Introduction

Chronic wounds are common conditions that greatly impact patients' quality of life [1]. They place a heavy burden on the healthcare system due to the high cost of dressing materials, amputation-related costs, and the prolonged, continuous need for human resources for wound management [2].

The wide range of causes underlying ulceration includes arterial and venous insufficiency, neuropathy, microangiopathy, and several additional factors [3]. Besides treating the underlying cause, the goal of ulcer management is to promote healing through professional wound care; the gold standard methods are smart dressings and compression therapy [4].

Platelet-rich plasma (PRP) is an autologous serum prepared from whole blood by centrifugation, containing high concentrations of platelets, growth factors, and cytokines, which can promote stem cell regeneration and tissue remodeling [5,6]. By potentially shortening the recovery time of ulcers, PRP, as an additional treatment modality, could improve patients' quality of life and decrease the healthcare burden of wound management.

Although the effects of PRP on wound healing are heavily investigated, the current evidence is inconclusive [7]. Our goal is to investigate the therapeutic effect of PRP on the treatment of chronic wounds by summarizing the latest data in a comprehensive manner by conducting a systematic review and meta-analysis.

## 2. Materials and Methods

Our study was performed according to the Cochrane Handbook's recommendations for the Systematic Reviews of Interventions, Version 6.3 [8]. The results are reported following the guidelines of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 Statement [9]. The review protocol was registered on PROSPERO under registration number CRD42021287881 (see <https://www.crd.york.ac.uk/prospéro>, accessed on 28 October 2021); no amendments to the information provided at registration were made.

The systematic literature search was performed in four databases: MEDLINE (via PubMed), Cochrane Library (CENTRAL), Embase, and Web of Science from inception to 29 October 2021. The query (ulcer \* OR chronic ulcer OR chronic wound OR diabetic foot) AND (platelet rich plasma OR PRP OR platelet rich plasma gel OR PRPG OR platelet rich in growth factors OR PRGF) was applied to all fields in the search engines. No language or other restrictions were imposed.

Randomized clinical trials (RCTs) reporting on patients with chronic wounds treated with PRP were included, comparing additional PRP treatment with conventional ulcer therapy alone. The following population–intervention–control–outcome (PICO) framework was used:

- P—Adult patients with chronic wounds;
- I—Platelet-rich plasma (PRP) treatment;
- C—Conventional ulcer therapy;
- O—Primary outcome: change in wound size (complete closure, reduction of wound area, healing rate); secondary outcomes: healing time, infection, pain, adverse events, amputation, recurrence, and quality of life.

EndNote X9 (Clarivate Analytics, Philadelphia, PA, USA) was used for the selection of the articles. Two independent authors (F.A.M. and K.D.K.) screened the publications separately for the title, abstract (Cohen's Kappa: 0.81), and full text (Cohen's Kappa: 0.88), and disagreements were resolved by a third author (F.D.).

Two authors (F.A.M. and K.D.K.) independently extracted the data into an Excel spreadsheet (Office 365, Microsoft, Redmond, WA, USA). We collected the following data from the eligible articles: first author, year of publication, study type, study location, number of centers included in the study, study design, demographic data, details of the received treatments, and data regarding our outcomes for statistical analysis. A third reviewer (F.D.) resolved the discrepancies. Secondary outcomes were included if three publications reporting on them were found.

The quality assessment of the outcomes was performed separately by two reviewers (F.A.M. and K.D.K.) using the revised tool for assessing the risk of bias (RoB 2) [10]. A third reviewer (F.D.) resolved any occurring disagreements. To assess the quality of the evidence, we followed the recommendation of the "Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)" workgroup [11].

The statistical analyses were made with R (R Core Team 2022, v4.2.1) [12]. For calculations and plots, we used the meta (Schwarzer 2022, v5.5.0) [13] and dmetar (Cuijpers, Furukawa, and Ebert 2022, v0.0.9000) [14] packages.

For the dichotomous outcomes, the odds ratio (OR) with a 95% confidence interval (CI) was used for the effect measure; to calculate the OR, the total number of patients in each group and those with the event of interest were extracted from each study. Raw data from the selected studies were pooled using a random effect model with the Mantel-Haenszel method [15–17]. For the pooled results, the exact Mantel–Haenszel method (no continuity correction) was used to handle zero cell counts [18]. In individual studies, the zero cell count

problem was adjusted by treatment arm continuity correction [19]. In the case of continuous outcomes, a standardized mean difference (SMD) with a 95% CI was calculated as the effect size. As different results were used from the same study, a three-level meta-analysis model was used along with estimating an additional within the study heterogeneity variance parameter. The inverse variance weighting method was used to calculate the pooled SMD. To estimate the heterogeneity variance measure,  $\tau^2$ , the restricted maximum-likelihood estimator was applied with a t-distribution-based confidence interval [20].

Between-study heterogeneity was described by Higgins and Thompson's  $I^2$  statistics [21]. As the subgroup analysis, the fixed-effects (plural) model (aka. the mixed-effects model) was used. Common  $\tau$  values at the subgroup levels were assumed in the subgroup analysis, as we had a limited number of studies in some groups. A "Q" omnibus test (of all levels of the subgroup) was also calculated for comparison of the subgroup's pooled effect sizes. If the study number for the given outcome was over five, the Hartung–Knapp adjustment [22] was applied (below six studies, no adjustment was applied).

A funnel plot of the logarithm of the effect size and comparison with the standard error for each trial was used to evaluate publication bias. Publication bias was assessed with Egger's test using the Harbord method [23] to calculate the test statistic. Outlier and influence analyses were carried out following the recommendations of Harrer et al. [20] and Viechtbauer and Cheung [24].

### 3. Results

Our systematic search provided a total of 2688 articles; after duplicate removal, we screened 1910 duplicate-free articles. Following the title, abstract, and full-text selection, we identified 46 RCTs matching our PICO framework [25–70] and two additional articles [71,72] after the citation search. The full text of 10 articles could not be retrieved, even after contacting the authors [73–82]. The summary of the selection process is shown in Figure 1.




Figure 1. PRISMA Flow Diagram of the screening and selection process.

We conducted a quantitative analysis of our primary outcome, the change in wound size. The secondary outcomes are detailed in the systematic review section due to the widely varying and poorly defined outcome measures used for their assessment.

The characteristics of the identified RCTs for the systematic review and meta-analysis are detailed in Table 1.

**Table 1.** Characteristics of the included studies.

First Author, Year of Publication	Type of Publication	Study Type	Country	Ulcer Etiology	Outcome
Abd El-Mabood, 2018 [25]	Journal article	RCT	Egypt	Diabetic	Complete closure, healing rate, infection, and pain
Ahmed, 2017 [26]	Journal article	RCT	Egypt	Diabetic	Complete closure, healing rate, and infection
Alamdari, 2021 [27]	Journal article	RCT	Iran	Diabetic	Healing time, and amputation
Amato, 2020 [28]	Journal article	RCT	Italy	Mixed	Reduction of wound area, complete closure, infection, and pain
Anitua, 2008 [29]	Journal article	RCT	Spain	Mixed	Reduction of wound area and infection
Burgos-Alonso, 2018 [30]	Journal article	RCT	Spain	Venous	Reduction of wound area, complete closure, infection, pain, adverse events, and quality of life
Cardenosa, 2017 [31]	Journal article	RCT	Spain	Venous	Reduction of wound area, pain, and adverse events
Chandanwale, 2020 [32]	Journal article	RCT	India	Arterial	Reduction of wound area
de Oliveira, 2017 [33]	Journal article	RCT	Brazil	Venous	Reduction of wound area and infection
Driver, 2006 [34]	Journal article	RCT	US	Diabetic	Reduction of wound area, healing rate, complete closure, healing time, and adverse events
Elbarbary, 2020 [35]	Journal article	RCT	India	Venous	Reduction of wound area, complete closure, healing time, and recurrence
Elgarhy, 2020 [36]	Journal article	RCT	India	Venous	Reduction of wound area, complete closure, and healing time
Elsaid, 2020 [37]	Journal article	RCT	Egypt	Diabetic	Reduction of wound area, complete closure, and healing time
Game, 2018 [38]	Journal article	RCT	UK	Diabetic	Reduction of wound area, complete closure, healing time, infection, pain, amputation, and adverse events
Glukhov, 2017 [39]	Journal article	RCT	Russia	Venous	Complete closure, and pain
Goda, 2018 1 [41]	Journal article	RCT	Egypt	Diabetic	Healing rate, and complete closure
Goda, 2018 2 [40]	Journal article	RCT	Egypt	Venous	Reduction of wound area, and complete closure
Gude, 2019 [42]	Journal article	RCT	US	Diabetic	Complete closure, and amputation
Helmy, 2021 [43]	Journal article	RCT	Egypt	Venous	Reduction of wound area, complete closure, healing time, pain, adverse events, and recurrence
Hongying, 2020 [44]	Journal article	RCT	China	Pressure	Reduction of wound area, and complete closure
Kakagia, 2007 [71]	Journal article	RCT	Greece	Diabetic	Reduction of wound area, and complete closure
Karimi, 2016 [45]	Journal article	RCT	Iran	Diabetic	Reduction of wound area, complete closure, and amputation
Khorvash, 2017 [46]	Journal article	RCT	Iran	Diabetic	Reduction of wound area, infection, pain, and quality of life
Kulkarni, 2019 [47]	Journal article	RCT	India	N/A	Reduction of wound area, healing time, and adverse events



Table 1. Cont.


First Author, Year of Publication	Type of Publication	Study Type	Country	Ulcer Etiology	Outcome
Li, 2015 [48]	Journal article	RCT	China	Diabetic	Reduction of wound area, complete closure, healing time, infection, amputation, and adverse events
Milek, 2019 [49]	Journal article	RCT	Poland	Venous	Reduction of wound area and complete closure
Mohammad, 2017 [50]	Journal article	RCT	Iran	Diabetic	Reduction of wound area
Moneib, 2018 [51]	Journal article	RCT	Egypt	Venous	Reduction of wound area, complete closure, pain, and adverse events
Obolenskiy, 2014 [53]	Journal article	RCT	Russia	Mixed	Complete closure and healing time
Obolenskiy, 2017 [52]	Journal article	RCT	Russia	Mixed	Healing rate, complete closure, and healing time
Pires, 2021 [54]	Journal article	RCT	Brazil	Venous	Infection
Pu, 2019 [55]	Journal article	RCT	China	Arterial	Reduction of wound area, healing rate, and amputation
Qin, 2019 [56]	Journal article	RCT	China	Diabetic	Reduction of wound area
Rainys, 2019 [57]	Journal article	RCT	Lithuania	N/A	Reduction of wound area, complete closure, infection, and adverse events
Ramos-Torrecilla, 2015 [58]	Journal article	RCT	Spain	Pressure	Reduction of wound area, complete closure, and infection
Saad Setta, 2011 [59]	Journal article	RCT	Egypt	Diabetic	Complete closure and healing time
Saha, 2020 [60]	Journal article	RCT	India	Leprosy	Reduction of wound area, complete closure, and pain
Semenic, 2018 [61]	Journal article	RCT	Slovenia	Mixed	Reduction of wound area and adverse events
Senet, 2003 [72]	Journal article	RCT	France	Venous	Reduction of wound area, healing rate, complete closure, infection, and adverse events
Singh, 2018 [63]	Journal article	RCT	India	Diabetic	Complete closure, healing time, amputation, and adverse events
Singh, 2021 [62]	Journal article	RCT	India	Pressure	Reduction of wound area
Sokolov, 2017 [64]	Journal article	RCT	Bulgaria	Not defined	Complete closure
Somani, 2017 [65]	Journal article	RCT	India	Venous	Reduction of wound area and complete closure
Tsachiridi, 2019 [66]	Journal article	RCT	Greece	Pressure	Reduction of wound area and healing rate
Tsai, 2019 [67]	Journal article	RCT	US	Mixed	Reduction of wound area
Ucar, 2020 [68]	Journal article	RCT	Turkey	Pressure	Reduction of wound area
Yang, 2017 [69]	Journal article	RCT	China	Diabetic	Healing rate, healing time, infection, pain, and adverse events
Yuvasri, 2020 [70]	Journal article	RCT	India	Venous	Reduction of wound area and complete closure

### 3.1. Primary Outcome

The results of the studies assessing the change in wound size are detailed in Table S2 in the Supplementary Materials. Studies evaluating the change in wound size by measuring the baseline and post-treatment wound size or complete closure are included in our quantitative analysis.

#### 3.1.1. Complete Closure

Thirty-three study groups of 29 RCTs with a total of 2198 wounds showed that the odds for complete closure were significantly higher in the PRP group than in the control group (OR = 5.32; CI: 3.37; 8.40;  $I^2 = 58\%$ ) (see Figure 2).



**Figure 2.** Forest plot for complete closure: platelet-rich plasma compared to conventional ulcer therapy [25,26,28,30,34–45,48,51–53,57–59,63,64,69–72].


When subgrouping was based on ulcer etiologies, the odds for complete closure were significantly higher in the PRP group than in the control group, both in diabetic foot ulcers (OR = 2.26; CI: 1.50; 3.41;  $I^2 = 12.0\%$ ) as well as venous leg ulcers (OR = 8.02; CI: 3.63; 17.71;  $I^2 = 10.0\%$ ). The test for the subgroup difference showed a significant difference between the two groups ( $\chi^2 = 9.88$ ;  $df = 1$ ;  $p = 0.002$ ); the odds for complete closure were significantly higher in venous ulcers than in the diabetic foot ulcers treated with PRP (see Figure S1).

Subgrouping based on the way PRP was applied showed similar results. The odds for complete closure were significantly higher both in the topically applied (OR = 4.74; CI: 2.87; 7.83;  $I^2 = 60\%$ ) and injected (OR = 9.42; CI: 3.32; 26.76;  $I^2 = 0\%$ ) PRP groups than in the control group, with no significant subgroup difference ( $\chi^2 = 2.34$ ;  $df = 1$ ;  $p = 0.126$ ) (see Figure S2).

The odds for complete closure were significantly higher in the PRP group than in the control group in the short (OR = 6.03; CI: 3.21; 11.33;  $I^2 = 47\%$ ), medium (OR = 3.38; CI: 1.15; 9.89;  $I^2 = 73\%$ ), and long (OR = 8.24; CI: 1.66; 40.87;  $I^2 = 0\%$ ) follow-up categories, as well with no significant subgroup differences ( $\chi^2 = 2.50$ ;  $df = 3$ ;  $p = 0.476$ ) (see Figure S3).

### 3.1.2. Reduction of Wound Area

The pooled SMDs from 18 study groups of 16 RCTs with a total of 1062 wounds showed a significant difference between the post-treatment wound size of the PRP and the control groups (SMD =  $-1.21$ , CI:  $-1.74$ ;  $-0.68$ ;  $I^2 = 92.5\%$ ), with the PRP group showing greater improvement (see Figure 3).



**Figure 3.** Forest plot for the change of wound size: platelet-rich plasma compared to conventional ulcer therapy [31,32,35,36,43,45,47,49,50,55,57,60,65,66,68,70].

Subgrouping based on ulcer etiology, the application method, and follow-up length showed similar results (see Figures S4–S6). The post-treatment wound size was significantly smaller in the PRP group than in the control group in the diabetic (SMD =  $-0.68$ , CI:  $-1.31$ ;  $-0.06$ ;  $I^2 = 93.64\%$ ), venous (SMD =  $-1.26$ , CI:  $-2.28$ ;  $-0.24$ ;  $I^2 = 90.76\%$ ), topically applied (SMD =  $-0.94$ , CI:  $-1.43$ ;  $-0.46$ ;  $I^2 = 91.26\%$ ), and injected (SMD =  $-1.03$ , CI:  $-1.79$ ;  $-0.26$ ;  $I^2 = 86.63\%$ ) subgroups, as well as in the short follow-up subgroup (SMD =  $-1.00$ , CI:  $-1.64$ ;  $-0.35$ ;  $I^2 = 89.41\%$ ). However, the difference between the PRP and the control groups was not significant in the medium (SMD =  $-1.38$ , CI:  $-2.96$ ;  $0.19$ ;  $I^2 = 54.51\%$ ) and long (SMD =  $-0.63$ , CI:  $-1.64$ ;  $0.37$ ;  $I^2 = 93.88\%$ ) follow-up groups. No significant subgroup differences were recorded.

### 3.2. Secondary Outcomes

The secondary outcomes are summarized in Table 2. Recurrence rates and quality of life are not reported, as less than three studies included them as an outcome.

**Table 2.** Main conclusions of the studies assessing the secondary outcomes.

First Author, Year of Publication	Main Conclusion
	Healing Time
Alamdari, 2021 [27]	Shorter healing time in the PRP group than in the control group
Driver, 2006 [34]	Shorter healing time in the PRP group than in the control group
Elbarbary, 2020 [35]	Shorter healing time in the PRP group than in the control group *
Elgarhy, 2020 [36]	Shorter healing time in the topical and injected PRP groups than in the control group *
Elsaid, 2020 [37]	Shorter healing time in the PRP group than in the control group *
Game, 2018 [38]	Shorter healing time in the PRP group than in the control group *
Helmy, 2021 [43]	Shorter healing time in the PRP group than in the control group *
Kulkarni, 2019 [47]	Shorter healing time in the PRP group than in the control group *
Li, 2015 [48]	Shorter healing time in the PRP group than in the control group *

Table 2. Cont.

First Author, Year of Publication	Main Conclusion
Healing Time	
Obolenskiy, 2014 [53]	Shorter healing time in the PRP group than in the control group
Obolenskiy, 2017 [52]	Shorter healing time in the PRP group than in the control group *
Saad Setta, 2011 [59]	Shorter healing time in the PRP group than in the control group *
Singh, 2018 [63]	Shorter healing time in the PRP group than in the control group *
Yang, 2017 [69]	Shorter healing time in the PRP group than in the control group *
Infection Rates	
Abd El-Mabood, 2018 [25]	More infection in the control group than in the PRP group *
Ahmed, 2017 [26]	More infection in the control group than in the PRP group *
Amato, 2020 [28]	More infection in the control group than in the PRP group *
Anitua, 2008 [29]	No statistically significant difference between the PRP and the control groups
Burgos-Alonso, 2018 [30]	No statistically significant difference between the PRP and the control groups
de Oliveira, 2017 [33]	No statistically significant difference between the PRP and the control groups
Game, 2018 [38]	No statistically significant difference between the PRP and the control groups
Khorvash, 2017 [46]	No statistically significant difference between the PRP and the control groups
Li, 2015 [48]	No statistically significant difference between the PRP and the control groups
Pires, 2021 [54]	No statistically significant differences in antimicrobial resistance between <i>P. aeruginosa</i> and <i>S. aureus</i> in the PRP and control groups. PRP decreased bacteriological growth or the microbial load and resistance profile in the case of <i>P. aeruginosa</i>
Rainys, 2019 [57]	No statistically significant difference between the PRP and the control groups
Ramos-Torrecilla, 2015 [58]	No signs of infection were recorded during the study
Senet, 2003 [72]	No statistically significant difference between the PRP and the control groups
Yang, 2017 [69]	More infection in the control group than in the PRP group *
Pain	
Abd El-Mabood, 2018 [25]	Pain occurred more frequently in the control group *
Amato, 2020 [28]	Pain occurred more frequently in the control group *
Burgos-Alonso, 2018 [30]	No statistically significant difference in pain reduction between the PRP and the control groups
Cardenosa, 2017 [31]	Pain reduction was higher in the PRP group *
Game, 2018 [38]	No statistically significant difference in pain reduction between the PRP and the control groups
Glukhov, 2017 [39]	All patients subjectively experienced pain reduction in both groups
Helmy, 2021 [43]	All patients subjectively experienced pain reduction in the PRP group
Khorvash, 2017 [46]	pain reduction was higher in the PRP group *
Moneib, 2018 [51]	All patients subjectively experienced pain reduction in both groups
Saha, 2020 [60]	Administration-related pain was reported by 10 participants in the PRP group
Yang, 2017 [69]	pain reduction was higher in the PRP group *
Amputation Rates	
Alamdari, 2021 [27]	No statistically significant difference between the PRP and the control groups
Game, 2018 [38]	No statistically significant difference between the PRP and the control group
Gude, 2019 [42]	Two amputations in the control group and no amputation in the PRP group
Karimi, 2016 [45]	No statistically significant difference between the PRP and the control groups
Li, 2015 [48]	Four amputations in the control group one amputation in the PRP group
Pu, 2019 [55]	No statistically significant difference between the PRP and the control groups
Singh, 2018 [63]	Two amputations in the control group, and no amputation in the PRP group
Adverse Events	
Burgos-Alonso, 2018 [30]	No statistically significant difference between the PRP and the control groups
Cardenosa, 2017 [31]	No adverse events recorded
Chandanwale, 2020 [32]	No adverse event in the PRP group
Driver, 2006 [34]	No administration related serious adverse event was recorded in either group; one case of Contact dermatitis in the PRP group and one case of maceration in the control group
Game, 2018 [38]	No statistically significant difference between the PRP and the control groups
Helmy, 2021 [43]	No adverse events recorded
Kulkarni, 2019 [47]	No adverse event in the PRP group

Table 2. Cont.

First Author, Year of Publication	Main Conclusion
	Adverse Events
Li, 2015 [48]	No adverse events were recorded in the PRP group
Moneib, 2018 [51]	No adverse events recorded
Rainys, 2019 [57]	No statistically significant difference between the PRP and the control groups, and no serious adverse event was recorded
Semenic, 2018 [61]	No adverse events recorded
Senet, 2003 [72]	No statistically significant difference between the PRP and the control groups
Singh, 2018 [63]	No adverse events recorded
Yang, 2017 [69]	No statistically significant difference between the PRP and the control groups

PRP-platelet-rich plasma; \* indicates significant difference ( $p < 0.05$ ).

### 3.3. Risk of Bias Assessment

The result of the assessment of the risk of bias of the studies included in the meta-analysis and systematic review are detailed in Figures S7–S18 in the Supplementary Materials. None of the studies included in the meta-analysis was at a high risk of bias. In thirty studies [26,28–30,32,34,39,42,43,47–53,56,58,59,61,62,64–72], the ‘randomization process’ domain, in twelve studies [28,42,44,48,50,53,56,59,63,65,68,71], the ‘deviations from intended interventions’ domain, in one study [29], the ‘missing outcome data’ domain, in five studies [44,50,56,59,71], the ‘measurement of the outcome’ domain, and in eight studies [26,33,42,57,58,63,65,70], the ‘selection of the reported result’ domain, were rated as ‘some concerns’ for our primary outcome.

### 3.4. Quality of Evidence

The quality of the evidence for our outcomes is detailed in the Summary of Findings Table (see Table S1 in the Supplementary Materials).

### 3.5. Publication Bias

The funnel plot assessing the publication bias can be seen in the Supplementary Materials (Figures S19 and S20). No evidence of serious publication bias can be observed in the funnel plot for complete closure; however, the funnel plot for the reduction of the wound area indicates publication bias.

## 4. Discussion

On the basis of our systematic review and meta-analysis, PRP is an effective add-on treatment modality to enhance wound healing. The odds for complete wound closure were significantly higher in the PRP group than in the control group, and PRP also resulted in a significantly greater reduction of the wound area compared to conventional therapy.

The subgroup analyses, which were conducted to decrease the heterogeneity, showed similar results and also highlighted differences between the ulcer etiologies and PRP application methods. Injected PRP seemed to result in greater improvement than topically applied PRP; however, due to the relatively low sample size of this subgroup, conclusions should be drawn with caution. As for ulcer etiologies, while PRP was superior to conventional therapy regarding complete closure and the reduction of the wound area in diabetic and venous ulcers as well, better results were recorded in the venous ulcer group. The reason for this phenomenon could be that diabetic ulcers are more difficult to heal; however, the fact that PRP was more frequently administered by injection in the venous ulcer group could also be a contributing factor, as we saw better results in the injected PRP subgroup discussed above. PRP was also shown to be effective after short, medium, and long follow-up times regarding complete closure.



Although we did not conduct quantitative analysis on the healing time due to the varying reporting methods of the studies, all the included studies reported shorter healing times in the PRP group than in the conventional therapy group [27,34–38,43,47,48,52,53,59,63,69].

The infection rate is another critical outcome that requires further investigation with more specific criteria for its assessment. Nine studies did not record a significant difference between the PRP and the control groups regarding infection rates [29,30,33,38,46,48,57,58,72], whereas four studies recorded a significantly lower number of infections in the PRP group [25,26,28,69], suggesting that PRP could decrease the risk of infection.

No substantial difference was recorded between the PRP and the control group regarding pain [25,28,30,31,38,39,43,46,51,60,69], amputation rates [38,42,45,48,55,63], and adverse events [30–32,34,38,43,47,48,51,57,61,63,69,72].

#### 4.1. Strengths and Limitations

There are several strengths to our study. We summarized the latest data on PRP in wound management in a comprehensive manner, assessing the most objective outcome measure, the change in the wound area. Our results clearly support the superiority of PRP over conventional therapy alone. While previous studies only assessed the efficacy of PRP in different ulcer etiologies separately, we conducted an overall analysis; we believe, as well, that it is crucial to assess the wound-healing properties of PRP in general [7]. We only included RCTs and implemented a rigorous methodology to guarantee the highest possible quality of evidence and conducted a quantitative analysis only on the outcomes that were objectively reported to avoid drawing false conclusions based on poorly recorded secondary outcomes. Our limitations included publication bias and the diversity of the control groups, as a wide range of dressings was used as a part of the conventional therapy.

#### 4.2. Implications for Research

Future studies should report their outcomes uniformly to enable further comprehensive analysis. As the most objective way of assessing the clinical efficacy of PRP in wound management is to record the change in wound size, the baseline and post-treatment wound area should always be reported. However, better reporting guidelines are required that entail detailed descriptive statistics, including the median and interquartile range besides the mean and standard deviation. Additionally, the varying methods used to measure wound size can also lead to further bias: chronic wounds often affect the leg, and simply photographing the wound and measuring it with software does not take into account that wounds often affect the total leg circumference. Also, assessing the wound size by only measuring its width and length can give false results due to the often asymmetrical ulcer areas. We suggest that the most applicable way of precise measurement is tracing the outline of the wound on carbon paper, which can be digitalized and available for further calculations.

In addition to the baseline and post-treatment wound area, the number of completely closed wounds is also a critical outcome measure, showing the clinical efficacy of the treatment; therefore, it should always be reported.

#### 4.3. Implications for Practice

The importance of the early application of research results in clinical practice is undisputable [83]. Due to its wound-healing properties, platelet-rich plasma could become a widely used, valuable tool in chronic wound management. PRP can be administered topically and intralesionally, as well, and can also be applied along with the wide range of available smart dressings. These combinations enable personalized treatment strategies by providing a variety of options for treating physicians.

## 5. Conclusions

Platelet-rich plasma is a safe and effective modality to enhance wound healing. By implementing it in clinical practice, PRP could become a widely used, valuable tool, as it could improve patients' quality of life and decrease the healthcare burden of wound management.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/jcm11247532/s1>, Table S1: Summary of findings table. Table S2: Characteristics of the studies assessing the change of wound size. Figure S1: Forest plot for complete closure, subgrouping based on ulcer etiologies. Figure S2: Forest plot for complete closure, subgrouping based on PRP application method. Figure S3: Forest plot for complete closure, subgrouping based on follow-up time. Figure S4: Forest plot for wound area reduction, subgrouping based on ulcer etiologies. Figure S5: Forest plot for wound area reduction, subgrouping based on PRP application method. Figure S6: Forest plot for wound area reduction, subgrouping based on follow-up time. Figure S7: Risk of bias assessment of the included studies assessing the change of wound size, using the revised tool for assessing risk of bias in randomized trials (Rob 2). Figure S8: Risk of bias assessment of the included studies assessing the change of wound size, broken down to tools, shown in percentage. Figure S9: Risk of bias assessment of the included studies assessing healing time, using the revised tool for assessing risk of bias in randomized trials (Rob 2). Figure S10: Risk of bias assessment of the included studies assessing healing time, broken down to tools, shown in percentage. Figure S11: Risk of bias assessment of the included studies assessing infection rates, using the revised tool for assessing risk of bias in randomized trials (Rob 2). Figure S12: Risk of bias assessment of the included studies assessing infection rates, broken down to tools, shown in percentage. Figure S13: Risk of bias assessment of the included studies assessing pain, using the revised tool for assessing risk of bias in randomized trials (Rob 2). Figure S14: Risk of bias assessment of the included studies assessing pain, broken down to tools, shown in percentage. Figure S15: Risk of bias assessment of the included studies assessing amputation rates, using the revised tool for assessing risk of bias in randomized trials (Rob 2). Figure S16: Risk of bias assessment of the included studies assessing amputation rates, broken down to tools, shown in percentage. Figure S17: Risk of bias assessment of the included studies assessing adverse events, using the revised tool for assessing risk of bias in randomized trials (Rob 2). Figure S18: Risk of bias assessment of the included studies assessing adverse events, broken down to tools, shown in percentage. Figure S19: Funnel plot for complete closure. Figure S20: Funnel plot for the reduction of wound area.

**Author Contributions:** F.A.M.: conceptualization, project administration, data curation, visualization, and writing original draft. P.F.: methodology, formal analysis, validation, and visualization. F.D.: conceptualization, data curation and methodology. K.D.K.: conceptualization, data curation, and visualization. L.V.K.: conceptualization and methodology. D.C.: conceptualization, methodology, and supervision. P.H.: conceptualization, methodology, and supervision. A.B.: conceptualization, methodology, supervision, and writing original draft. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** No ethical approval was required for this review, as all data were already published in peer-reviewed journals. No patients were involved in the design, conduction, or interpretation of our study.

**Data Availability Statement:** The datasets used in this study can be found in the full-text articles included in the systematic review and meta-analysis.

**Acknowledgments:** We would like to thank Norbert M. Wikonkál and Antal Jobbágy for their valuable insights and support.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Kapp, S.; Miller, C.; Santamaria, N. The quality of life of people who have chronic wounds and who self-treat. *J. Clin. Nurs.* **2018**, *27*, 182–192. [[CrossRef](#)]
2. Olsson, M.; Järbrink, K.; Divakar, U.; Bajpai, R.; Upton, Z.; Schmidtchen, A.; Car, J. The humanistic and economic burden of chronic wounds: A systematic review. *Wound Repair Regen.* **2019**, *27*, 114–125. [[CrossRef](#)]

3. Morton, L.M.; Phillips, T.J. Wound healing and treating wounds: Differential diagnosis and evaluation of chronic wounds. *J. Am. Acad. Derm.* **2016**, *74*, 589–605, quiz 5–6. [[CrossRef](#)]
4. Powers, J.G.; Higham, C.; Broussard, K.; Phillips, T.J. Wound healing and treating wounds: Chronic wound care and management. *J. Am. Acad. Derm.* **2016**, *74*, 607–625, quiz 25–26. [[CrossRef](#)]
5. Hesseler, M.J.; Shyam, N. Platelet-rich plasma and its utility in medical dermatology: A systematic review. *J. Am. Acad. Derm.* **2019**, *81*, 834–846. [[CrossRef](#)]
6. Eppley, B.L.; Woodell, J.E.; Higgins, J. Platelet quantification and growth factor analysis from platelet-rich plasma: Implications for wound healing. *Plast. Reconstr. Surg.* **2004**, *114*, 1502–1508. [[CrossRef](#)]
7. Qu, W.; Wang, Z.; Hunt, C.; Morrow, A.S.; Urtecho, M.; Amin, M.; Shah, S.; Hasan, B.; Abd-Rabu, R.; Ashmore, Z.; et al. The effectiveness and safety of platelet-rich plasma for chronic wounds: A systematic review and meta-analysis. *Mayo Clin. Proc.* **2021**, *96*, 2407–2417. [[CrossRef](#)]
8. *Cochrane Handbook for Systematic Reviews of Interventions*; Cochrane: London, UK, 2022.
9. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The prisma 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* **2021**, *372*, n71. [[CrossRef](#)]
10. Sterne, J.A.C.; Savovic, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. Rob 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* **2019**, *366*, l4898. [[CrossRef](#)]
11. Iorio, A.; Spencer, F.A.; Falavigna, M.; Alba, C.; Lang, E.; Burnand, B.; McGinn, T.; Hayden, J.; Williams, K.; Shea, B.; et al. Use of grade for assessment of evidence about prognosis: Rating confidence in estimates of event rates in broad categories of patients. *BMJ* **2015**, *350*, h870. [[CrossRef](#)]
12. R Core Team. *R: A Language and Environment for Statistical Computing*; R Foundation for Statistical Computing: Vienna, Austria, 2022.
13. Schwarzer, G. *Meta: General Package for Meta-Analysis, Version 6.0-0*; R Foundation for Statistical Computing: Vienna, Austria, 2022.
14. Cuijpers, P.; Furukawa, T.; Ebert, D.D. *dMetar: Companion R Package for the Guide Doing Meta-Analysis in R*; R Foundation for Statistical Computing: Vienna, Austria, 2022.
15. Mantel, N.; Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. *J. Natl. Cancer Inst.* **1959**, *22*, 719–748.
16. Robins, J.; Greenland, S.; Breslow, N.E. A general estimator for the variance of the mantel-haenszel odds ratio. *Am. J. Epidemiol.* **1986**, *124*, 719–723. [[CrossRef](#)]
17. Thompson, S.G.; Turner, R.M.; Warn, D.E. Multilevel models for meta-analysis, and their application to absolute risk differences. *Stat. Methods Med. Res.* **2001**, *10*, 375–392. [[CrossRef](#)]
18. *The Handbook of Research Synthesis and Meta-Analysis*, 2nd ed.; Russell Sage Foundation: New York, NY, USA, 2009.
19. Sweeting, M.J.; Sutton, A.J.; Lambert, P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat. Med.* **2004**, *23*, 1351–1375. [[CrossRef](#)]
20. Harrer, M.; Cuijpers, P.; Furukawa, T.A.; Ebert, D.D. *Doing Meta-Analysis with r: A Hands-On Guide*, 1st ed.; Chapman & Hall/CRC Press: Boca Raton, FL, USA; London, UK, 2021.
21. Higgins, J.P.T.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. *Stat. Med.* **2002**, *21*, 1539–1558. [[CrossRef](#)]
22. Knapp, G.; Hartung, J. Improved tests for a random effects meta-regression with a single covariate. *Stat. Med.* **2003**, *22*, 2693–2710. [[CrossRef](#)]
23. Harbord, R.M.; Egger, M.; Sterne, J.A.C. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. *Stat. Med.* **2006**, *25*, 3443–3457. [[CrossRef](#)]
24. Viechtbauer, W.; Cheung, M.W.L. Outlier and influence diagnostics for meta-analysis. *Res. Synth. Methods* **2010**, *1*, 112–125. [[CrossRef](#)]
25. Abd El-Mabood, E.A.; Ali, H.E. Platelet-rich plasma versus conventional dressing: Does this really affect diabetic foot wound-healing outcomes? *Egypt. J. Surg.* **2018**, *37*, 16–26. [[CrossRef](#)]
26. Ahmed, M.; Reffat, S.A.; Hassan, A.; Eskander, F. Platelet-rich plasma for the treatment of clean diabetic foot ulcers. *Ann. Vasc. Surg.* **2017**, *38*, 206–211. [[CrossRef](#)]
27. Alamdari, N.M.; Sha, A.; Mirmohseni, A.; Besharat, S. Evaluation of the efficacy of platelet-rich plasma on healing of clean diabetic foot ulcers: A randomized clinical trial in Tehran, Iran. *Diabetes Metab. Syndr. Clin. Res. Rev.* **2021**, *15*, 621–626. [[CrossRef](#)] [[PubMed](#)]
28. Amato, B.; Farina, M.A.; Campisi, S.; Ciliberti, M.; di Donna, V.; Florio, A.; Grasso, A.; Miranda, R.; Pompeo, F.; Farina, E.; et al. Cgf treatment of leg ulcers: A randomized controlled trial. *Open Med.* **2020**, *14*, 959–967. [[CrossRef](#)] [[PubMed](#)]
29. Anitua, E.; Aguirre, J.J.; Algorta, J.; Ayerdi, E.; Cabezas, A.I.; Orive, G.; Andia, I. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2008**, *84*, 415–421. [[CrossRef](#)] [[PubMed](#)]
30. Burgos-Alonso, N.; Lobato, I.; Hernandez, I.; Sebastian, K.S.; Rodriguez, B.; March, A.G.; Perez-Salvador, A.; Arce, V.; Garcia-Alvarez, A.; Gomez-Fernandez, M.C.; et al. Autologous platelet-rich plasma in the treatment of venous leg ulcers in primary care: A randomised controlled, pilot study. *J. Wound Care* **2018**, *27*, S20–S24. [[CrossRef](#)]





31. Cardenosa, M.E.; Dominguez-Maldonado, G.; Cordoba-Fernandez, A. Efficacy and safety of the use of platelet-rich plasma to manage venous ulcers. *J. Tissue Viability* **2017**, *26*, 138–143. [[CrossRef](#)]
32. Chandanwale, K.A.; Mahakalkar, C.C.; Kothule, A.K.; Khithani, D.V. Management of wounds of peripheral arterial disease using platelet rich plasma. *J. Evol. Med. Dent. Sci.* **2020**, *9*, 2239–2245. [[CrossRef](#)]
33. de Oliveira, M.G.; Abbade, L.P.F.; Miot, H.A.; Ferreira, R.R.; Deffune, E. Pilot study of homologous platelet gel in venous ulcers. *An. Bras. Dermatol.* **2017**, *92*, 499–504. [[CrossRef](#)]
34. Driver, V.R.; Hanft, J.; Fylling, C.P.; Beriou, J.M. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. *Ostomy/Wound Manag.* **2006**, *52*, 68–70, 72, 74 passim.
35. Elbarbary, A.H.; Hassan, H.A.; Elbendak, E.A. Autologous platelet-rich plasma injection enhances healing of chronic venous leg ulcer: A prospective randomised study. *Int. Wound J.* **2020**, *17*, 992–1001. [[CrossRef](#)]
36. Elgarhy, L.H.; El-Ashmawy, A.A.; Bedeer, A.E.; Al-Bahnasy, A.M. Evaluation of safety and efficacy of autologous topical platelet gel vs platelet rich plasma injection in the treatment of venous leg ulcers: A randomized case control study. *Dermatol. Ther.* **2020**, *33*, e13897. [[CrossRef](#)]
37. Elsaïd, A.; El-Said, M.; Emile, S.; Youssef, M.; Khafagy, W.; Elshobaky, A. Randomized controlled trial on autologous platelet-rich plasma versus saline dressing in treatment of non-healing diabetic foot ulcers. *World J. Surg.* **2020**, *44*, 1294–1301. [[CrossRef](#)]
38. Game, F.; Jeffcoate, W.; Tarnow, L.; Jacobsen, J.L.; Whitham, D.; Harrison, E.F.; Ellender, S.J.; Fitzsimmons, D.; Londahl, M.; LeucoPatch, I.I.T.T. Leucopatch system for the management of hard-to-heal diabetic foot ulcers in the uk, denmark, and sweden: An observer-masked, randomised controlled trial. *Lancet Diabetes Endocrinol.* **2018**, *6*, 870–878. [[CrossRef](#)] [[PubMed](#)]
39. Glukhov, A.A.; Aralova, M.V. The study of the effectiveness of the drug combination of collagen and platelet-rich plasma for the regional treatment of venous ulcers. *Res. J. Pharm. Biol. Chem. Sci.* **2017**, *8*, 2258–2263.
40. Goda, A.A. Autogenous leucocyte-rich and platelet-rich fibrin for the treatment of leg venous ulcer: A randomized control study. *Egypt. J. Surg.* **2018**, *37*, 316–321. [[CrossRef](#)]
41. Goda, A.A.; Metwally, M.; Ewada, A.; Ewees, H. Platelet-rich plasma for the treatment of diabetic foot ulcer: A randomized, double-blind study. *Egypt. J. Surg.* **2018**, *37*, 178–184. [[CrossRef](#)]
42. Gude, W.; Hagan, D.; Abood, F.; Clausen, P. Aurix gel is an effective intervention for chronic diabetic foot ulcers: A pragmatic randomized controlled trial. *Adv. Ski. Wound Care* **2019**, *32*, 416–426. [[CrossRef](#)]
43. Helmy, Y.; Farouk, N.; Dahy, A.A.; Abu-Elvoud, A.; Khattab, R.F.; Mohammed, S.E.; Gad, L.A.; Altramsy, A.; Hussein, E.; Farahat, A. Objective assessment of platelet-rich plasma (prp) potentiality in the treatment of chronic leg ulcer: Rct on 80 patients with venous ulcer. *J. Cosmet. Dermatol.* **2021**, *20*, 3257–3263. [[CrossRef](#)]
44. Hongying, J.; Liang, Z.; Xi, Y.; Jing, H.; Xiaona, X.; Zhengyan, L.; Hongchen, H. Effect of platelet-rich plasma on pressure ulcers after spinal cord injury. *Chin. J. Tissue Eng. Res.* **2020**, *25*, 1149–1153.
45. Karimi, R.; Afshar, M.; Salimian, M.; Sharif, A.; Hidariyan, M. The effect of platelet rich plasma dressing on healing diabetic foot ulcers. *Nurs. Midwifery Stud.* **2016**, *5*, e30314. [[CrossRef](#)]
46. Khorvash, F.; Pourahmad, M.; Khoshchingol, N.; Avijgan, M.; Mohammadi, M.; Sahebazar, K. Comparing the effects of the platelet-rich plasma gel with wound therapeutic methods on the treatment of diabetic foot. *J. Isfahan Med. Sch.* **2017**, *35*, 1389–1395.
47. Kulkarni, S.R.; Chawla, A. Study of efficacy of platelet rich plasma dressing in management of chronic non-healing leg ulcers. *J. Evol. Med. Dent. Sci.* **2019**, *8*, 1307–1310.
48. Li, L.; Chen, D.; Wang, C.; Yuan, N.; Wang, Y.; He, L.; Yang, Y.; Chen, L.; Liu, G.; Li, X.; et al. Autologous platelet-rich gel for treatment of diabetic chronic refractory cutaneous ulcers: A prospective, randomized clinical trial. *Wound Repair Regen.* **2015**, *23*, 495–505. [[CrossRef](#)] [[PubMed](#)]
49. Milek, T.; Nagraba, L.; Mitek, T.; Wozniak, W.; Mlosek, K.; Olszewski, W.; Ciostek, P.; Deszczynski, J.; Kuchar, E.; Stolarczyk, A. Autologous platelet-rich plasma reduces healing time of chronic venous leg ulcers: A prospective observational study. In *Advances in Biomedicine*; Pokorski, M., Ed.; Springer: Cham, Switzerland, 2019; Volume 1176, pp. 109–117.
50. Mohammad, A.; Rohangiz, K.; Morteza, S.; Alireza, S.; Abolfazl, A. Comparison of platelet rich plasma and normal saline dressing effectiveness in the improvement of diabetic foot ulcers. *J. Diabet. Nurs.* **2017**, *5*, 246–255.
51. Moneib, H.A.; Youssef, S.S.; Aly, D.G.; Rizk, M.A.; Abdelhakeem, Y.I. Autologous platelet-rich plasma versus conventional therapy for the treatment of chronic venous leg ulcers: A comparative study. *J. Cosmet. Dermatol.* **2018**, *17*, 495–501. [[CrossRef](#)] [[PubMed](#)]
52. Obolenskiy, V.N.; Ermolova, D.A.; Laberko, L.A. Clinical and economic effectiveness of the use of platelet-rich plasma in the treatment of chronic wounds. *Wound Med.* **2017**, *19*, 27–32. [[CrossRef](#)]
53. Obolenskiy, V.N.; Ermolova, D.A.; Laberko, L.A.; Semenova, T.V. Efficacy of platelet-rich plasma for the treatment of chronic wounds. *EWMA J.* **2014**, *14*, 37–41.
54. Pires, B.; de Oliveira, B.G.R.B.; Bokehi, L.C.; Luiz, R.R.; Carvalho, B.T.F.; Santana, R.F.; de Souza, P.A.; de Paula, G.R.; Teixeira, L.A. Clinical and microbiological outcomes associated with use of platelet-rich plasma in chronic venous leg ulcers: A randomized controlled trial. *J. Wound Ostomy Cont. Nurs. Off. Publ. Wound Ostomy Cont. Nurses Soc.* **2021**, *48*, 292–299. [[CrossRef](#)]
55. Pu, D.; Lei, X.; Leng, W.; Zheng, Y.; Chen, L.; Liang, Z.; Chen, B.; Wu, Q. Lower limb arterial intervention or autologous platelet-rich gel treatment of diabetic lower extremity arterial disease patients with foot ulcers. *Ann. Transl. Med.* **2019**, *7*, 485. [[CrossRef](#)] [[PubMed](#)]

56. Qin, X.; Wang, J. Clinical study of local injection of autologous platelet-rich plasma in treatment of diabetic foot ulcer. *Chin. J. Reparative Reconstr. Surg.* **2019**, *33*, 1547–1551.
57. Rainys, D.; Cepas, A.; Dambrauskaite, K.; Nedzelskiene, I.; Rimdeika, R. Effectiveness of autologous platelet-rich plasma gel in the treatment of hard-to-heal leg ulcers: A randomised control trial. *J. Wound Care* **2019**, *28*, 658–667. [[CrossRef](#)]
58. Ramos-Torrecillas, J.; Garcia-Martínez, O.; de Luna-Bertos, E.; Ocaña-Peinado, F.M.; Ruiz, C. Effectiveness of platelet-rich plasma and hyaluronic acid for the treatment and care of pressure ulcers. *Biol. Res. Nurs.* **2015**, *17*, 152–158. [[CrossRef](#)] [[PubMed](#)]
59. Saad Setta, H.; Elshahat, A.; Elsherbiny, K.; Massoud, K.; Safe, I. Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: A comparative study. *Int. Wound J.* **2011**, *8*, 307–312. [[CrossRef](#)] [[PubMed](#)]
60. Saha, S.; Patra, A.C.; Gowda, S.P.; Mondal, N.; Rahaman, S.; Ahmed, S.K.S.; Debbarma, S.; Vitthal, K.P.K.; Sarkar, S.; Sil, A.; et al. Effectiveness and safety of autologous platelet-rich plasma therapy with total contact casting versus total contact casting alone in treatment of trophic ulcer in leprosy: An observer-blind, randomized controlled trial. *Indian J. Derm. Venereol. Leprol.* **2020**, *86*, 262–271.
61. Semenič, D.; Cirman, T.; Rožman, P.; Smrke, D.M. Regeneration of chronic wounds with allogeneic platelet gel versus hydrogel treatment: A prospective study. *Acta Clin. Croat.* **2018**, *57*, 434–442. [[CrossRef](#)] [[PubMed](#)]
62. Singh, G.; Borah, D.; Khanna, G.; Jain, S. Efficacy of local autologous platelet-rich plasma in the treatment of pressure ulcer in spinal cord injury patients. *Cureus* **2021**, *13*, e18668. [[CrossRef](#)]
63. Singh, S.P.; Kumar, V.; Pandey, A.; Pandey, P.; Gupta, V.; Verma, R. Role of platelet-rich plasma in healing diabetic foot ulcers: A prospective study. *J. Wound Care* **2018**, *27*, 550–556. [[CrossRef](#)]
64. Sokolov, T.; Manukova, A.; Karakoleva, S.; Valentinov, B.; Petrova, N. Analysis of the results of applying the method platelet-rich plasma (prp) for the treatment of problematic skin wounds. *J. IMAB* **2017**, *23*, 1460–1465. [[CrossRef](#)]
65. Somani, A.; Rai, R. Comparison of efficacy of autologous platelet-rich fibrin versus saline dressing in chronic venous leg ulcers: A randomised controlled trial. *J. Cutan. Aesthetic Surg.* **2017**, *10*, 8–12.
66. Tsachiridi, M.; Galyfos, G.; Andreou, A.; Sianou, A.; Sigala, F.; Zografos, G.; Filis, K. Autologous platelet-rich plasma for nonhealing ulcers: A comparative study. *Vasc. Spec. Int.* **2019**, *35*, 22–27. [[CrossRef](#)]
67. Tsai, H.C.; Lehman, C.W.; Chen, C.M. Use of platelet-rich plasma and platelet-derived patches to treat chronic wounds. *J. Wound Care* **2019**, *28*, 15–21. [[CrossRef](#)]
68. Ucar, O.; Celik, S. Comparison of platelet-rich plasma gel in the care of the pressure ulcers with the dressing with serum physiology in terms of healing process and dressing costs. *Int. Wound J.* **2020**, *17*, 831–841. [[CrossRef](#)]
69. Yang, L.; Gao, L.; Lv, Y.; Wang, J. Autologous platelet-rich gel for lower-extremity ischemic ulcers in patients with type 2 diabetes. *Int. J. Clin. Exp. Med.* **2017**, *10*, 13796–13801.
70. Yuvasri, G.; Rai, R. Comparison of efficacy of autologous platelet-rich fibrin versus unna's paste dressing in chronic venous leg ulcers: A comparative study. *Indian Dermatol. Online J.* **2020**, *11*, 58–61. [[PubMed](#)]
71. Kakagia, D.D.; Kazakos, K.J.; Xarchas, K.C.; Karanikas, M.; Georgiadis, G.S.; Tripsiannis, G.; Manolas, C. Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. *J. Diabetes Its Complicat.* **2007**, *21*, 387–391. [[CrossRef](#)] [[PubMed](#)]
72. Senet, P.; Bon, F.-X.; Benbunan, M.; Bussel, A.; Traineau, R.; Calvo, F.; Dubertret, L.; Dosquet, C. Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers. *J. Vasc. Surg.* **2003**, *38*, 1342–1348. [[CrossRef](#)]
73. Baranovskiy, Y.G.; Ilchenko, F.N.; Shapovalova, E.Y.; Kaliberdenko, V.B.; Shanmugaraj, K.; Keerthanaa, B. Influence of autologous platelet concentrates on the dynamics of regenerative processes in treatment of trophic ulcers of lower extremities. *Indian J. Public Health Res. Dev.* **2019**, *10*, 1850–1855.
74. Capoano, R.; Businaro, R.; Tesori, M.C.; Donello, C.; Lombardo, F.; Vasco, V.R.L.; Capriotti, L.; Corsi, M.; Raimo, T.D.; Leopizzi, M.; et al. Wounds difficult to heal: An effective treatment strategy. *Curr. Vasc. Pharmacol.* **2017**, *15*, 582–588. [[CrossRef](#)]
75. Li, L.; Wang, C.; Wang, Y.; He, L.P.; Yang, Y.Z.; Chen, L.H.; Chen, D.W.; Li, X.J.; Ran, X.W. Impact of topical application of autologous platelet-rich gel on medical expenditure and length of stay in hospitals in diabetic patients with refractory cutaneous ulcers. *J. Sichuan Univ. (Med. Sci. Ed.)* **2012**, *43*, 762–765.
76. Liu, G.Y.; Deng, X.L.; Sun, Y.; Wang, M.Z.; Gao, J.; Gou, J. Effect of autologous platelet-rich gel on the treatment of diabetic foot ulcers. *J. Xi'an Jiaotong Univ. (Med. Sci.)* **2016**, *37*, 264–267.
77. Madhumitha, M.; Srinivasan, S. A study of efficacy of autologous platelet rich plasma in the treatment of chronic diabetic foot ulcers. *Int. J. Pharm. Res.* **2019**, *11*, 190–196.
78. Martí, X.; Linares, P.; Bonell, A.; Acosta, M.; Llorca, C.; Lapedra, O. Growth factors used in healing venous ulcers. *Chirurgia* **2008**, *21*, 17–20.
79. Slaninka, I.; Klein, L.; Čáp, R.; Hošek, F.; Guňka, I.; Šedivý, O.; Jiška, S.; Kaška, M. Optimizing the treatment procedure in crural ulcers—A pilot study of the surgical method. *Rozhl. Chir.* **2015**, *94*, 69–73. [[PubMed](#)]
80. Smagin, M.A.; Shumkov, O.A.; Soluianov, M.I.; Demura, A.U.; Smagin, A.A.; Lykov, A.P.; Nimaev, V.V. Treatment of torpid trophic ulcers in patients of the older age group. *Adv. Gerontol.* **2020**, *33*, 373–378. [[PubMed](#)]
81. Wang, L.; Liu, G.; Li, Z.; Jia, B.C.; Wang, Y. Clinical application of platelet-rich fibrin in chronic wounds combined with subcutaneous stalking sinus. *Chin. J. Burn.* **2018**, *34*, 637–642.

- 
82. Gupta, A.; Channaveera, C.; Sethi, S.; Ranga, S.; Anand, V. Efficacy of intralesional platelet-rich plasma in diabetic foot ulcer. *J. Am. Podiatr. Med. Assoc.* **2021**, *111*, 7. [[CrossRef](#)]
  83. Hegyi, P.; Erőss, B.; Izbéki, F.; Párniczky, A.; Szentesi, A. Accelerating the translational medicine cycle: The academia europaea pilot. *Nat. Med.* **2021**, *27*, 1317–1319. [[CrossRef](#)]

## Systematic Review

# Platelet-Rich Plasma in Alopecia Areata—A Steroid-Free Treatment Modality: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Fanni Adél Meznerics <sup>1,2</sup>, Kata Illés <sup>2,3</sup>, Fanni Dembrowszky <sup>2,4</sup>, Péter Fehérvári <sup>2,5</sup>, Lajos Vince Kemény <sup>1</sup> , Kata Dorottya Kovács <sup>1</sup>, Norbert Miklós Wikonkál <sup>1</sup>, Dezső Csupor <sup>2,4,6</sup> , Péter Hegyi <sup>2,4,7</sup> and András Bánvölgyi <sup>1,\*</sup>

- <sup>1</sup> Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, 1085 Budapest, Hungary; meznerics.fanni@stud.semmelweis.hu (F.A.M.); kemeny.lajos@med.semmelweis-univ.hu (L.V.K.); katedorotie@gmail.com (K.D.K.); wikonkal.norbert@med.semmelweis-univ.hu (N.M.W.)
- <sup>2</sup> Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary; illes.kata@bajcsy.hu (K.I.); dembrowszky.fanni@semmelweis-univ.hu (F.D.); fehevari.peter@univet.hu (P.F.); csupor.dezso@pharmacognosy.hu (D.C.); p.hegyi@tm-centre.org (P.H.)
- <sup>3</sup> Department of Otorhinolaryngology, Head and Neck Surgery, Bajcsy-Zsilinszky Hospital, 1106 Budapest, Hungary
- <sup>4</sup> Institute for Translational Medicine, Medical School, Szentágotthai Research Centre, University of Pécs, 7624 Pécs, Hungary
- <sup>5</sup> Department of Biomathematics and Informatics, University of Veterinary Medicine, 1078 Budapest, Hungary
- <sup>6</sup> Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary
- <sup>7</sup> Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, 1085 Budapest, Hungary
- \* Correspondence: banvolgyi.andras@med.semmelweis-univ.hu



**Citation:** Meznerics, F.A.; Illés, K.; Dembrowszky, F.; Fehérvári, P.; Kemény, L.V.; Kovács, K.D.; Wikonkál, N.M.; Csupor, D.; Hegyi, P.; Bánvölgyi, A. Platelet-Rich Plasma in Alopecia Areata—A Steroid-Free Treatment Modality: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *Biomedicines* **2022**, *10*, 1829. <https://doi.org/10.3390/biomedicines10081829>

Academic Editor: Ubaldo Armato

Received: 10 June 2022

Accepted: 25 July 2022

Published: 29 July 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** Background: Alopecia areata (AA) is a chronic autoimmune condition that can lead to a serious deterioration in patients' quality of life. The first line of treatment in patchy AA is triamcinolone acetonide (TrA); however, the efficacy of the treatment varies greatly. Our aim was to investigate the therapeutic effects of platelet-rich plasma (PRP) in the treatment of AA. Method: We performed a systematic literature search in four databases. Randomized clinical trials (RCT) reporting on patients with AA treated with PRP were included, comparing PRP with TrA or a placebo. The primary outcome was the Severity of Alopecia Tool (SALT) score. Results: Our systematic search provided a total of 2747 articles. We identified four studies eligible for quantitative analysis. The pooled mean differences from the four studies did not exhibit a significant difference in the mean change in the SALT score when PRP and TrA groups were compared (MD = −2.04, CI: −4.72–0.65;  $I^2 = 80.4%$ ,  $p = 0.14$ ). Conclusions: PRP is a promising topical, steroid-free treatment modality in the therapy of AA. No significant difference was found between PRP and TrA treatment; however, further high-quality RCTs are needed to further assess the efficacy of PRP treatment and strengthen the quality of evidence.

**Keywords:** alopecia areata; patchy alopecia; platelet-rich plasma; treatment; topical

## 1. Introduction

Alopecia areata (AA) is an autoimmune condition characterized by inflammation-induced hair loss due to the collapse of the hair follicles' immune privilege [1]. It can affect the scalp, the beard, or even the whole body, leading to a serious deterioration in patients' quality of life [2]. In the case of AA of the scalp, three categories can be differentiated based on the extent of the disease-affected area: limited patchy AA with less than 50% scalp involvement, extensive patchy AA with more than 50% scalp involvement, and alopecia totalis, affecting the whole scalp [3].

A wide spectrum of topical and systemic agents is used in the management of AA; however, there is a lack of consensus on a standard treatment modality due to the disease's varying response to therapy [4]. The limited patchy forms of AA are usually treated with topical agents, such as corticosteroids, contact immunotherapy (1-chloro,2,4-dinitrobenzene (DNCB), squaric acid dibutylester (SADBE), and 2,3-diphenylcyclopropenone (DPCP)), and minoxidil; however, the efficacy of the latter treatments is questionable [5]. According to guidelines, the first line of treatment in limited patchy AA is triamcinolone acetonide (TrA) administered intralesionally [5,6]. Besides the frequently disputed efficacy of TrA treatment, side effects, such as skin atrophy, teleangiectasia, and hypopigmentation, frequently occur. Additionally, the use of steroids is alarming to many; a phenomenon called steroid phobia exists [7]. These provide additional reasons to look for new topical, steroid-free treatment modalities.

Platelet-rich plasma (PRP) is a relatively new, presently evolving treatment modality that is playing an increasingly important role in the field of dermatology. The efficacy of PRP varies greatly and is being investigated in numerous dermatological disorders, such as androgenic alopecia, acne scar treatment, or chronic wound management [8–10]. PRP is prepared from whole blood by a centrifugation process to achieve a product that is rich in platelets, growth factors, and cytokines. Based on the number of centrifugations, single-spin and double-spin preparation methods can be differentiated [11,12]. PRP was shown to stimulate cell proliferation in the dermal papilla (DP), increase DP cell survival through antiapoptotic effects, and stimulate hair regrowth by prolonging the anagen phase of the hair cycle [13].

The Severity of Alopecia Tool (SALT) score, the most widely used method to monitor the response to therapy, is an objective outcome measure to evaluate the severity of the disease. It is determined by visually assessing the percentage of hair loss, resulting in a score from 0 to 100 analogous to the percentage of the affected area [14]. In limited patchy AA, the SALT score is lower than 50, indicating that the scalp involvement is below 50% [3,14].

Several studies have reported promising results of PRP in the treatment of AA [15–20], but there has been no systematic evaluation of randomized trials reporting on the therapeutic effect of PRP on AA to date. Our aim was to investigate the therapeutic effects of PRP in the treatment of limited patchy AA by conducting a systematic review and meta-analysis, comparing PRP with the first line of treatment in limited patchy AA, TrA [10,13]. Our hypothesis was that PRP is as good as TrA in the treatment of AA.

## 2. Materials and Methods

Our systematic review and meta-analysis are reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 Statement [21]. This study was performed following the Cochrane Handbook's recommendations for Systematic Reviews of Interventions Version 6.3. [22]. The review protocol was registered on PROSPERO (York, UK) under registration number CRD42021282807 (see <https://www.crd.york.ac.uk/prospere>, accessed on 14 October 2021); no amendments to the information provided at registration were made.

### 2.1. Literature Search and Eligibility Criteria

We performed a systematic literature search in four medical databases: MEDLINE (via PubMed), Cochrane Library (CENTRAL), Embase, and Web of Science, from inception to 15 October 2021. We applied the query ((alopecia areata OR patchy alopecia) AND (platelet rich plasma OR PRP OR steroid OR corticosteroid OR triamcinolone)) to all fields in the search engines. No language or other restrictions were imposed.

Randomized clinical trials (RCTs) reporting on patients with AA treated with PRP were included, comparing PRP with TrA or a placebo. The following population–intervention–control–outcome (PICO) framework was used:

P—Adult patients with patchy AA;



I—Intralesional autologous PRP injections to the AA-affected areas;  
C<sub>1</sub>—Intralesional placebo injections to the AA-affected areas;  
C<sub>2</sub>—Intralesional (TrA) injections to the AA-affected areas;  
O—Primary outcome: SALT score; secondary outcomes: hair dystrophy, patient safety, cytokine expression, burning/itching sensation, Hair Regrowth Grade scale, Patient Global Assessment score, cell proliferation.

Publications without separate intervention and control groups (split scalp studies) were excluded.

## 2.2. Study Selection and Data Collection

We used EndNote X9 (Clarivate Analytics, Philadelphia, PA, USA) for the articles' selection. Two independent authors (F.A.M. and K.I.) screened the publications separately for the title, abstract, and full text, and disagreements were resolved by a third author (F.D.).

Two authors (F.A.M. and K.D.K.) independently extracted data into a predefined Excel spreadsheet (Office 365, Microsoft, Redmond, WA, USA). The following data were collected from each eligible article: first author, year of publication, study type, study location, number of centers included in the study, study design, demographic data (sample sizes, age, and percentage of participating females), details of the received treatments, and data regarding our outcomes (baseline SALT score and SALT score after treatment, and secondary outcomes) for statistical analysis. A third reviewer (F.D.) resolved the discrepancies. Based on the baseline SALT scores and the post-treatment SALT scores reported in the included studies, we calculated the mean change in the SALT score in both the PRP and TrA groups, and the mean difference (MD) between the two groups.

## 2.3. Quality Assessment and Quality of Evidence

The quality assessment of the outcomes was carried out separately by two reviewers (F.A.M. and K.D.K.) using the revised tool for assessing the risk of bias (RoB 2) [23]. Disagreements were resolved by a third reviewer (F.D.). The recommendations of the "Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)" workgroup were followed to evaluate the quality of evidence [24].


## 2.4. Data Synthesis and Analysis

The mean baseline SALT score and SALT score after treatment were extracted for both the TrA and PRP groups. We calculated the change in the mean SALT scores for each study, and, where applicable, we also extracted the standard deviation (SD) of within-group differences. If this latter value was not published, but t-tests or ANOVA were used, we calculated the SD from the reported *p* values, or in the case of non-parametric tests, we obtained a conservative estimate of the SDs by adding together the reported before- and after-treatment SDs. Meta-analysis using random effects (DerSimonian and Laird) was performed following the recommendations of the Cochrane Handbook and Harrer et al. using R version 6.3 [22,25–27]. The heterogeneity of the studies was assessed with the Cochran Q test, with a significance level of 0.05 and I<sup>2</sup> statistic, and forest plots were constructed.

## 3. Results

### 3.1. Search and Selection

Our systematic search provided a total of 2747 articles; after duplicate removal, we screened 2002 duplicate-free articles. After the title, abstract, and full-text selection, we identified six RCTs matching our PICO framework [15–20]; of these articles, we could use four RCTs for our quantitative synthesis [15,17–19]. The results of the other two articles [16,20] and the results of two additional articles, which also included a placebo as a comparator [18,20], are discussed in the systematic review with the secondary outcomes. The summary of the selection process is shown in Figure 1.



**Figure 1.** PRISMA flow diagram of the screening and selection process according to PRISMA 2020 guidelines [21].

### 3.2. Main Characteristics of the Included Studies

The characteristics of the identified RCTs for the systematic review and meta-analysis are detailed in Tables 1 and 2.

**Table 1.** Main characteristics of the included studies.

First Author, Year of Publication	Country	Study Design	Number of Patients	Intervention	Control	Administration	Timepoints of Evaluation (weeks) <sup>a</sup>
Studies included in meta-analysis							
Albalat, 2019 [15]	Egypt	RCT	80	PRP injection (double-spin method)	TrA injection (5 mg/mL)	3–5 sessions, 2-week intervals	12
Fawzy, 2020 [17]	Egypt	RCT	31	PRP injection (single-spin method)	TrA injection (5 mg/mL)	3 sessions, 4-week intervals	12
Hegde, 2020 [18]	India	RCT	50	PRP injection (double-spin method)	TrA injection (10 mg/mL), placebo	3 sessions, 4-week intervals	16
Kapoor, 2020 [19]	India	RCT	40	PRP injection (single-spin method)	TrA injection (10 mg/mL)	4 sessions, 3-week intervals	3, 6, 9, 12 <sup>b</sup> , 24
Studies included only in systematic review							
Balakrishnan, 2020 [16]	India	RCT	32	PRP injection (double-spin method)	TrA injection (10 mg/mL)	3 sessions, 4-week intervals	0, 4, 8, 12
Trink, 2013 [20]	Italy	RCT	30	PRP injection (single-spin method)	TrA injection (2,5 mg/mL), placebo	3 sessions, 4-week intervals	8, 24, 48

<sup>a</sup> weeks after the first treatment session; <sup>b</sup> timepoint used in our calculations. RCT: randomized clinical trial; PRP: platelet-rich plasma; TrA: triamcinolone acetate.

**Table 2.** Patient characteristics of the studies included in the meta-analysis.


First Author, Year of Publication	Intervention (PRP) Group					Control (TrA) Group				
	Number of Patients	Age, Mean (SD)	Sex (Female % of Total)	Baseline SALT Score, Mean (SD)	Post-Treatment SALT Score, Mean (SD)	Number of Patients	Age, Mean (SD)	Sex (Female % of Total)	Baseline SALT Score, Mean (SD)	Post-Treatment SALT Score, Mean (SD)
Albalat, 2019 [15]	40	30.8 (7.5)	15.0	1.7 (0.9)	0.4 (0.7)	40	36.3 (11.3)	15.0	1.7 (0.8)	0.5 (0.8)
Fawzy, 2020 [17]	17	31.4 (10.6)	23.5	5.6 (8.4)	3.8 (8.4)	14	34.2 (12.3)	28.6	4.2 (4.4)	1.4 (1.8)
Hegde, 2020 [18]	25	N/A	N/A	7.2 (3.8)	4.0 (5.3)	25	N/A	N/A	8.8 (5.8)	3.1 (5.1)
Kapoor, 2020 [19]	20	25.4 (4.9)	45.0	4.4 (2.5)	3.2 (2.0)	20	28.8 (8.6)	65.0	9.0 (1.4)	3.1 (0.8)

SD: standard deviation; N/A: data not available; PRP: platelet-rich plasma; TrA: triamcinolone acetate; SALT score: Severity of Alopecia Tool score.

### 3.3. Primary Outcome (SALT score)

#### 3.3.1. PRP Compared to Triamcinolone Acetate

Two studies evaluated the post-treatment SALT score 12 weeks after the first treatment session [15,17], one study 16 weeks after the first treatment session [18], and one at multiple timepoints: weeks 3, 6, 9, 12, and 24 [19] (see Table 1). We used the SALT score of the 12th-week evaluation of this study for our meta-analytical calculations. The pooled MDs from four RCTs with a total of 201 subjects did not show a significant difference in the mean change in the SALT scores between the PRP and TrA groups (MD = −2.04; CI: −4.72–0.65;  $I^2 = 80.4\%$ ;  $n = 14$ ) (see Figure 2).



**Figure 2.** Forest plot for the mean decrease in the SALT score; platelet-rich plasma (PRP) compared to triamcinolone acetate (TrA).

Due to the high heterogeneity, we performed a leave-one-out analysis; the results are detailed in Table 3.

All studies included in our systematic review and meta-analysis showed a significant decrease in the SALT scores for PRP and TrA groups [15–20].

Two of the six publications originally selected used the SALT score as a primary outcome; however, due to missing data, we could not include them in our meta-analysis.

Balakrishnan et al. found no statistically significant difference between the SALT scores of the two groups when compared at different timepoints; however, the response in the PRP group was better than that in the TrA group [16]. When the decrease in the SALT score at different timepoints was investigated, there was a significant difference in the decrease in the SALT score between the PRP group and the TrA group at the second evaluation, 4 weeks after the first treatment session ( $p = 0.028$ ) [16]. After the last evaluation (12 weeks after the first treatment session), there was no statistically significant difference



between the two groups [16]. Trink et al. found that the SALT score decreased significantly in the PRP group compared with the TrA group ( $p < 0.001$ ) [20].

**Table 3.** Results of leave-one-out analysis.

Study	Quantitative Data Synthesis					Heterogeneity	
	PRP Group (n)	TrA Group (n)	Effect Size	95% CI	p Value	I <sup>2</sup>	T <sup>2</sup>
Overall Effect	102	99	−2.04	[−4.72; 0.65]	0.14	80.4%	2.24
Leave-one-out sensitivity analysis							
Albalat, 2019 [15]	62	59	−3.79	[−5.75; −1.83]	0.001	0.0%	0.04
Fawzy, 2020 [17]	85	85	−2.15	[−5.14; 0.83]	0.15	87.0%	5.57
Hegde, 2020 [18]	77	74	−1.94	[−5.62; 1.73]	0.30	85.0%	7.32
Kapoor, 2020 [19]	82	79	−0.57	[−2.54; 1.41]	0.57	9.0%	1.29

PRP: platelet-rich plasma; TrA: triamcinolone acetonide; CI: confidence interval.

The number of patients with complete hair regrowth is detailed below, since we could not conduct a meta-analysis due to the highly variable evaluation timepoints of the studies.

Trink et al., found that, 12 months after the first treatment session, complete remission was achieved in 26.6% of the patients in the TrA group and 60.0% of the patients in the PRP group [20]. Albalat et al. reported 16 patients (40.0%) in the TrA group and 18 patients (45.0%) in the PRP group with complete remission 8 weeks after the first treatment session [15]. Hegde et al. found that 10 patients (40.0%) in the TrA group and 11 patients (44.0%) in the PRP group achieved nearly complete hair regrowth 5 months after the first treatment ( $p = 0.779$ ) [18].

Two studies also used additional categorical scales to describe the decrease in the SALT score, both referring to them as the Hair Regrowth Grade (HRG) scale [16,19]. Comparing the HRG scale between PRP and TrA treatment, Balakrishnan et al. found no statistical significance, while Kapoor et al., reported a significant difference ( $p = 0.0002$ ): more patients from the TrA group were in the grade IV (50–74% reduction in SALT score) and grade V (>74% reduction in SALT score) categories after treatment compared with the PRP group [16,19].

### 3.3.2. PRP Compared to Placebo

Trink et al., found that PRP significantly increased hair regrowth in AA lesions compared with the placebo ( $p < 0.001$ ). PRP treatment also led to increased hair regrowth when compared with the untreated side of the scalp ( $p < 0.001$ ) [20].

Hegde et al. found that, 12 weeks after the first treatment session, PRP showed a higher percentage of regrowth than the placebo ( $p = 0.0108$ ) [18].

## 3.4. Secondary Outcomes

### 3.4.1. Patient Safety

#### Adverse Effects

Balakrishnan et al., Hegde et al., and Trink et al. did not record any side effects in the enrolled patients, nor were serious side effects observed in the study by Albalat et al. [15,16,18,20]. The only side effects observed in the study by Albalat et al. were erythema and a burning sensation after treatment sessions, without significant differences between the two groups [15]. Kapoor et al. reported atrophy in five patients from the TrA group, and the difference between the PRP and TrA groups was significant ( $p = 0.047$ ) [19].

### Administration-Related Pain

Three patients in the study by Balakrishnan et al. reported severe pain during administration in the PRP group, while there was none in the TrA group. Hegde et al. and Kapoor et al. also found significant differences between the two groups regarding pain ( $p < 0.05$ ): significantly higher visual analog scale (VAS) scores were recorded and a higher number of patients reported pain in the PRP group ( $p < 0.0001$ ) [18,19].

### Recurrence Rates

Trink et al. reported a 38% relapse in the TrA group and no relapse in the PRP group 6 months after the first treatment. Twelve months after the first treatment, 71% of the patients in the TrA group experienced a recurrence of the disease, whereas this rate was 31% of the PRP-group patients [20]. At the follow-up visit 6 months after the first treatment, two patients (5%) in the PRP group and 10 patients (25%) in the TrA group reported recurrence, according to Albalat et al. [15].

Further secondary outcomes are detailed in the Supplementary Results in the Supplementary Materials.

### 3.5. Risk of Bias Assessment

The results of the assessment of the risk of bias of the studies included in the meta-analysis and systematic review can be seen in Figures S1–S16 in the Supplementary Materials. None of the studies included in the meta-analysis were at high risk of bias. In three articles, the randomization process [15,17,19], and in two articles, the measurement of the outcome [18,19], were ranked as “some concerns”. Deviation from the intended intervention, missing outcome data, and the selection of the reported results domains were at low risk of bias.

### 3.6. Quality of Evidence

The quality of evidence was low for the primary outcome (SALT score).

## 4. Discussion

The studies included in our systematic review and meta-analysis all showed a significant decrease in the SALT score in both the PRP and TrA groups [15–20]. The pooled MDs from the four RCTs with a total of 201 subjects did not show a significant difference in the mean change in the SALT score between the PRP and TrA groups. Although we could not conduct a meta-analysis comparing PRP with a placebo, the included studies all concluded the superiority of PRP treatment [18,20]. These results could prove the efficacy of PRP as a steroid-free treatment modality. However, several factors could have influenced these results, such as the different doses of TrA used and the length of the follow-up.

The strength of the effect of TrA can be dose-dependent: RCTs investigating the most effective dilution of TrA showed that the 10 mg/mL dose achieved the best therapeutic response; however, due to the dose-dependent increasing risk of adverse effects, it is advised to start the treatment with lower doses [28,29]. Two of the four studies included in our meta-analysis used 5 mg/mL TrA, and two studies used 10 mg/mL TrA as a comparator [19]. The decrease in the SALT score was higher in the studies using a higher dose of TrA; nevertheless, one of the latter studies registered atrophy in five cases, assumably due to the higher doses of TrA. On the contrary, PRP can be used in an unlimited number of treatment sessions without increasing the risk of adverse effects [15,16,18–20].

Complete remission and recurrence are also important factors when choosing a therapy. Only one included RCT followed up patients for more than 6 months, and they recorded a higher number of cases with complete remission and lower recurrence rates with PRP compared with TrA one year after the first treatment session [20]. Albalat et al. followed up patients for 6 months, and they also recorded lower recurrence rates in the PRP group 6 months after the first treatment session [15].

Pain is also a considerable factor that can affect the utility of a therapeutic modality. Pain related to the treatment was more frequently reported in the PRP group; however, it could possibly be decreased with the application of a pre-treatment topical lidocaine–prilocaine cream with occlusion or with a minimally invasive application technique, such as microneedling [16,18,19,30].

#### 4.1. Strengths and Limitations

Our systematic search was conducted only 6 months before the submission of this manuscript; therefore, it includes every relevant study regarding this topic. We implemented a rigorous selection protocol and only included RCTs to obtain the highest possible quality of evidence, and it is also notable that all included studies were published recently. To our knowledge, this is the first meta-analysis to date comparing the efficacy of PRP to TrA, the first line of treatment of limited patchy AA.

The two main limitations of this study are the small sample size and high heterogeneity. Besides the small sample size, the inclusion of the study of Kapoor et al. can also be a potential reason for the high heterogeneity. Kapoor et al. used higher doses of TrA, the treatment sessions were more frequent compared with the other studies, and the baseline SALT score was also higher in the TrA group than in the PRP group. These discrepancies could explain the significantly higher mean decrease in the SALT score in the TrA group ( $p < 0.0001$ ). The leave-one-out analysis showed that, when excluding the study of Kapoor et al.,  $I^2$  decreased to 9.0% and the confidence interval narrowed. Different preparation methods of PRP in the included studies could also lead to high heterogeneity, since the superiority of the double-spin method to the single-spin method was shown in previous studies [11,12].

#### 4.2. Implications for Research

Our study demonstrated the efficacy of PRP in the treatment of patchy AA; however, further high-quality RCTs providing both within- and between-group detailed descriptive statistics are needed to better assess the efficacy and to strengthen the quality of evidence. The implementation of objective, comparable outcome measurements besides the SALT score could help to better assess complete remission, recurrence rates, and adverse effects. This would contribute to a better understanding of the pros and cons of each treatment modality and would also enable future systematic analysis using these parameters to further strengthen the quality of the current evidence.

Future RCTs should also focus on the comparison of PRP with different doses of TrA, since, while high doses of TrA lead to better improvement, they may also increase the risk of adverse effects [28,29]. A steroid-free treatment option, such as PRP, as a first-choice treatment could be beneficial, even if it shows slower improvement.

Follow-up protocols longer than 4 months would make it possible to see further differences between the two treatment modalities in order to better assess the complete remission and recurrence rates.

#### 4.3. Implications for Practice

Platelet-rich plasma is a steroid-free treatment modality that can be used in a virtually unlimited number of treatment sessions without increasing the risk of steroid-specific adverse effects [15,16,18–20]. The adverse effects of TrA treatment, such as atrophy, teleangiectasia, and hypopigmentation, can be especially problematic in the facial region. Since PRP is also safely used in facial rejuvenation, it could be an optimal therapeutic choice in facially localized AA [7,31,32]. The application of PRP with microneedling or fractional carbon dioxide laser treatment could be a more convenient method of administration, particularly in the facial region and in extensive cases of AA [30].

## 5. Conclusions

Platelet-rich plasma is a promising topical steroid-free treatment modality in the therapy of alopecia areata. No significant difference was found between PRP and TrA treatment; however, further high-quality RCTs are needed to better assess the efficacy of PRP and to strengthen the quality of evidence. PRP can be used in a virtually unlimited number of treatment sessions without increasing the risk of steroid-specific adverse effects, and it can also be an alternative option in the treatment of facially localized AA, in extensive cases of AA, or in cases of steroid phobia.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/biomedicines10081829/s1>, Supplementary Results: Secondary outcomes. Figure S1: Risk of bias assessment of the SALT score outcomes of the studies included in the meta-analysis using the revised tool for assessing the risk of bias in randomized trials (Rob 2). Figure S2: Risk of bias assessment of the SALT score outcomes of the studies included in the meta-analysis, broken down to tools, shown as percentage. Figure S3: Risk of bias assessment of the SALT score outcomes of the studies included in the systematic review using the revised tool for assessing the risk of bias in randomized trials (Rob 2). Figure S4: Risk of bias assessment of the SALT score outcomes of the studies included in the systematic review, broken down to tools, shown in percentage. Figure S5: Risk of bias assessment of the adverse effect outcomes of the studies included in the systematic review using the revised tool for assessing the risk of bias in randomized trials (Rob 2). Figure S6: Risk of bias assessment of the adverse effect outcomes of the studies included in the systematic review, broken down to tools, shown as percentages. Figure S7: Risk of bias assessment of the administration-related pain outcomes of the studies included in the systematic review using the revised tool for assessing the risk of bias in randomized trials (Rob 2). Figure S8: Risk of bias assessment of the administration-related pain outcomes of the studies included in the systematic review, broken down to tools, shown as percentages. Figure S9: Risk of bias assessment of the recurrence rate outcomes of the studies included in the systematic review, using the revised tool for assessing the risk of bias in randomized trials (Rob 2). Figure S10: Risk of bias assessment of the recurrence rate outcomes of the studies included in the systematic review, broken down to tools, shown as percentages. Figure S11: Risk of bias assessment of the dermoscopic evaluation outcomes of the studies included in the systematic review, using the revised tool for assessing the risk of bias in randomized trials (Rob 2). Figure S12: Risk of bias assessment of the dermoscopic evaluation outcomes of the studies included in the systematic review, broken down to tools, shown as percentages. Figure S13: Risk of bias assessment of the Ki-67-level outcomes of the studies included in the systematic review, using the revised tool for assessing the risk of bias in randomized trials (Rob 2). Figure S14: Risk of bias assessment of the Ki-67-level outcomes of the studies included in the systematic review, broken down to tools, shown as percentages. Figure S15: Risk of bias assessment of the burning/itching sensation outcomes of the studies included in the systematic review, using the revised tool for assessing the risk of bias in randomized trials (Rob 2). Figure S16: Risk of bias assessment of the burning/itching sensation outcomes of the studies included in the systematic review, broken down to tools, shown as percentages.

**Author Contributions:** (CRediT (Contributor Roles Taxonomy) author statement) [1] F.A.M.: conceptualization, project administration, data curation, visualization, and writing—original draft. K.I.: conceptualization and data curation. F.D.: conceptualization, data curation, and methodology. P.F.: methodology, formal analysis, validation, and visualization. L.V.K.: conceptualization and methodology. K.D.K.: conceptualization and data curation. N.M.W.: conceptualization and supervision. D.C.: conceptualization, methodology, and supervision. P.H.: conceptualization, methodology, and supervision. A.B.: conceptualization, methodology, supervision, and writing—original draft. All authors provided critical conceptual input and approved the final version of the article. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** No ethical approval was required for this review, as all data were already published in peer-reviewed journals. No patients were involved in the design, conducting, or interpretation of our study.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** Authors declare no conflict of interest.

## References

- Bertolini, M.; McElwee, K.; Gilhar, A.; Bulfone-Paus, S.; Paus, R. Hair follicle immune privilege and its collapse in alopecia areata. *Exp. Dermatol.* **2020**, *29*, 703–725. [[CrossRef](#)] [[PubMed](#)]
- Rencz, F.; Gulácsi, L.; Péntek, M.; Wikonkál, N.; Baji, P.; Brodsky, V. Alopecia areata and health-related quality of life: A systematic review and meta-analysis. *Br. J. Dermatol.* **2016**, *175*, 561–571. [[CrossRef](#)] [[PubMed](#)]
- Pratt, C.H.; King, L.E., Jr.; Messenger, A.G.; Christiano, A.M.; Sundberg, J.P. Alopecia areata. *Nat. Rev. Dis. Primers* **2017**, *3*, 17011. [[CrossRef](#)]
- Fukumoto, T.; Fukumoto, R.; Magno, E.; Oka, M.; Nishigori, C.; Horita, N. Treatments for alopecia areata: A systematic review and network meta-analysis. *Dermatol. Ther.* **2021**, *34*, e14916. [[CrossRef](#)]
- Messenger, A.G.; McKillop, J.; Farrant, P.; McDonagh, A.J.; Sladden, M. British association of dermatologists' guidelines for the management of alopecia areata 2012. *Br. J. Dermatol.* **2012**, *166*, 916–926. [[CrossRef](#)] [[PubMed](#)]
- Meah, N.; Wall, D.; York, K.; Bhoyrul, B.; Bokhari, L.; Sigall, D.A.; Bergfeld, W.F.; Betz, R.C.; Blume-Peytavi, U.; Callender, V.; et al. The alopecia areata consensus of experts (ace) study: Results of an international expert opinion on treatments for alopecia areata. *J. Am. Acad. Dermatol.* **2020**, *83*, 123–130. [[CrossRef](#)]
- Contento, M.; Cline, A.; Russo, M. Steroid phobia: A review of prevalence, risk factors, and interventions. *Am. J. Clin. Dermatol.* **2021**, *22*, 837–851. [[CrossRef](#)]
- Hesseler, M.J.; Shyam, N. Platelet-rich plasma and its utility in the treatment of acne scars: A systematic review. *J. Am. Acad. Dermatol.* **2019**, *80*, 1730–1745. [[CrossRef](#)] [[PubMed](#)]
- Qu, W.; Wang, Z.; Hunt, C.; Morrow, A.S.; Urtecho, M.; Amin, M.; Shah, S.; Hasan, B.; Abd-Rabu, R.; Ashmore, Z.; et al. The effectiveness and safety of platelet-rich plasma for chronic wounds: A systematic review and meta-analysis. *Mayo Clin. Proc.* **2021**, *96*, 2407–2417. [[CrossRef](#)]
- Gupta, A.K.; Cole, J.; Deutsch, D.P.; Everts, P.A.; Niedbalski, R.P.; Panchaprateep, R.; Rinaldi, F.; Rose, P.T.; Sinclair, R.; Vogel, J.E.; et al. Platelet-rich plasma as a treatment for androgenetic alopecia. *Dermatol. Surg.* **2019**, *45*, 1262–1273. [[CrossRef](#)]
- El-Husseiny, R.; Saleh, H.; Moustafa, A.; Salem, S. Comparison between single- versus double-spin prepared platelet-rich plasma injection in treatment of female pattern hair loss: Clinical effect and relation to vascular endothelial growth factor. *Arch. Dermatol. Res.* **2021**, *313*, 557–566. [[CrossRef](#)] [[PubMed](#)]
- Salem, S.A.; Elhusseiny, R.M.; Saleh, H.M. A split scalp study of single versus double spin platelet-rich plasma injections in treatment of female pattern hair loss: Clinical effect and relation to vascular endothelial growth factor in prp. *QJM Int. J. Med.* **2021**, *114*, 557–566. [[CrossRef](#)]
- Li, Z.J.; Choi, H.I.; Choi, D.K.; Sohn, K.C.; Im, M.; Seo, Y.J.; Lee, Y.H.; Lee, J.H.; Lee, Y. Autologous platelet-rich plasma: A potential therapeutic tool for promoting hair growth. *Dermatol. Surg.* **2012**, *38*, 1040–1046. [[CrossRef](#)] [[PubMed](#)]
- Olsen, E.A.; Roberts, J.; Sperling, L.; Tosti, A.; Shapiro, J.; McMichael, A.; Bergfeld, W.; Callender, V.; Mirmirani, P.; Washenik, K.; et al. Objective outcome measures: Collecting meaningful data on alopecia areata. *J. Am. Acad. Dermatol.* **2018**, *79*, 470–478.e3. [[CrossRef](#)]
- Albalat, W.; Ebrahim, H.M. Evaluation of platelet-rich plasma vs intralesional steroid in treatment of alopecia areata. *J. Cosmet. Dermatol.* **2019**, *18*, 1456–1462. [[CrossRef](#)] [[PubMed](#)]
- Balakrishnan, A.; Joy, B.; Thyvalappil, A.; Mathew, P.; Sreenivasan, A.; Sridharan, R. A comparative study of therapeutic response to intralesional injections of platelet-rich plasma versus triamcinolone acetonide in alopecia areata. *Indian Dermatol. Online J.* **2020**, *11*, 920–924.
- Fawzy, M.M.; Hay, R.A.; Mohammed, F.N.; Sayed, K.S.; Ghanem, M.E.D.; Ezzat, M. Trichoscopy as an evaluation method for alopecia areata treatment: A comparative study. *J. Cosmet. Dermatol.* **2021**, *20*, 1827–1836. [[CrossRef](#)] [[PubMed](#)]
- Hegde, P.; Relhan, V.; Sahoo, B.; Garg, V.K. A randomized, placebo and active controlled, split scalp study to evaluate the efficacy of platelet-rich plasma in patchy alopecia areata of the scalp. *Dermatol. Ther.* **2020**, *33*, e14388. [[CrossRef](#)]
- Kapoor, P.; Kumar, S.; Brar, B.K.; Kukar, N.; Arora, H.; Brar, S.K. Comparative evaluation of therapeutic efficacy of intralesional injection of triamcinolone acetonide versus intralesional autologous platelet-rich plasma injection in alopecia areata. *J. Cutan. Aesthet. Surg.* **2020**, *13*, 103–111.
- Trink, A.; Sorbellini, E.; Bezzola, P.; Rodella, L.; Rezzani, R.; Ramot, Y.; Rinaldi, F. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. *Br. J. Dermatol.* **2013**, *169*, 690–694. [[CrossRef](#)] [[PubMed](#)]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The prisma 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* **2021**, *372*, n71. [[CrossRef](#)] [[PubMed](#)]
- Chandler, J.; Hopewell, S. Cochrane methods—Twenty years experience in developing systematic review methods. *Syst. Rev.* **2013**, *2*, 76. [[CrossRef](#)] [[PubMed](#)]



23. Sterne, J.A.C.; Savovic, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. Rob 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* **2019**, *366*, 14898. [[CrossRef](#)] [[PubMed](#)]
24. Schünemann, H.J.; Vist, G.E.; Glasziou, P.; Akl, E.A.; Skoetz, N.; Guyatt, G.H. Chapter 14: Completing 'summary of findings' tables and grading the certainty of the evidence. In *Cochrane Handbook for Systematic Reviews of Interventions, Version 6.3 (Updated February 2022)*; Higgins, J.P.T., Chandler, J., Cumpston, M., Li, T., Page, M.J., Welch, V.A., Eds.; Cochrane: Oxford, UK, 2022. Available online: <http://www.training.cochrane.org/handbook> (accessed on 1 March 2022).
25. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials revisited. *Contemp. Clin. Trials* **2015**, *45*, 139–145. [[CrossRef](#)] [[PubMed](#)]
26. Harrer, M.; Cuijpers, P.; Furukawa, T.A.; Ebert, D.D. *Doing meta-Analysis with R: A Hands-On Guide*; Chapman and Hall/CRC: Boca Raton, FL, USA, 2021.
27. Team, R.C. *R: A Language and Environment for Statistical Computing*; R Foundation for Statistical Computing: Vienna, Austria, 2021.
28. Chu, T.W.; AlJasser, M.; Alharbi, A.; Abahusseini, O.; McElwee, K.; Shapiro, J. Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: An intrasubject pilot study. *J. Am. Acad. Dermatol.* **2015**, *73*, 338–340. [[CrossRef](#)] [[PubMed](#)]
29. Rajan, M.B.; Bhardwaj, A.; Singh, S.; Budania, A.; Bains, A.; Thirunavukkarasu, P.; Kumar, M.P. Identification of novel step-up regimen of intralesional triamcinolone acetonide in scalp alopecia areata based on a double-blind randomized controlled trial. *Dermatol. Ther.* **2021**, *34*, e14555. [[CrossRef](#)] [[PubMed](#)]
30. Ragab, S.E.M.; Nassar, S.O.; Morad, H.A.; Hegab, D.S. Platelet-rich plasma in alopecia areata: Intradermal injection versus topical application with transepidermal delivery via either fractional carbon dioxide laser or microneedling. *Acta Dermatovenerol. Alp. Pannonica Adriat.* **2020**, *29*, 169–173. [[CrossRef](#)]
31. Maisel-Campbell, A.L.; Ismail, A.; Reynolds, K.A.; Poon, E.; Serrano, L.; Grushchak, S.; Farid, C.; West, D.P.; Alam, M. A systematic review of the safety and effectiveness of platelet-rich plasma (prp) for skin aging. *Arch. Dermatol. Res.* **2020**, *312*, 301–315. [[CrossRef](#)]
32. Pototschnig, H.; Madl, M.T. Successful treatment of alopecia areata barbae with platelet-rich plasma. *Cureus* **2020**, *12*, e7495. [[CrossRef](#)]